













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 






A Study of Prognostic Markers 




Claribel P. L. Simmons 
 
  i 
Contents 
 
Declaration ............................................................................................................... i 
Acknowledgements ................................................................................................ ii 
Abstract .................................................................................................................. iii 
Lay Summary ........................................................................................................... i 
Abbreviations ........................................................................................................... i 
Chapter 1 Introduction ........................................................................................ 1 
1.1 Cancer terminology and its origins in ancient history................................... 1 
1.1.1 Classical Greek history of cancer and its link to macroscopic 
inflammation ...................................................................................................... 1 
1.2 Cancer and its link to microscopic inflammation .......................................... 3 
1.2.1 Cancer biology and its relationship to inflammation ............................. 3 
1.2.2 Important features of tumour production, tumour propagation and 
metastatic disease ............................................................................................. 5 
1.2.3 Clinical symptomatology and its relationship to inflammation ............... 7 
1.3 Clinical markers of inflammation and prognosis .......................................... 8 
1.3.1 Combined Clinical Markers of Prognosis ........................................... 11 
1.4 The importance of prognostication ............................................................ 12 
1.5 Conclusion ................................................................................................ 13 
1.5.1 Thesis Aim ......................................................................................... 13 
Chapter 2 Systematic review of prognostic tools in patients with advanced 
cancer 15 
2.1 Background .............................................................................................. 15 
2.2 Methods .................................................................................................... 18 
2.2.1 Eligibility Criteria ................................................................................ 18 
2.2.2 Data extraction and analysis .............................................................. 19 
2.3 Results...................................................................................................... 19 
2.3.1 General Considerations ..................................................................... 19 
2.3.2 Summary of individual tools ............................................................... 30 
PaP (Palliative Prognostic Score) and D-PaP (Delirium PaP) ....................... 30 
Vitamin B12/CRP Index (BCI) ...................................................................... 33 
  ii 
Palliative Prognostic Index (PPI) .................................................................. 34 
PPS (Palliative Performance Scale) ............................................................. 36 
The Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic 
Score (mGPS) .............................................................................................. 38 
Prognosis in Palliative Care Study (PiPS) .................................................... 40 
2.4 Discussion ................................................................................................ 41 
2.5 Conclusion ................................................................................................ 47 
Chapter 3 Exploratory Analysis of Potential Prognostic Markers in Advanced 
Lung Cancer – a biobank analysis study ............................................................ 49 
3.1 Background .............................................................................................. 49 
3.2 Materials and Methods .............................................................................. 52 
3.3 Results...................................................................................................... 54 
3.4 Discussion ................................................................................................ 62 
3.5 Conclusion ................................................................................................ 67 
Chapter 4 IPAC study: Inflammatory biomarkers in the Prognostication of 
Advanced Cancer.................................................................................................. 68 
4.1 Introduction ............................................................................................... 68 
4.2 Aims ......................................................................................................... 68 
4.3 Methods .................................................................................................... 69 
4.3.1 Study Setting ..................................................................................... 69 
4.3.2 Ethics ................................................................................................. 69 
4.3.3 Inclusion and Exclusion Criteria ......................................................... 70 
4.3.4 Study Assessments ........................................................................... 71 
Evaluation of patients ................................................................................... 71 
Demographic patient data and disease details ............................................. 72 
Clinical indices ............................................................................................. 72 
Clinician predicted survival ........................................................................... 73 
Laboratory biomarkers ................................................................................. 73 
Follow up information ................................................................................... 74 
Statistical methods ....................................................................................... 74 
4.3.5 Sample Size Calculation .................................................................... 76 
4.4 Results...................................................................................................... 76 
4.5 Discussion ................................................................................................ 91 
Chapter 5 Discussion ....................................................................................... 96 
  iii 
5.1 Background to the Thesis ......................................................................... 96 
5.2 Main Findings ........................................................................................... 97 
5.3 Potential Implications of Thesis Findings ................................................ 101 
5.4 Future directions ..................................................................................... 102 
5.5 Strengths and Limitations ....................................................................... 103 
5.6 Final Words ............................................................................................ 105 
References .......................................................................................................... 107 
Appendix I: Systematic review search .............................................................. 118 
Appendix II: Published Papers/ Information Sheets ......................................... 120 
 
List of Figures 
Figure 1-1: An Illustration of the interaction between cancer and inflammation ......... 4 
Figure 2-1 Flowchart detailing the search process .................................................. 20 
Figure 3-1 Kaplan Meier curve demonstrating the relationship between weight loss 
and survival............................................................................................................. 58 
Figure 3-2 Kaplan-Meier curve demonstrating the relationship between performance 
status and survival .................................................................................................. 59 
Figure 3-3 Kaplan-Meier curve demonstrating the relationship between mGPS and 
survival ................................................................................................................... 60 
Figure 4-1 Bar chart demonstrating the relationship between clinician predicted 
survival and performance status ............................................................................. 90 
List of Tables 
Table 2-1 Summary of individual prognostic tools ................................................... 21 
Table 2-2 Prognostic Tools and survival predictions ............................................... 23 
Table 2-3 Details of individual prognostic markers within each tool ......................... 29 
Table 2-4 The PaP Tool .......................................................................................... 32 
Table 2-5 The D-PAP Tool ...................................................................................... 33 
Table 2-6 The BCI Tool ........................................................................................... 34 
Table 2-7 The PPI Tool ........................................................................................... 36 
Table 2-8 The PPS Tool ......................................................................................... 38 
Table 2-9 The GPS and mGPS Tools ..................................................................... 39 
  iv 
Table 2-10 The PiPS Tool ....................................................................................... 41 
Table 3-1 Patient Demographics (n= 390) .............................................................. 55 
Table 3-2 The relationship between clinic-pathological factors and survival in patients 
with metastatic lung cancer (n=390)........................................................................ 57 
Table 3-3 Relationship between mGPS, performance status, and survival at 3 
months .................................................................................................................... 61 
Table 4-1 Clinicopathological characteristics of patients with advanced cancer 
(n=478) ................................................................................................................... 78 
Table 4-2 The relationship between clinicopathological factors and survival (30 day 
and 3 month) in patients with advanced cancer ...................................................... 80 
Table 4-3 The relationship between clinicopathological factors and survival (30 day 
and 3 month) in patients with advanced cancer: univariate and multivariate analysis
 ............................................................................................................................... 82 
Table 4-4 The relationship between performance status, mGPS and the survival rate 
(%) at 30 days and 3 months, in patients with advanced cancer (n=478) ................ 84 
Table 4-5 The relationship between circulating neutrophil counts, ECOG-PS and 
mGPS in patients with advanced cancer (n=469).................................................... 86 
Table 4-6 The relationship between the neutrophil count and Performance Status 
and the survival rate at 30 days and 3 months, in patients with advanced cancer 
(n=469) ................................................................................................................... 87 
Table 4-7 The relationship between Lactate Dehydrogenase, ECOG-PS and mGPS 
in patients with advanced cancer (n=446). .............................................................. 89 
 
  i 
Declaration 
 
I declare that the thesis has been composed by myself and that the work has not been 
submitted for any other degree or professional qualification. All work is my own unless 
specifically stated. 
Claribel P.L. Simmons 2018 
  
  ii 
Acknowledgements 
 
Hippocrates wrote ‘Wherever the art of Medicine is loved, there is also a love of 
Humanity’ and the work contained within this thesis would not have been possible 
without the wonderful help and tremendous guidance offered to me by so many 
people.  
The Edinburgh and Glasgow teams of the University of Edinburgh Palliative and 
Support Care Research Unit provided me with invaluable tutelage, direction and 
information. Sister Rita, Professor John Welsh and everyone at St Margaret of 
Scotland Hospice provided me with enlightenment, strength and advice.  
I am grateful to Medical Research Scotland who had faith in me to complete the studies 
presented in this thesis and provided 3 years of funding. I am indebted to Dr Kerry 
McWilliams for her help with the systematic review, Dr Ioannis Giolbasanis for his 
biobank of data and help with the biobank analysis, Professor Kenneth Fearon for his 
advice, critique and expertise and Professor Donald McMillan for his help with all the 
studies, invaluable experience in this field and discussions on survival analysis. I am 
also very grateful for the literary expertise and advice of Mrs. Harriet Harris – she has 
also been a wonderful ear and problem solver.  
A huge thank you to Professor Marie Fallon for giving me this opportunity, providing 
inspirational counsel and supporting me throughout the journey. 
Another huge thank you is owed to Dr Barry Laird, who has provided immense 
knowledge, guidance, help and endless positive encouragement.  
Finally, none of this work would have been possible without the love and support of 




  iii 
Abstract 
 
Background: Prognostication is a core skill fundamental to the clinical management of 
patients with advanced cancer. This skill is exercised to guide appropriate clinical 
decisions, plan supportive services and allocate resource utilisation. Prognostication 
by clinicians is often erroneous, optimistic, informal and subjective. Clinicians base 
survival predictions upon clinical experience, clinical intuition and knowledge of cancer 
trajectories. Prognostic factors have been identified and validated in patients with 
cancer. These can be clinical markers or biomarkers. Clinical markers including weight 
loss and Performance Status (PS), and biomarkers such as C-reactive protein (CRP), 
lactate dehydrogenase (LDH), White cell count (WCC) and albumin, all representative 
of systemic inflammation, have been shown to be predictive of survival. Several 
prognostic factors have been combined to develop prognostic tools to improve 
prognostication accuracy. The aims were to examine all these prognostic markers and 
the tools, to clarify which prognostic markers are most predictive of survival in 
advanced cancer.  
Methods: To meet these aims a systematic review, an analysis of a prospectively 
collected biobank of patients with lung cancer and finally a large de novo multi-centre 
(UK) observational cohort study (Inflammatory biomarkers in Prognosis in Advanced 
Cancer [IPAC] study), were undertaken. The latter examined prognostic factors and 
was informed by the systematic review and biobank analysis. The prognostic factors 
evaluated throughout included demographic factors, disease characteristics, clinical 
factors and biomarkers. Literature appraisal and synthesis, survival analysis and 
logistic regression methods were employed as appropriate. 
Results: The systematic review concluded that numerous prognostic tools predict 
survival in patients with advanced cancer; however comparison was difficult due to the 
heterogeneity of the tools and the methods used to determine their accuracy. Some 
tools incorporate prognostic factors that have been independently validated to be of 
prognostic significance in advanced cancer whilst other tools may include some 
factors which are not validated. The prognostic tools demonstrating greatest accuracy 
in determining survival are the Palliative Performance Scale (PPS), the Palliative 
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Prognostic Score (PaP), the Palliative Prognostic Index (PPI), and the Glasgow 
Prognostic Score (GPS) including the modified variant (mGPS). These tools have all 
been externally validated in more than 2000 patients with advanced cancer and were 
independently associated with survival (p<0.001). 
The biobank analysis identified the markers (clinical and biomarkers) which are most 
predictive of survival in advanced lung cancer. The prognostic markers included in 
many of the prognostic tools with greatest survival prediction accuracy are PS and 
mGPS (p<0.001).  
A prospectively acquired biobank identified the markers (clinical and biomarkers) 
which are most predictive of survival in advanced incurable lung cancer. The 
prognostic markers which are included in many of the prognostic tools with greatest 
survival prediction accuracy are PS and mGPS.  
The prospective observational study demonstrated that CPS (Clinician Predicted 
Survival), mGPS, ECOG-PS (Eastern Cooperative Oncology Group - Performance 
Status), dyspnoea, Global Health, cognitive impairment, anorexia, weight loss, LDH, 
WCC and neutrophil count (NC) predicted survival at 30 days (univariate analysis). 
CPS, ECOG-PS, mGPS, dyspnoea, Global Health, cognitive impairment, anorexia, 
weight loss, LDH, WCC and NC, predicted survival at 3 months. On multivariate 
analysis, ECOG-PS, mGPS and neutrophil count predicted survival at 30 days while 
ECOG-PS, mGPS, weight loss, LDH and WCC predicted survival at 3 months. 
 
Conclusion: In patients with advanced cancer, the most accurate prognostic factors 
include clinical markers (Performance Status, weight loss) and biomarkers of the 
systemic inflammatory response (CRP and albumin [combined in the mGPS], NC, 
WCC). The next step in this work is assessing how these can be utilised in clinical 
practice. 
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Lay Summary 
 
Assessing how long a patient with cancer has to live is very important to guide their 
medical care and aids future planning, both in terms of the patient’s preferences and 
medical management. It is difficult for clinicians to give an estimate of how long a 
patient has left to live and frequently their estimate is incorrect, often over-estimating 
their expected survival time. Clinicians estimate a patient’s survival time based upon 
their knowledge of the patient’s condition and their experience in looking after other 
patients with similar conditions. This varies from clinician to clinician. Factors that help 
survival estimation are known and include patient factors and blood tests. The blood 
tests are often related to inflammation or systemic upset. Several of these tests have 
been used together and combined into a tool to improve survival estimation.  
 
Three studies were performed as part of this thesis to evaluate survival factors, in an 
attempt to clarify the survival factors of greatest significance in advanced cancer. 
These studies were a review of previous studies, a study looking at survival factors in 
patients with lung cancer, and a large prospective study designed to test all the survival 
factors in patients with advanced cancer. The survival factors included demographic 
details of the patients and details of their cancer including symptoms, fitness level, 
weight loss and blood tests. The survival results were analysed using the appropriate 
statistical packages to ensure accurate analysis.  
 
The first study was a review of previous studies looking at the numerous tools 
estimating survival for patients with incurable cancer. Studies selected for review had 
a study population of at least 100 patients and patients were diagnosed with incurable 
cancer. Fifty one studies were included. The review concluded that there are 
numerous tools estimating survival in patients with advanced cancer however direct 
comparison is difficult due to the variety of tools and variations in their study design 
and presentation of results. Some tools incorporate survival factors which have been 
studied extensively and have been proven to estimate survival in their own right. Some 
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tools incorporate survival factors which have not been tested as rigorously. The tools 
which have been rigorously tested in patients with cancer and have been shown to 
accurately estimate survival are the Palliative Performance Scale (PPS), the Palliative 
Prognostic Score (PaP), the Palliative Prognostic Index (PPI), and the Glasgow 
Prognostic Score (GPS).  
 
The second study looked at survival factors in patients with incurable lung cancer 
which are namely Performance Status (fitness), the modified Glasgow Prognostic 
Score (mGPS: a survival factor using blood factors of inflammation) and weight loss. 
These are known survival factors in advanced lung cancer however have never been 
directly compared. This study was an analysis of an existing set of data from Greece. 
The data of 390 patients were analysed and using appropriate statistical packages, 
comparison of these survival factors was performed. Fitness and the mGPS best 
predicted survival and when combined, survival accuracy improved more.  
 
The third study, our IPAC study, then evaluated all the established survival factors in 
real time to compare them fully with each other to ascertain their survival estimate 
accuracy. The design was modelled on the second study and was conducted in 
several hospitals and hospices throughout the UK. Data collected about each patient 
included markers of their fitness, blood tests looking at inflammation, details of their 
cancer and cancer treatment, symptoms, and clinical signs. The data of 478 patients 
were analysed using appropriate statistical modelling packages. The IPAC study 
identified the factors at best predicting survival were the clinician’s knowledge of the 
patient, the patient’s fitness, the patient’s Global Health questionnaire result, blood 
tests looking at inflammation, breathlessness, confusion, loss of appetite and weight 
loss. When all the factors were compared, the factors best predicting survival were the 
blood tests looking at inflammation, the patient’s fitness and weight loss.  
 
This thesis has identified and tested the prognostic accuracy of many survival factors 
in patients with advanced cancer. The blood tests looking at inflammation have all 
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been shown to be predictive of survival. When specific blood tests looking at 
inflammation are combined (mGPS) their prognostic accuracy increases. Using 
objective markers of systemic inflammation in cancer can aid survival prediction and 
thus improve clinical management in patients with advanced cancer. 
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Chapter 1 Introduction 
Chapter 1 Introduction 
 
1.1 Cancer terminology and its origins in ancient 
history 
 
Cancer is a malignant tumour resulting from an uncontrolled division of cells. 
Inflammation has been linked to cancer for more than a thousand years and in 
order to understand the significance of inflammation with regard to cancer, the 
history of cancer and its terminology must be reviewed. 
 
 
1.1.1 Classical Greek history of cancer and its link to 
macroscopic inflammation 
 
Carcinos refers to both the Greek word for crab and the ancient mythological 
creature Karkinos (or Carcinos), a giant crab who was crushed by Heracles in 
battle. Karkinos was then placed among the stars, as a reward by the goddess 
Hera, an enemy of Heracles. The astronomical constellation of the crab is 
referred to as the constellation Cancer. The ancient Egyptians worshipped the 
stars and metaphorical symbolism was important to daily life. In Ancient 
Egyptian astronomy, the Cancer constellation was illustrated by the figure for 
a crab. The Egyptians viewed Cancer, both the constellation and its 
metaphorical crab as a sacred emblem of immortality and it implied 
indestructibility, however it was also viewed as being closely connected to 
death. The features of being ineradicable and its link to death are from where 
the origins of the word cancer come.  
 
2  
Chapter 1 Introduction 
Hippocrates (460-370 BC), a Greek physician who is widely considered to be 
the ‘Father of Medicine’ used the term ‘carcinos’ to described tumours, both 
benign and malignant; what we refer to as cancers. He examined patients with 
large masses, some of which were ulcerating in nature. His examination 
findings concluded that these lesions were ‘hard as a rock, exquisitely painful 
with a superficial surface of ulceration which bled or had sores that oozed and 
refused to heal’. He named this condition Karkinos, from the Greek word for 
crab. His choice of name and reasoning behind it referred to the hard shell of 
a crab, the ferocious pinch of a crab claw and the tenacity with which a crab 
bites and refuses to let go. This resembled how stubbornly a malignant tumour 
adhered to the body, no matter how it was manipulated. Hippocrates had 
already witnessed that while some masses were benign, others were 
malignant and tended to spread quickly through the body, similar to a crab’s 
claws extending out, and resulted in death1. After the death of Hippocrates, 
other Greek physicians continued to research cancer, including one notable 
physician called Claudius Galenus.  
 
Claudius Galenus, a Greek surgeon to gladiators (AD129 – c200) used 
Hippocrates’ term “cancer” to describe certain inflammatory tumours of the 
breast in which the superficial veins appeared swollen and radiated like the 
claws of a crab. Later the name was extended to include all malignant and 
infiltrating growths. These signs noted on clinical inspection by Hippocrates 
and Galenus were of macroscopic inflammation and therefore were the first 
links to cancer and inflammation. Cancer and inflammation were investigated 
further, by a Roman called Aulus Cornelius Celsus who was a medical 
encyclopaedist. It is thought that he may have been a practising surgeon, but 
he is notable for advancing Hippocrates’ theories regarding macroscopic 
inflammation in cancer. In the 1st century AD Celsus described the four cardinal 
signs of inflammation namely rubor (redness), calor (heat), tumor (swelling) 
and dolor (pain)2.  
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1.2 Cancer and its link to microscopic inflammation 
 
It was not until the 19th century that the link between inflammation and cancer 
was noted microscopically by Rudolf Virchow, a German doctor and the ‘father 
of modern pathology’. 
 
The microscopic examination of leukocytes within tumours by Virchow 
provided the first indication of a possible link between inflammation and 
cancer3. There is now good evidence that inflammation impacts upon every 
step of tumorigenesis from initiation through tumour productions and onto 
metastatic progression4. The tumour microenvironment has been investigated 
and it is known that various components interact to play a critical role in 
establishing fertile ground for tumour growth and progression5. The host 
reaction to a cancer also promotes an inflammatory microenvironment which 
can promote cancer development6.  
 
 
1.2.1 Cancer biology and its relationship to inflammation 
 
It is important to gain an appreciation of cancer biology and its relationship to 
inflammation, tumour production and metastatic disease, however a detailed 
analysis is beyond the remit of this thesis. As a brief summary, general 
hallmarks of cancer-related inflammation include the presence of inflammatory 
cells and inflammatory mediators (e.g. chemokines, cytokines and 
prostaglandins) in tumour tissues, tissue remodelling and angiogenesis similar 
to that seen in chronic inflammatory processes and tissue repair. Inflammatory 
cells and mediators are present in the microenvironment of most, if not all, 
4  
Chapter 1 Introduction 
tumours, irrespective of the trigger for development. The cytokines interleukin-
6 (IL-6), tumour necrosis factor alpha (TNFα) and interleukin-1- alpha (IL-1α) 
and beta (IL-1β) are critical mediators of the systemic inflammatory response. 
As a result, these cytokines are main stimulators for the synthesis of an acute 
phase response7. A variety of other modulators may affect acute phase 
responses which include glucocorticoids, insulin and growth factors such as 
epidermal growth factor, hepatocyte growth factor and transforming growth 
factor β7. To this effect, the presence of a systemic inflammatory response 
detected through the measurement of acute phase reactants is considered a 
poor prognostic factor for various cancers. The interaction between cancer and 
inflammation is summarised in Figure 1-1. 
 
 
Figure 1-1: An Illustration of the interaction between cancer and inflammation 
The figure demonstrates the interplay between inflammation due to cancer, the cancer 
microenvironment and both contributing to further inflammation.  
"Reprinted from The Lancet, Vol. 357, Balkwill et al; Inflammation and Cancer: Back to 
Virchow?, Pages 539-45., Copyright (2001), with permission from Elsevier." 
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1.2.2 Important features of tumour production, tumour 
propagation and metastatic disease 
 
All solid tumours at some point outpace their blood supply and become oxygen 
and nutrient deprived. This results in necrotic cell death at the tumour’s core 
and the release of proinflammatory mediators such as IL-1 and HMGB1 (high 
mobility group box 1, homo sapiens)8. The ensuing inflammatory response 
promotes neoangiogenesis and provides surviving cancer cells with additional 
growth factor, produced by newly recruited inflammatory and immune cells4,9. 
This intrinsic inflammatory response which follows tumour development, in turn 
promotes the tumour microenvironment. 
 
Based on the continuous cell renewal and proliferation induced by tumour 
associated inflammation, tumours have been referred to as ‘wounds that do 
not heal’10. In some animal models, dominant oncogenes are unable to induce 
cancer unless accompanied by injury and subsequent tissue regeneration11,12.  
 
Tumours secrete a vascular permeability factor called vascular endothelial 
growth factor (VEGF) that can lead to persistent extravasation of fibrin and 
fibronectin and continuous generation of extracellular matrix. Platelets in 
wounds are a critical source of cytokines, especially transforming growth 
factor-β (TGF β) and VEGF. Release of such factors from platelets may also 
be important in tumourangiogenesis13.  
 
There is now evidence that inflammatory cytokines and chemokines, which 
can be produced by the tumour cells, tumour-associated leucocytes and 
platelets, may contribute directly to malignant progression. Many cytokines 
and chemokines are inducible by hypoxia, which is a major physiological 
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difference between tumour and normal tissue14. Examples are TNF, IL-1α and 
β, IL-6 and chemokines. These are examples of pro-inflammatory chemokines. 
IL-6 is a pro-inflammatory cytokine and is highly correlated with C-reactive 
protein. The latter can be more easily measured in patients. 
TNF stimulates fibroblast growth and can also induce death of diseased cells 
at the site of inflammation. The chronic production of Nuclear factor kappa light 
chain enhancer of activated B cells (NF-kB) in malignant disease acts as an 
endogenous tumour promotor contributing to the tissue remodelling and 
stromal development necessary for tumour growth and spread. Animal models 
have demonstrated that antagonism of IL-1α reduces tumour development. 
Chemokines recruit leucocytes to sites of inflammation, which triggers an 
uncontrolled accumulation of leukocytes, even after the initial antigenic 
stimulus has disappeared.  
 
NF-κB is important in cancer progression since this nuclear transcription factor 
is known to influence the tumour microenvironment directly. NF-κB has been 
shown to promote cancer progression directly in several cancers. NF-κB 
amplifies epidermal growth factor (EGF) signalling in glioblastoma, promotes 
the tumour microenvironment in Hodgkin’s disease through Hodgkin and 
Reed-Sternberg cells, induces growth factor secretion by inflammatory cells in 
hepatocellular carcinoma, induces inflammatory cell trophic and angiogenic 
cells in colorectal cancer, induces B cells directly to cause hormone-free 
survival of cancer cells in prostate cancer, promotes tumour cell survival in 
multiple myeloma and induces trophic factor in multiple myeloma15. NF-κB is 
viewed as a growth factor in cancer cells and therefore has an important role 
in tumour metastasis, thereby directly linking inflammation and the pro-
inflammatory cytokines to tumour progression, which is metastasis in clinical 
terms.   
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These inflammatory chemokines are thought to be critically important in cancer 
cell motility, homing and proliferations at specific metastatic sites16. Cancer 
metastasis is complicated in that it arises from the cancer cell invasion, 
angiogenesis, the movement of cancer cells within the blood stream, 
extravasations, organ specific targeting and growth. Clinically, metastasis is 
the most critical aspect of tumorigenesis because over 90% of cancer mortality 
is caused by metastasis.  
 
 
1.2.3 Clinical symptomatology and its relationship to 
inflammation 
 
Symptoms in cancer are the physical and psychological manifestations of the 
underlying disease process and there is evidence demonstrating that the 
majority of cancer symptoms are associated with inflammation17. Symptoms 
such as pain, fatigue and anorexia are highly prevalent in patients with 
advanced cancer18. The symptoms of pain, anorexia, cognitive dysfunction 
and breathlessness have all been shown to be associated with systemic 
inflammation in patients with advanced cancer17. Studies have linked 
increased concentrations of pro-inflammatory cytokines including IL-1 receptor 
antagonist, TNF-α, IL-6, IL-8 and epidermal growth factor to severe levels of 
fatigue, cognitive impairment, and reduced quality of life19.  
 
The symptom of pain in patients with advanced cancer has been shown to 
correlate positively with CRP, raising the possibility of a relationship between 
pain and systemic inflammation in cancer20. Animal models have suggested 
the ability of pro-inflammatory cytokines, including TNFα, to induce 
exaggerated pain responses21.  
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Other symptoms present in patients with advanced cancer include weakness, 
malaise, fever and depressed activity. These non-specific symptoms have 
collectively been named ‘sickness behaviour’ and have been documented in 
all animal species studied with systemic inflammation secondary to infection22. 
There is evidence to support a role for pro-inflammatory cytokines in inducing 
sickness behaviours23,24. Sickness behaviours include the symptoms of 
lethargy, depression, anorexia and reduced social functioning, and it has been 
hypothesised that the pro-inflammatory cytokines released in cancer are also 
related to these symptoms24.  
 
It can therefore be seen that high levels of tumour burden are associated with 
high levels of systemic inflammation and symptomatology. This raises the 
possibility that biomarkers of systemic inflammation together with 
symptomatology may be of potential use in a clinical setting, that they can be 
used as markers of disease severity in advanced cancer, and in turn be 
associated with prognosis.  
 
 
1.3 Clinical markers of inflammation and prognosis  
 
In the clinical environment, certain inflammatory biomarkers and clinical 
markers are thought to be useful in prognostication and surrogate markers of 
disease severity and systemic inflammation. These markers are surrogate 
markers of the pro-inflammatory tumour microenvironment and systemic 
cytokine response.   
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Systemic inflammation resulting from tumour presence results in changes in 
protein metabolism and the establishment of the acute phase response. A key 
component of this is the hepatic production of acute phase proteins such as 
C-reactive protein (CRP). As the half-life of CRP is 19 hours, levels only remain 
elevated when there is on-going stimulus. CRP is regulated by interleukin-6 
(IL-6). CRP can therefore be viewed as a surrogate marker of IL-625,26. 
Elevated levels of CRP, as a marker of the systemic inflammatory response, 
have been shown to be an important prognostic factor independent of tumour 
stage27.  The magnitude of the elevation in CRP has also been shown to 
correlate with reduced survival in patients with cancer, particularly advanced 
cancer, independent of tumour stage. Studies have found that serum CRP 
concentration is a useful prognostic indicator in patients with unresectable 
pancreatic cancer28, gastro-oesophageal cancer28, urinary bladder cancer29, 
renal cancer30, and non-small cell lung cancers31. The presence of an acute 
phase protein response has also been identified as an index of tumour 
recurrence32. 
 
The relationship between CRP and albumin is similar in patients with cancer 
regardless of tumour type. Albumin concentration is a reflection of both 
systemic inflammation and the amount of lean tissue. In patients with cancer, 
serum albumin concentration reduces as CRP increases33,34. An abnormal low 
albumin itself, however, has not been shown to be an independent prognostic 
indicator35,36.  
 
Other biomarkers, have been found to be associated directly with prognosis in 
advanced cancer. For example white cell count (WCC) has been identified as 
a statistically significant prognostic marker in patients with non-small cell lung 
cancer (NSCLC) on univariate analysis and the same study also demonstrated 
that CRP and WCC both independently correlated with prognosis37. 
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Leucocytosis and lymphocytopenia have been identified as predictors of 
survival in advanced cancer38,39. 
 
The reduction of pyruvate by nicotinamide adenine dinucleotide (NADH) to 
form lactate is catalysed by LDH. NADH is involved in all cell damage repair 
and enzyme reactions in the body. It is therefore involved in the propagation 
of the tumour microenvironment. LDH and lactate are known to reflect the 
tumour burden and the invasive potential of tumour. Elevation of the serum 
enzyme LDH has been associated with reduced survival. This has been 
reported in lung cancer40, renal cancer41, head and neck cancer42, pancreatic 
cancer43, colorectal cancer44, prostate cancer45, and haematological 
cancers46. It has also been identified as an independent prognostic factor of 
poor survival in patients with advanced cancer both in the terminal47 and non-
terminal stages of illness48. 
 
Clinical markers have also been investigated as prognostic indicators of 
survival. These include Performance Status (PS). PS is a measurement of the 
level of a patient’s functioning in terms of being able to care for themselves, 
and physical activity level. The Karnofsky Performance Scale (KPS) is the 
most commonly used tool for quantifying the functional status of patients with 
cancer49. It is an 11 point rating scale which ranges from normal function (score 
100) to dead (score 0). A direct relationship has been confirmed between KPS 
and survival50. One study of the KPS noted that it accurately predicted early 
deaths, however it also noted that elevated initial KPS scores did not 
necessarily predict long survival51. PS in combination with tumour type, 
however, has been shown to be a useful prognostic indicator52. Survival data 
for individual cancers exist but are not tailored to an individual patient. The 
addition of PS in combination with tumour type in predicting prognosis is easy 
to apply in a clinical setting, relevant to the individual patient and quick to 
perform.   
11  
Chapter 1 Introduction 
 
1.3.1 Combined Clinical Markers of Prognosis  
 
As stated, certain symptoms in cancer are linked directly to systemic 
inflammation. There are specific clinical symptoms or indices which have been 
validated to show a direct association with cancer survival and will be 
discussed later in this thesis. Some clinical biomarkers are used in 
combination and demonstrate the burden of systemic inflammation upon 
prognosis in advanced cancer. 
 
There are many other important clinical markers. Certain clinical signs in 
addition to symptoms which together characterise the clinical condition termed 
‘the common terminal pathway’ have a prognostic impact. These are nutritional 
status, symptoms of the cancer anorexia-cachexia syndrome, dysphagia and 
xerostomia53. Dyspnoea, anorexia-cachexia, dysphagia and xerostomia were 
identified in The National Hospice Study as having independent predictive 
value in estimating survival time54. Early satiety55, fatigue56, cognitive 
impairment57, and nausea58 have also been seen to be independently 
associated with reduced survival. Absence of depressed mood has been 
identified as an independent predictor of survival58. Conversely, it is of interest 
that studies have also demonstrated a relationship between depression or 
depressed mood and cancer progression59. 
 
In pancreatic cancer it has been noted that the absolute number of symptoms 
increases with deteriorating PS and this combination is associated with shorter 
survival60. Similarly, in gastric cancer persistent vomiting at diagnosis has been 
shown to be independently inversely associated with length of survival61.  
There are other signs and symptoms which have occasionally been shown to 
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be significant, namely constipation, dizziness, anxiety, diarrhoea, 
haemorrhage and poly-morbidity53.  
In summary a prognostic factor provides information on survival and is not 
influenced by treatment. At this point, it is important to emphasise the 
difference between prognostic and predictive factors. This thesis focusses on 
prognostic factors in advanced cancer. A predictive factor is a condition, 
finding or biomarker that can be used to help predict the effect of a therapeutic 
intervention such as chemotherapy or radiotherapy. A predictive factor can be 
a target for therapy. Predictive factors may be predictive for one treatment and 
not another. Predictive factors may alone be proven to have prognostic value 
after identification and validation however the term prognostic and predictive 




1.4 The importance of prognostication 
 
Prognostic indicators and prognostication as a whole are crucial in cancer care 
management. Prognostication helps the clinician predict the likely disease 
trajectory, helps guide treatment plans, predict response to treatment and this 
allows the patient to be given a tailored treatment plan which avoids 
unnecessary investigations and treatments. It also aids the clinician in 
predicting the length of survival which also assists patients with future planning 
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1.5 Conclusion 
 
Systemic inflammation has always been implicated in both cancer genesis and 
maintenance of the cancer state; Mantovani described inflammation as the 7th 
hallmark of cancer62. In some cancers, pre-existing inflammation may predict 
tumour development (e.g. ulcerative colitis and colonic carcinoma). The 
presence of inflammation may also be necessary for the maintenance of the 
tumour microenvironment and promote tumour growth. Markers of 
inflammation in cancer have been discovered and can be linked to tumour 
progression and ultimately survival in advanced cancer. These are termed 
prognostic markers.  
 
Numerous prognostic markers have been identified, both clinical (e.g. 
symptoms and signs) and laboratory based (e.g. biomarkers such as. CRP). 
They have been tested on univariate analysis for accuracy of survival 
prediction in advanced cancer. They have been combined in prognostic tools 
to act synergistically and improve prognostic accuracy. Which tool or marker 
is best, however, is as yet undetermined since despite much research, they 
have not been directly compared in a single study. 
 
 
1.5.1 Thesis Aim 
 
The overall aim of this thesis was to examine prognostic markers and 
prognostic tools in advanced cancer. Specific aims were: 
● To identify the validated prognostic markers and prognostic tools in 
advanced cancer. 
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● To compare all the validated prognostic markers in advanced cancer and 
then determine which prognostic marker is of greatest significance in 
estimating survival in advanced cancer.  
● To perform a systematic review and to examine prognostic tools for use in 
patients with advanced cancer.  Since 2003, a number of additional prognostic 
tools have been developed and validated using several of the prognostic 
factors and the aim of the systematic review was to examine these tools. This 
is examined in Chapter 2. This systematic review has been published as a 
peer reviewed paper in the Journal of Pain and Symptom Management, a copy 
of which is in Appendix II.  
● To analyse a biobank data set with the purpose of testing and potentially 
validating prognostic markers of greatest significance in patients with 
advanced lung cancer. This is examined in Chapter 3. This study has been 
published as a peer reviewed paper in Lung Cancer, a copy of which is in 
Appendix II.  
● To perform a prospective observational study to examine fully all the 
prognostic markers already established as having independent prognostic 
significance in the systematic review and biobank analysis, and determine 
which are most predictive of survival in patients with advanced cancer. This is 
examined in Chapter 4. This study has been submitted for publication.  
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Chapter 2 Systematic review of prognostic 
tools in patients with advanced 
cancer 
 
The chapter is based on the paper by Simmons et al63(Appendix II). 
2.1 Background 
 
The prediction of probable prognostic outcome is a core skill fundamental to 
the clinical management of patients with advanced cancer. The Tumour, Node, 
Metastasis (TNM) staging system is an anatomical staging system based upon 
the tumour size, lymph nodes affected and the presence of metastases64. It 
was developed in the 1940s and is still used today to classify cancer stage, 
primarily to guide treatment decisions.  The letter T refers to the primary 
tumour, its size and whether it has extended into adjacent structures. N refers 
to the extent of lymph node involvement and M refers to the presence or 
absence of metastasis. The precise TNM classification of each cancer stage 
varies according to the underlying primary cancer. Metastatic staging also 
varies in relation to the number and type of organs involved depending on the 
primary cancer. Although not developed as a prognostic tool per se, it may be 
used as a surrogate prognostic tool. However in patients with metastatic 
disease, the ceiling value of TNM classification is reached and as such it does 
not provide any discriminatory power beyond this. When a patient has an “M1” 
TNM classification, other measures are needed to guide clinical management. 
For example, if a patient has an M1 classification they may be amenable to 
and receive benefit from anti-cancer therapy, but conversely may not, and as 
such the decision as to whether to give anti-cancer therapy can be challenging. 
This is where a patient’s PS is very important and will help guide further 
management.  As mentioned in Chapter 1, the KPS is the most commonly 
used tool for quantifying the functional status of patients. Another tool used is 
the Eastern Cooperative Oncology Group (ECOG) Performance Status scale 
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which was developed by the Eastern Cooperative Oncology Group and scores 
patients as being fully active (ECOG 0) to dead (ECOG 5)65. Both KPS and 
ECOG are excellent tools for assessing the degree of functional impairment 
experienced by a patient, however they are limited due to being subjective and 
frequently dependent upon what a patient reports as their functional ability, 
rather direct observation by the clinician. Such subjectivity can lead to 
inaccuracy in the assessment of PS and make planning further management 
more difficult. It is for this reason that prognostic tools were developed to 
estimate survival and thus could be used to plan further clinical management. 
This is of clinical relevance since currently, treatments such as chemotherapy 
and radiotherapy are often given late in the disease and at times, given 
inappropriately66,67. The treatment focus for patients with advanced cancer 
should be optimum overall clinical management, rather than prescribing 
additional medications with potential side effects to add to the list of symptoms 
already suffered as a direct consequence of their cancer. The focus of life 
prolonging treatments has moved from discussing their risks, including 
mortality risks, to focussing on their overall benefits, including improved quality 
of life for patients with an advanced stage of cancer with limited lifetime left.  
 
In the clinic, prognosis is based on various factors including stage of disease, 
PS, the treating clinician’s previous clinical experience and their knowledge of 
cancer trajectories. Using these individual factors, which are frequently 
subjective, to estimate prognosis can result in prognostication by clinicians 
being often erroneous, optimistic, informal and subjective68,69 with one in five 
prognoses being inaccurate70. A combination of specific prognostic factors, 
tested and validated for their accuracy in estimating survival, may result in 
better prognostication.  
 
The prognostic tools that have been validated for use in advanced cancer 
comprise of several indices, the majority of which have been proven on 
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univariate analysis to have prognostic significance in patients with advanced 
cancer. Systematic review of existing tools may allow identification of the 
significant individual prognostic markers in advanced cancer and also review 
which tool has the greatest accuracy in terms of survival prediction. The tools 
with greatest prognostic accuracy can be inferred to be comprised of 
prognostic markers with greatest prognostic accuracy and also highlight the 
prognostic markers which should be included for further examination in a 
prospective study.  
 
In 2005, the European Association for Palliative Care (EAPC) recommended 
key prognostic factors for use in advanced cancer and these recommendations 
were published in the Journal of Clinical Oncology, with the aim of improving 
prognostic accuracy in patients with advanced cancer53. The 
recommendations were informed by eight studies examining different 
prognostic tools which had been published in the preceding decade (1993-
2003). The tools were notable for their ease and rapidity of use in determining 
life expectancy and included the Terminal Cancer Prognostic Score 
(incorporating dysphagia, cognitive failure and weight loss), the Palliative 
Performance Scale, the Palliative Prognostic Index, the Palliative Prognostic 
Score and the Delirium- Palliative Prognostic Score. The tools were assessed 
for bias based upon a quality and study type classification system (Level I to 
IV) which was adaptation of a classification system on the Centre for Evidence 
based Medicine Website. The EAPC concluded that the level of evidence for 
these tools was either Level II (heterogeneous met-analyses or confirmatory 
studies) or Level III (exploratory studies) both with a low risk of bias. 
 
Since 2003, a number of additional prognostic tools have been developed and 
validated using several of these key prognostic factors. As part of this thesis, 
a systematic review was performed to examine these. The aim of the 
systematic review was to examine prognostic tools for use in patients with 
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advanced cancer in the period since the previous recommendations were 





The following databases were searched; Medline (2003–2015), Embase 
Classic + and Embase (2003-2015) using the search terms stated in Appendix 
I. The searches focussed on studies of prognostic tools in patients with 
advanced cancer regardless of the original primary tumour site. The date of 
the last literature search was 30th April 2015. Given that this was a systematic 
review, ethical approval was not required. 
 
 
2.2.1 Eligibility Criteria 
 
Eligible studies met the following criteria: population with advanced cancer 
(defined as an incurable cancer); original studies; study population (n) greater 
>100; study population aged > 18 years; quantitative clinical and/or biomarkers 
were examined; a multivariate statistical model was described; the tool had 
been examined and validated in two or more independent data sets; published 
in English; published after 2003 (end date of original literature search) 71. The 
primary outcome measurement examined was survival prediction based on the 
use of the prognostic tool in the specific patient population. Studies were 
excluded if: a univariate survival analysis only was described; the tool was 
designed for use in one specific population with one specific cancer type (e.g. 
only patients with specific stage of lung cancer) or qualitative indices were 
exclusively used to predict survival. 
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2.2.2 Data extraction and analysis 
 
The initial database search was undertaken and duplicates removed. Two 
researchers (CS and KM) independently screened each study for eligibility 
based on the title, then abstract and finally each full text article. Any 
discrepancies between the two researchers were settled after discussion with 
a third party (BL). From this the necessary data for descriptive and quantitative 
analyses, were extracted onto a paper proforma initially, then transcribed into 
an electronic table once agreement had been reached as to the papers to 
include in the systematic review. This process was based on the mandate of 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
Symposium (PRISMA)72. The data extracted included the descriptors of the 
patient population, length of survival and information regarding survival 
prediction. The analysis of each study was performed using standard quality 
assessment criteria which were then summarised for statistical analysis and 
comparison where possible73. Studies were presented according to the 





2.3.1 General Considerations 
 
The literature search process is shown in Figure 2-1. Following title and 
abstract review, 179 articles were reviewed in full which resulted in 51 studies 
fulfilling the eligibility criteria. Where studies examined populations with both 
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cancer and non-cancer diagnoses, only those populations with cancer were 
included. 
In total 1038 studies did not fulfil the inclusion criteria. The reasons for 
exclusion included if a univariate statistical model was described, the model 
was specific to a population with one cancer type e.g. patients with lung 
cancer, the model focussed on non-malignant life limiting conditions e.g. 
cardiac failure, qualitative indices were exclusively used to predict survival, the 
model focussed upon subjective patient indices e.g. patient generated 
subjective global assessment, the model was based upon exclusive or direct 
relationship to the histological staging of the cancer, the model was based 
upon or tested after therapeutic intervention e.g. post surgery, post 
radiotherapy, and if the model was based upon or tested in patients receiving 




Figure 2-1 Flowchart detailing the search process 
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From the 51 eligible studies, seven different prognostic tools were identified 
which were evaluated across different places of care, different primary cancer 
types and assessed survival prediction ranging from 3 weeks to overall 
survival.  A summary of these is detailed in Table 2-1.  
 
 
Table 2-1 Summary of individual prognostic tools 





Clinical  Biomarkers  
PaP 4 2 Mixed and 
single 
8 
D-PaP 5 2 Mixed only 2 











Mixed  2 
PPI 5 0 Mixed only 9 
PPS 6 0 Mixed only 19 
GPS/ 
mGPS 
0 2 Mixed and 
single 
10 
The term “Clinical” refers to signs elicited by clinical examination or symptoms described by 
the study subjects. The term “Biomarkers” refers to serum biomarkers of prognostic 
significance. *Studies which were eligible for inclusion. PaP refers to The Palliative Prognostic 
Score, D-PaP refers to The Delirium- Palliative Prognostic Score, BCI refers to B12/CRP 
index, PiPS refers to Prognosis in Palliative Care Study (Parts A and B), PPI refers to Palliative 
Prognostic Index, PPS refers to Palliative Performance Scale, GPS refers to The Glasgow 
Prognostic Score and mGPS refers to the Modified Glasgow Prognostic Score. 
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The tools identified were the Palliative Prognostic Score (PaP) [8 studies], 
Delirium-PaP (D-PaP) [2 studies], B12/CRP Index (BCI) [1 study], Prognosis 
in Palliative Care Study (PiPS) [2 studies], Palliative Prognostic Index (PPI) [9 
studies], Palliative Performance Scale (PPS) [19 studies] and the Glasgow 
Prognostic Score (GPS) [10 studies].  All seven tools could predict survival in 
advanced cancer with statistical significance (p<0.05). 
 
Table 2-2 details each of the prognostic tools and reports survival prediction. 
These prognostic tools used a combination of clinical and/or serum biomarker 
parameters. The most common clinical parameters used were PS  which was 
included in six tools and anorexia and dyspnoea, both of which were included 
in four tools each.  The most common biomarkers were C-reactive protein 
(CRP), WCC, Lymphocyte count and Albumin. CRP was included in four tools 
and WCC, Lymphocyte count and Albumin were each included in three tools. 
The number of parameters used in each tool ranged from two (GPS, BCI) to 
17 (PiPS B), and the median number reported was seven. All seven tools were 
independent in their ability to predict survival in advanced cancer, p<0.05. The 
individual clinical and serum biomarkers are summarised in Table 2-3. 
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Table 2-2 Prognostic Tools and survival predictions 
Tool No. of 
studies 







if not HR 
p value Summary of predictive 
accuracy 
PaP 8 Glare et 
al74 
Australia 2004 Various 100 Categorical 
(4wk) 




Italy 2008 Various 173 Continuous 26 - Unclear 0.022 p=0.022 
Naylor et 
al76 
Brazil 2010 Various 250 Categorical  
(30d) 




Japan 2010 Various 208 Continuous 2- 12 0.536-
3.72 




Canada 2011 Various 777 Continuous 5 0.279-
0.476 
- <0.001 HR 0.279-0.476 p<0.001 
Maltoni et 
al79 
Italy 2012 Various 549 Categorical  
(21d and 30d) 
3 - AUC/ log <0.0001 AUC  0.72, log rank 322.65 
Kim et al80 Canada 2014 Various 415 Categorical 
(4wk) 
- - - - Optimal scores for predicting 
4wk survival over 10 
Hui et al81 USA 2014 Various 222 Continuous 15 1.08 - 0.008 95% CI 1.02-1.13 
 (n=2694)   
D-
PaP 
2 Maltoni et 
al79 
Italy 2012 Various 549 Categorical  
(21d and 30d) 
3 - AUC <0.0001 AUC  0.73  (95%CI 0.71-
0.74) , p<0.0001 
Scarpi at 
al82 
Italy 2011 Various 361 Categorical  
(30d) 
4 1.6 - <0.001 HR 1.6 (95%CI 1.22-1.99) 
p<0.0001 
 (n=910)    
BCI 1 Kelly et 
al83 
UK 2007 Various 329 Categorical 
(90d) 
4 - 10 - Log rank <0.001 Log rank test for Trend χ2 = 
18.38 p<0.001 
 (n=329)    
PiPS 2 Kim et al84 Korea 2013 Various 202 Categorical 
(2wk, 7wk, >8wk) 
- - Sens./Spec. - Sensitivity 37.1% -64%, 
Specificity 61.6% -87.7% 
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Gwilliam 
et al85 
UK 2011 Various 1018 Continuous < 1 - 14 - AUC - AUC=  0.79-0.86 
 (n=1220)    
PPI 9 Stone et 
al86  
Japan 2008 Various 194 Continuous <1 - 10 - PPV, NPV - PPV 86%, NPV 76% 
Hakim et 
al87 




Italy 2012 Various 549 Categorical  
(21d and 30d) 
3 - AUC/ log <0.0001 AUC  0.62, log rank 80.54  
Cheng et 
al88 
Taiwan 2012 Various 623 Categorical  
(21d) 
1-10 0.2-0.5 - ≤0.001 HR 0.2 for PPI 0-4, HR 0.5 
for PPI 4.5-6 
Kim et al80 Canada 2014 Various 415 Categorical 
(4wk) 
- - scores - Optimal scores for predicting 
4wk survival over 4.5 
Arai et al89 Japan 2014 Various 374 Categorical 
(3wk) 
- 6.6 - <0.01 Initial PPI associated with 
death within 3 weeks HR 1.3 
(95% CI 1.2-1.4) p<0.01 
A change in PPI associated 
with death within 3 weeks 
HR 6.6 (95% CI 4.9-9.0) 
p<0.01 
Kao et al 
90 
Taiwan 2014 Various 2392 Continuous 5 0.63 AUC <0.001 Combination of initial PPI 
and change in PPI is useful 
AUC  0.71(95%CI 0.694-
0.731), 72.5% accuracy, 
sensitivity 66.9%, specificity 
77%, PPV 70.6%, NPV 
73.8% 
Hui et al81 USA 2014 Various 222 Continuous 15 - - 0.003 Correlation with survival on 
univariate analysis only 
Miura et 
al91 
Japan 2015 Various 1160 Categorical  
(3wk, 6wk) 
Up to 8 1.56 other <0.001 PPI ≥6, HR 1.56 (95% CI 
1.27-1.92), p<0.001 
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(For 3 week prognosis: 
Sensitivity 0.684, 
Specificity0.705, PPV 0.620, 
NPV 0.760) 
(For 6 week prognosis: 
Sensitivity 0.583, Specificity 




   
PPS 19 Head et 
al92 




USA 2005 Various 214 Categorical 
(7d, 30d, 90d, 180d) 
- 0.96 - <0.001 Better accuracy in predicting 






Spain 2006 Various 250 Continuous 5 4.33, 
2.5 
- ≤0.003 HR 4.33 for PPS <40 p= 
0.000, HR 2.5 for PPS =50 
p=0.003 
 
Lau et al95 
 
Canada 2006 Various 647 Continuous 1 1.204-
18.022 






USA 2007 Various 157 Continuous 1 1.65 - <0.0001 HR 1.65 p<0.0001 
 
Lau et al97 
 
Canada 2008 Various 126 Continuous 2 0.291-
0.937 
- ≤0.811 HR 0.291-0.937 p 0.001-
0.811 
 
Lau et al98 Canada 2009 Various 347 Continuous 3 0.039-
0.402 
Log rank <0.001 HR and Log rank p<0.001 
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USA 2009 Various 492 Continuous 3 - Cox <0.001 B -0.04, SE 0.01, Exp 0.96 
Younis et 
al100 
USA 2009 Various 180 Continuous - 1.73 - <0.001 HR1.73 p<0.001 
Lau et al101 
 
Canada 2009 Various 5097 Continuous 1 0.056-
0.542 




Canada 2011 Various 1622 Continuous 13 - OR ≤0.1982 OR 0.460-1.705, p<0.0001 




USA 2011 Various 590 Continuous - - Brier score - Hosmer-Lemshow goodness 
of fit p-value >0.1 for PPS, 





Canada 2011 Various 777 Continuous 5 0.214-
0.722 






USA 2012 Various 7391 Categorical  
(7d) 





Italy 2012 Various 549 Categorical  
(21d and 30d) 
3 - Other <0.001 Log rank 97.8  p<0.001, C 
index 0.63 
 
Mei et al105 
 




Log ,OR ≤0.03 HR reported, Log rank 
p<0.05, OR 0.98 (0.96-1.00) 
p=0.03 
Kim et al80 Canada 2014 Various 415 Categorical 
(4wk) 
- - - - Optimal scores for predicting 
survival ≤ 30 
Lee et al106 South 
Korea 
2014 Various 606 Continuous 1 2.66 - - Change in score >30% 
significantly associated with 
survival, 95% CI 2.19-3.22 
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Jang et 
al107 
Canada 2014 Various 1655 Continuous 19 - Log rank, 
AUC 
<0.001 AUC  0.63 





GPS 10 Sharma et 
al108 










UK 2006 Pancreas 187 Categorical 
(12mth) 

























UK 2012 Lung 
(Mesothelioma) 








- <0.01 HR 1.51-2.27 
Miura et 
al91 
Japan 2015 Various 1160 Categorical  
(3wk, 6wk) 
3 – 8  1.36 Other 0.046 GPS = 2, HR 1.36 (95% CI 
1.01-1.87), p=0.046 
(For 3 week prognosis: 
Sensitivity 0.879, 
Specificity0.410, PPV 0.512, 
NPV 0.828) 
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The table summarises the clinical studies examining each of the prognostic tools and includes the country of origin, cancer type examined, the sample size 
for each study, survival outcome measurement, median survival, hazard ratio (HR) and description of statistical analysis with summary of statistical 
conclusion. PaP refers to The Palliative Prognostic Score, D-PaP refers to The Delirium- Palliative Prognostic Score, BCI refers to B12/CRP index, PiPS 
refers to Prognosis in Palliative Care Study (Parts A and B), PPI refers to Palliative Prognostic Index, PPS refers to Palliative Performance Scale and GPS 
refers to The Glasgow Prognostic Score. Some studies compared several of these tools in one paper which explains the disparity in the total number of 




(For 6 week prognosis: 
Sensitivity 0.822, Specificity 
0.484, PPV 0.733, NPV 
0.611) 
 (n= 5163 
) 
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Table 2-3 Details of individual prognostic markers within each tool 
 
This table details the individual clinical and biomarkers used in individual prognostic tools. The number of markers ranges from two (GPS) to 17 (PiPS-B). PaP 
refers to The Palliative Prognostic Score, D-PaP refers to The Delirium- Palliative Prognostic Score, BCI refers to B12/CRP index, PiPS refers to Prognosis in 
Palliative Care Study (Parts A and B), PPI refers to Palliative Prognostic Index, PPS refers to Palliative Performance Scale, mGPS refers to The modified 
Glasgow Prognostic Score and GPS refers to The Glasgow Prognostic Score  
 
 
Tool Clinical Marker Biomarker  
PS CPS Anorexia Dyspnoea Delirium ambulation activity Evidence of 
disease 
























Fatigue Other WCC Lymph CRP Alb Vit 
B-
12 
PaP x x x x                    x x    
D-
PaP 
x x x x x                   x x    
BCI                          x  x 
PiPS
A 
x   x       x x x x x x x x x x x        
PiPS
B 




x x x x  
PPI x  x x x x x x x x                   
PPS x  x   x x x x                    
mGP
S 
                         x x  
GPS                          x x  
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2.3.2 Summary of individual tools 
 
PaP (Palliative Prognostic Score) and D-PaP (Delirium PaP)  
The PaP tool (Table 2-4) was constructed by the Italian Multicentre and Study 
Group in Palliative Care and validated in patients with advanced incurable 
cancer using thirty day survival probability.  The D-PaP Tool (Table 2-5) is a 
modified version of the PaP, incorporating a delirium assessment which 
slightly improved the predictive accuracy of the PaP. The PaP and D-PaP are 
the only prognostic tools included in this review which use clinician predicted 
survival (CPS) as one of their indices. The PaP has six parameters; four 
subjective (clinical) parameters and two objective biomarkers. The PaP and D-
PaP both rely heavily on CPS, a subjective parameter which can add an extra 
8.5 points to the total score (PaP maximum 17.5; D-PaP maximum 19.5). The 
other parameters (biomarkers and symptoms) contribute a maximum of 2.5 
points making this tool heavily reliant on the clinician’s expertise in 
prognostication.   
 
There have been eight studies (n=2694) examining the PaP in patients with 
advanced cancer. Patient cohorts were unselected cancer diagnoses and 
included patients with a variety of cancer diagnoses (colorectal, lung, 
melanoma, breast, adenocarcinoma of unknown primary, genitourinary, 
prostate, gastrointestinal, non-small cell lung, gynaecological [cervix, ovary, 
uterus, vagina], head and neck, stomach, oesophageal, urological, 
hepatobiliary and central nervous system, endocrine and haematological). The 
studies were from groups in Australia (1 study), Italy (2 studies), Brazil (1 
study), Japan (1 study), Canada (2 studies) and USA (1 study) thereby 
providing external validation of the tool. One study compared the performance 
of the PaP to other prognostic tools including the D-PaP, PPS, and PPI and 
concluded that the PaP showed greatest accuracy and reproducibility79. The 
PaP was also directly compared with the PPS and PPI tools in separate 
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studies78,80. One study comparing it with the PPS showed similar hazard ratios 
for the PPS (0.214 – 0.722) and the PaP (0.279 and 0.476) 78.  
 
Another study comparing the PaP with the PPI and PPS concluded that the 
PaP performed better80. Here the accuracy of these tools and their individual 
subgroups were compared with the accuracy of other tool subgroups and 
therefore resulted in a more detailed examination of the tools compared to 
other methods of evaluation. Statistical methods for data analysis varied 
among the eight studies looking at the PaP score and the heterogeneity of the 
survival accuracy results means direct comparison is difficult. However all 
studies reported accurate survival prediction based on hazard ratios.  
 
A key component of the PaP is CPS. From the eligible studies it was noted 
that oncologists’ (i.e. non palliative care specialists) CPS was shown to be well 
calibrated but individual predictions imprecise. Studies using the CPS from 
non-specialists still enabled the PaP to predict the short term survival (30 days) 
of patients with advanced cancer ‘reasonably well’, however this is based on 
the oncologists correctly predicting less than one month survival in 70% of the 
patients. There was no statistical comparison of this survival accuracy to the 
PaP.  
 
Two studies, comprising data on 910 patients reported the prognostic value of 
the D-PaP in patients with advanced incurable cancer79,82. Population cohorts 
included patients with gastrointestinal cancer, lung cancer, genitourinary 
cancer, hepatobiliary cancer, breast cancer and head and neck cancer. One 
study compared the performance of the D-PaP to other prognostic tools 
including the PaP, PPS, and PPI and concluded that the D-PaP was highly 
accurate and identified homogeneous subgroups in terms of survival, however, 
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D-PaP had not been validated as extensively as the other tools in advanced 
incurable cancer79. 
 
In conclusion, there is evidence that the PaP and D-PaP both predict survival 
in patients with advanced cancer. The D-PaP tool has not been as extensively 
validated compared with the PaP and both perform similarly when compared 
to each other. One study suggested that the D-PaP performed slightly better 
than the PaP (D-PaP score 0.860; PaP score 0.853), however only by a slight 
discriminating factor and therefore implying that modification of the PaP, a tool 
with a high discriminating ability score and more extensive validation, was not 
necessary82 . 
Table 2-4 The PaP Tool 

























Total WBC (x 109/L)  Normal ≤8.5 
High 8.6-11 




Lymphocyte Percentage Normal 20-40% 
Low 12-19.9% 














The PaP tool gives a score based on clinical criteria being present, which is used to estimate 
30 day survival.  
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Table 2-5 The D-PAP Tool 

























Total WBC (x 109/L)  Normal ≤8.5 
High 8.6-11 




Lymphocyte Percentage Normal 20-40% 
Low 12-19.9% 


















The D-PaP tool gives a score based on clinical criteria being present, namely delirium in 
addition to the PaP criteria, which is used to estimate 30 day survival. 
 
 
Vitamin B12/CRP Index (BCI)  
The BCI (Table 2-6) was developed by a group at the University of London, 
UK, following the EAPC’s recommendations in 2005. It was initially validated 
in patients with advanced incurable cancer admitted to an elderly care facility 
and has been validated to estimate up to 90 day mortality. Of interest is that 
the BCI incorporates vitamin B12 levels as a marker of prognosis; the authors’ 
rationale for this is that levels are elevated in myeloproliferative disorders, 
hepatocellular carcinoma and metastatic liver cancer. The BCI consists of two 
objective (biomarker) parameters, CRP and B12. However vitamin B12 is not 
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always analysed routinely in patients and this may reflect the lack of further 
research into this tool.  One study comprising 329 patients reported the 
prognostic accuracy of the BCI in patients with advanced cancer83. The patient 
population included those with a diagnosis of neurological, head and neck, 
lung, urological, haematological, gastrointestinal, gynaecological and breast 
cancers.  It reported statistical accuracy (log rank p<0.001) however, mortality 
rates differed from the sentinel study in that their mortality estimates did not 
fall into the 95% confidence intervals for the sentinel study.  It can be 
concluded that the BCI can predict survival independent of the conventional 
factors, but requires more external validation.   
Table 2-6 The BCI Tool 
Total BCI score = multiply serum vitamin B12 level (pmol/l) by serum CRP 
level (mg/l) 







The BCI score categorises patients into a risk group depending on score value.  
 
 
Palliative Prognostic Index (PPI) 
 
The PPI tool (Table 2-7) was developed in Japan in 1999, in patients with 
advanced incurable cancer. Depending on a patient’s PPI score, survival is 
divided into one of three groups and estimates survival up to 6 weeks. Risk 
group A (PPI score ≤4) has an estimated survival of more than six weeks. Risk 
group B (PPI score 5) has an estimated survival of less than six weeks but 
greater than three weeks. Risk group C (PPI score >6) has an estimated 
survival of less than three weeks. The PPI tool consists of nine subjective 
parameters (the Palliative Performance Scale [PPS], oral intake, oedema, 
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dyspnoea at rest and delirium) and reports the presence or absence of signs 
and symptoms, with similar weighting given to the different parameters. One 
of the parameters used is the PPS which is a prognostic tool in its own right.  
 
Nine studies comprising data on 6029 patients with advanced cancer looked 
at the prognostic value of the PPI.79,80,86-89,117-120 The patient groups included 
those with a diagnosis of lung, colorectal, breast, haematological, 
genitourinary, urological, hepatobiliary, gynaecological, haematological, 
gastrointestinal, and head and neck cancer.  
 
The studies were based in Japan (3 studies), Egypt (1 study), Italy (1 study), 
Taiwan (2 studies), USA (1 study) and Canada (1 study) thereby providing 
external validation of the tool. One study compared the performance of the PPI 
to other prognostic tools including the PaP, D-PaP and PPS, and other tools 
were found to be more accurate, in spite of the PPI showing statistically 
significant predictive capacity (p<0.01) 79. The survival of patients varies 
between different studies and differentiation of the three prognostic groups 
was noted to be difficult at times. Statistical methods for data analysis varied 
between all the studies and the heterogeneity of the results means direct 
comparison is difficult. The studies demonstrated the PPI aided survival 
prediction, however the accuracy was not uniform across the different PPI 
groups (HR range from 0.2 - 8.0). Indeed there is no consensus for the cut off 
points differentiating the three prognostic groups. Following on from this, more 
recent research has focussed on survival in relation to a change in the PPI 
score89. A worsening PPI score has consistently been found to demonstrate a 
3 week survival, a much shorter survival estimate compared with the other 
tools and more clinically relevant to the specialty of palliative medicine.  
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In conclusion, the PPI has been studied in 6029 patients and demonstrates 
accuracy in predicting survival; however consistency in the accuracy initially 
varied considerably in spite of fairly extensive validation when looking at PPI 
scores in isolation. A more recent approach is to review a change in PPI scores 
and this approach to researching the PPI appears more consistent, accurate 
and clinically useful.   
Table 2-7 The PPI Tool 































Longer than 6 weeks 
Shorter than 6 weeks 




The PPI tool gives a score based on clinical criteria being present which is used to estimate 3 
to 6 week survival. 
 
 
PPS (Palliative Performance Scale) 
 
The PPS (Table 2-8) was validated in a palliative care population in Canada. 
It was originally developed as a tool to measure functional status in palliative 
medicine and its indices reflect different aspects of a functional activity. It 
provides a percentage score based upon subjective indices giving a survival 
estimate up to 3 months. Survival accuracy of intermediate scores has been 
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noted to be variable. It consists of six subjective parameters. Many of these 
parameters are focussed on aspects of PS including ambulation, activity levels 
and PS itself. PS is the gold standard in assessing a patient’s fitness, therefore 
this tool is biased towards PS in that synonyms of PS are included as 
parameters (e.g. levels of ambulation, activity and self-care). One of the other 
parameters is conscious level, which could have been objectified by 
incorporating the GCS121.  
 
Nineteen studies comprising data on 21,672 patients with advanced cancer 
look at the prognostic value of the PPS. Patients included those with diagnoses 
of skin, central nervous system, haematological, colorectal, prostate, 
gastrointestinal, lung, gynaecological, genitourinary, head and neck, breast, 
urological and hepatopancreaticobiliary cancers. The studies were based in 
USA (7 studies), Spain (1 study), Canada (8 studies), Italy (1 study), Singapore 
(1 study) and South Korea (1 study) thereby providing external validation of 
the tool. In spite of variation in the reporting of the statistical methods, the PPS 
performed well in survival accuracy, however some of the results vary in 
significance. Hazard ratios vary from 0.39 up to 18.022. Due to the numerous 
subgroups within the tool, earlier studies in 2005 stated it was not highly 
discriminating in the intermediate scores. Studies taking place after 2005 
tackled this issue and focussed on the significance of a 10% decrement in PPS 
score or poorer PPS scores and demonstrated a strong ordering effect across 
the different PPS categories, with highly accurate scores for a PPS of 40% or 
less. Patients with PPS categories greater than 50% had lower hazard ratios 
than patients with lower PPS scores. The PPS was compared with the PPI and 
PaP and again its survival accuracy was noted to be best with a PPS of 30% 
or less. When the PPS was compared with the PaP, D-PaP and PPI, its 
accuracy was not greater than 50% in spite of subgroup analysis. Direct 
comparison with the PaP in another study showed similar hazard ratios for the 
PPS (0.214 – 0.722) and the PaP (0.279 and 0.476)78. 
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The PPS has been extensively studied in a large patient population with 
advanced cancer, including multiple cancer types. It has performed well in the 
majority of the studies looking at the tool individually, the only criticism being 
its better accuracy with lower PPS scores. It has also been compared several 
times with other prognostic tools with varying results and again demonstrates 
comparable accuracy to other tools with lower PPS scores. 
Table 2-8 The PPS Tool 
PPS Range Level of 
Function/condition 
 100% → 0% Normal → Death 
The PPS tool gives a percentage score based on level of functioning. 
 
 
The Glasgow Prognostic Score (GPS) and the modified Glasgow 
Prognostic Score (mGPS)  
 
The GPS was originally developed in patients with non-small cell lung cancer 
and subsequently refined to the modified GPS (mGPS) (Table 2-9). The GPS 
combines CRP and albumin to give a score of 0, 1 or 2, with increasing score 
suggesting decreased survival: CRP<10=0; CRP>10=1 (albumin >35); and 
CRP>10 + albumin<35 =2. It has been validated in individual cancer types in 
addition to large populations of patients with advanced incurable cancer 116. The 
GPS/mGPS is entirely objective as the information needed to calculate the 
score is based on biomarker results. The GPS/mGPS has been developed 
since the EAPC’s recommendations in 2005 and meets the requirements set 
that any prognostic tool is quick and easy to use, and its scoring system is very 
simple.   
 
Ten studies examining the GPS/mGPS (n=5163) have been performed in 
patients with advanced cancer, across a wide range of primary cancer types. 
39 
Chapter 2 Systematic Review 
Eight studies were from groups based in the UK, one study was from Japan 
and one study examined data from an international bio-bank of patients. There 
has, therefore, been extensive external validation of this tool. All the studies 
reported the accuracy of the GPS/mGPS using hazard ratios which ranged 
from 1.0 to 2.71. The GPS/mGPS has also been tested in individual cancer 
types, namely ovarian, gastro-oesophageal, pancreatic, renal and lung with 
similar survival accuracy, however these studies are out with the scope of this 
review. In terms of comparing the GPS/mGPS to other prognostic tools, 
comparison has been made with the PPI91 and PS116 (used in the PiPS, PPS, 
PaP, D-PaP and PPI tools)  and it performed similarly to PS in terms of 
prognostic accuracy.  
 
In conclusion, the GPS/mGPS has been studied extensively in a large cohort 
of patients with advanced cancer. It has been shown to predict survival 
independent of PS and has been externally validated. Its accuracy has been 
directly compared to the PPI, and has also been compared to PS, a key 
component of other prognostic tools. The GPS/mGPS is also able to predict 
survival accurately several months prior to death. It fulfils the EAPC’s 
recommendations of being quick and easy to use, along with robust evidence 
of its accuracy.  
Table 2-9 The GPS and mGPS Tools 
 CRP Alb Score 
GPS CRP <10 mg/L 
CRP > 10 mg/L 
Normal CRP 
CRP > 10 mg/L 
Albumin ≥ 35 g/L  
Albumin ≥ 35 g/L  
Albumin < 35 g/L  





mGPS CRP ≤ 10 mg/L 
CRP > 10 mg/L 
CRP > 10 mg/L 
albumin ≥ 35 g/L  
albumin ≥ 35 g/L  




The GPS/mGPS tools gives a score based on level of inflammation determined by C-reactive 
protein (CRP) and Albumin (Alb) levels. 
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Prognosis in Palliative Care Study (PiPS) 
 
The PiPS tool (Table 2-10) was developed in a UK population with locally 
advanced or metastatic cancer. There are two versions of the tool (PiPS A and 
PiPS B) and they differ in that PiPS B incorporates serum biomarkers when 
assessing survival. Data demonstrate that it predicts survival up to and greater 
than 55 days. The PiPS A has 13 subjective parameters whereas the PiPS B 
has nine subjective and eight objective (biomarker) parameters. Obviously the 
greater the number of parameters within a tool, the greater the information 
gained on the patient, which can assist in prognostication. Again the PiPS, 
similar to other tools, relies on subjective parameters, however in this case, 
they are orientated towards specific symptoms, signs and disease burden, and 
many are suggested by the EAPC as individual prognostic factors. The relative 
weighting of each of the prognostic factors is not available in the public domain, 
instead the tool is accessed electronically and a score issued. The strength of 
using a prognostic tool relies on utilising tools in which the evidence is clear 
and transparent.  
 
Two studies comprising 1220 (UK n= 1018, Korea n= 202) patients have been 
performed examining the PiPS. The patients included those with diagnoses of 
gastrointestinal, lung, unknown primary, breast, urological, gynaecological, 
central nervous system, haematological, and head and neck cancers. There 
has been external validation of this tool. One study measured survival 
accuracy using sensitivity (up to 64%) and specificity (up to 87.7%) 
predictions84. The area under the curve varied between 0.79 and 0.86. Direct 
comparison is difficult between the two studies. The smaller of the two studies 
concluded that the PiPS was superior to CPS. The larger study concluded that 
the PiPS was equal to if not better than the CPS. Overall, these data suggest 
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PiPS predicts survival in patients with advanced cancer, however further 
studies examining this and comparing it to other tools would be of interest.  
 
Table 2-10 The PiPS Tool 
PiPS A PiPS B Score 
Breast cancer 









Loss of weight in previous 
month 
ECOG (0-4) 
Global Health (1-7) 
Male Genital Organs 
Distant metastases 
Bone metastases 


















the indices is 
entered into 
electronic tool which 
calculates survival 
The PiPS tool gives an electronic score based on clinical criteria being present which is used 
to estimate survival 
 
 
2.4 Discussion  
 
Since the EAPC recommendations for prognostic tools were published in 
2005, there has been a multitude of prognostic tools developed and/or 
validated. Based on the findings of this systematic review, the prognostic tool 
which has been studied in the largest number of patients (n=21,672) is the 
PPS. Other prognostic tools which are notable in terms of their validation 
include the PaP, the PPI, and the GPS/mGPS, which have been studied in 
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more than 2000 patients with advanced cancer and predict survival, p<0.001. 
Based on the variety of tools available, the clinician is faced with the challenge 
of deciding which tool, if any, they should use. However, it would appear that 
these tools have not been incorporated into routine daily practice. Indeed, the 
KPS which was initially published in 1947, and refined through the Eastern 
Cooperative Oncology Group Performance Score, remains the most used and 
highly regarded in clinical practice122,123. The question, therefore, remains as 
to why such prognostic tools, reported here, are not widely used?  
 
One possible reason is that the majority of prognostic tools require multiple 
parameters, and many of these (e.g. CPS) are by definition, subjective. 
Furthermore, the multitude of tools now available, each using overlapping 
parameters, is confusing and makes comparison challenging.  
 
This systematic review addresses the question, by comparing all established 
prognostic tools for the first time. It is, therefore, a step towards recognising 
the importance of rationalising these subjective assessments into a simpler 
scheme with judicious selection and refinement of existing tools124.  
 
This review also demonstrates that the leading prognostic clinical and 
biomarkers recommended by the European Association for Palliative Care in 
2005, have been honed through validation to the PPI, the PPS, PaP and D-
PaP. New tools, namely the GPS/mGPS, have been developed which perform 
equally well and have been more extensively validated than some older tools 
which is contrary to PRISMA’s recommendation. Of note, however, is that the 
GPS/mGPS adheres most closely to the EAPC’s recommendation that a tool 
should be quick and easy to use.  
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However, nothing is faster and more easy to use than asking the clinician their 
survival prediction in a clinical setting. The CPS is one subjective parameter 
under much debate and is included in the PaP score. It has been argued that 
CPS is dependent on physicians having sufficient knowledge and experience 
to make this assessment adequately. The inclusion of CPS, therefore, does 
not detract from the PaP score being a unique combination of physician’s 
judgement, corrected and integrated with a series of other objective 
parameters, optimising the score. In spite of this, this tool is not used routinely. 
This may be due to its heavy reliance on CPS and perhaps clinicians do not 
need to use a tool which weights their existing opinion heavily, and therefore, 
they could argue, will not alter their survival estimate.  The other components 
of the PaP have been individually validated for their accuracy in estimating 
prognosis, however the individual weighting of each parameter is not known, 
given no study has compared every clinical and biomarker important in 
prognosis in advanced cancer.  Anecdotally, it is often said that the auxiliary 
healthcare assistants who perform daily personal care for patients are better 
at providing a survival estimate, compared to the clinician who sees the patient 
once they are presented to them after full personal care.  However it has been 
shown that the multidisciplinary team as a whole are better at predicting 
survival than one individual clinician, be that a doctor, nurse or other healthcare 
professional. 125. Again the heterogeneity of the studies examining survival 
accuracy of various members of the multidisciplinary team hampers further sub 
analysis. Healthcare assistants have been shown to be better able to predict 
imminent death compared to other members of the multidisciplinary team126. 
This proves the value of the clinicians, in ascertaining survival in a world where 
the use of technology is ever increasing. In palliative care it is the unique 
combination of empathy and care tailored to the individual which aids survival 
both quantitatively and qualitatively.   
 
It can be said that subjectivity and the inclusion of more subjective parameters 
is the short fall of incorporating the PPS into the PPI. A tool with many more 
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parameters may increase the prognostic accuracy, however it may increase 
bias and complexity, which may be counter-productive.  The components of 
this tool are heavily biased towards PS and disease burden, emphasising the 
importance of these objective clinical markers in prognosis.  
 
The PPS is not useful to the treating clinician in other respects due to having 
too many subgroups. A tool with many subgroups is only of use if the patient 
is being reviewed by the clinician with sufficient frequency to fall into all these 
groups where their deterioration and survival trajectory are able to be followed 
carefully. Realistically, patients are seen more frequently in palliative medicine 
and oncology compared to other specialties, however in a world where the 
population is increasing and ageing, the current practice may be difficult to 
sustain, and therefore the PPS may not be suitable to use in modern 
healthcare.  
 
A tool relying on objective parameters is attractive to a clinician, however the 
BCI is of no use clinically when vitamin B12 is not routinely tested in clinical 
practice unless there is a clinical indication. It could be argued that two simple 
blood tests help predict survival, however this tool is outperformed by the other 
tools both in terms of survival accuracy and validation.  
 
The GPS/mGPS is a tool which appears to match many of the desirable 
attributes of the tools in terms of survival accuracy, ease of use and objectivity 
and also incorporates two simple blood tests performed on a routine basis in 
patients regardless of the healthcare setting. These blood tests are cheaper to 
perform since they can be analysed in batches and are freely available in all 
UK laboratories irrespective of geography. In the clinical setting the 
GPS/mGPS is quick to calculate and may be preferred by more junior clinicians 
who can use this to estimate survival accurately, in spite of their own relative 
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inexperience in prognostication. Applicability of a tool in terms of ease of 
obtaining the relevant information and calculation speed are important issues 
to consider in a time pressured healthcare system.  
 
Many of the tools incorporate several parameters which, although may make 
it more laborious for the clinician to collate the information, have the advantage 
of accuracy of survival prediction. The PaP and D-PaP have the correct 
balance of objective and subjective parameters and have been validated in 
many populations. The treating clinician is more likely to trust these tools which 
incorporate objective clinical indices and are complementary to and value the 
addition of the clinician’s opinion and expertise in prognostication.  
 
Ultimately prognostication is used to guide patient care and the value of 
estimating survival of less than one month is important in the UK palliative care 
system, where there is a limited supply of inpatient palliative care beds. This 
is the advantage of the PPI which gives accurate survival estimates for a 
subgroup expected to survive less than three weeks.  
 
Identifying the optimal prognostic tool for use in patients with advanced cancer 
is challenging. In some ways the findings of this systematic review have made 
it less so by rigorously assessing the supporting evidence for each tool. 
However, the heterogeneity of the populations studied across the tools limits 
the strength of recommendation that can be made. For example, various 
settings (patients in a cancer centre versus those patients in a specialist 
palliative care unit), various tumour types (given, prognosis varies significantly 
in a patient with metastatic lung cancer versus one with metastatic breast 
cancer) and various survival methodology analyses (Hazard Ratio’s, PPV etc) 
means that a direct comparison of these tools is not possible.  
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Based on simplicity, its objective nature and similarity with PS in terms of 
survival prediction, the GPS/mGPS is placed in a favourable light. However 
the evidence within this review is insufficient to advocate its use over other 
existing prognostic tools116 116,127.   
 
The strengths of this review are that two researchers performed the data 
extraction of all the studies which looked at a broad array of patients with 
different cancers being looked after in different healthcare settings. This in-
depth review has resulted in a clear definition of the research priorities in this 
field.  
 
There are several limitations worthy of mention. Data looking at how well the 
tools performed in non-malignant terminal illnesses were excluded from the 
review. However, it could be argued that a tool which predicts death regardless 
of the underlying condition is more accurate and of greater use for all patients 
at the end of life. Studies were excluded if they were descriptive, that is 
qualitative research studies, and did not address survival accuracy related to 
individual tool scores. Other limitations were that the review selected only 
studies reported in the English language, excluded haematological 
malignancies and focussed on the adult populations. Direct comparison of the 
tools was limited due to heterogeneity of the results.  
 
Future research must therefore rigorously test and validate all the prognostic 
tools in all populations with all cancer types and compare them using the same 
statistical methods. The tools incorporating objective clinical indices, namely 
biomarkers, still require rigorous testing and validation in all populations and 
cancer types, using comparable statistical methods. Using the same 
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population to train and test a tool offers internal validation but more external 
validation is required to compare the different tools with each other. External 
validation is complex and time consuming, especially as it should be performed 
prospectively. The heterogeneity of the reporting measures in this review 
precluded direct comparison of all the prognostic tools, which is essential to 
compare their efficacy and accuracy, robustly.  Only some of the tools have 
been compared to each other. There is now a pressing need to rationalise such 
information and a prospective study is required to test all the tools in non-





The EAPC recommended there is an urgent need to rationalise core tools in 
patients with advanced cancer, that new tools are not required but that 
‘judicious selection and refinement of existing tools with appropriate properties 
should be advocated’128.  Since the report in 2005, it is clear that the decade-
old recommendations for developing and validating prognostic tools have been 
followed.  There is a greater awareness of the importance of accurate survival 
estimates demonstrated by ongoing validation of prognostic tools, with more 
of the tools being validated  incorporating biomarkers, all adhering to the 
recommendations of the EAPC. 
 
Evidence based medicine is now at the forefront of all clinical practice and the 
choice of prognostic tools used in patients with advanced cancer should not 
be an exception to this rule. This review demonstrates that although validation 
of prognostic tools has been performed, these tools are not yet ready for 
routine use in the clinic. Further validation was required in 2005 and some has 
occurred, however not enough for clinicians to incorporate the tools into their 
clinical practice. Prognosis remains a central tenet of care in cancer, and 
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validated tools, applied correctly, may serve to improve patient care. Future 
research should focus on the parameters of greatest prognostic significance 
from the best performing existing tools. They should then be tested and refined 
to create one accurate and simple tool with fewer parameters, which should 
then be validated in a prospective study rather than using retrospective data 
analysis of existing populations. 
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Chapter 3 Exploratory Analysis of Potential 
Prognostic Markers in Advanced Lung 
Cancer – a biobank analysis study 
 




By examining and comparing the available prognostic tools, it is clear there are 
numerous prognostic markers which, in combination, have been validated to be 
accurate in estimating survival. The literature review detailed in Chapter Two 
highlighted that the tools comprised of objective biomarkers perform equally as well 
as those comprised of more subjective clinical markers, and confirmed that 
inflammatory biomarkers have been demonstrated to help predict prognosis in 
advanced cancer, with the GPS/mGPS performing similarly to PS in terms of survival 
predictions63.  
 
This chapter reports a biobank analysis which was performed to focus on the 
prognostic markers of greatest significance in patients with advanced lung cancer. The 
purpose of this study was to perform retrospective analysis of an existing dataset of 
subjects with lung cancer, with the purpose of testing and potentially validating 
prognostic markers in advanced lung cancer.  The process could then be extrapolated 
to evaluate fully all prognostic markers in advanced cancer in a further prospective 
study which is outlined in Chapter 4.  
 
The majority of the tools utilise PS as a prognostic marker, yet it is a subjective index 
based upon information obtained by the clinician. However in spite of this, there is 
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clear reliance and bias towards PS and also weight loss, which are prognostic markers 
entrenched in current clinical practice.  
 
PS is an independent prognostic factor which is established in cancer and is often 
used to guide treatment 129. A PS is one of several criteria to be considered when 
treating patients with lung cancer130. The use of PS as a prognostic factor in lung 
cancer is particularly relevant as up to 40% of patients with lung cancer presenting at 
oncology clinics have an Eastern Cooperative Oncology Group (ECOG) Performance 
Status of 2 (defined as being ‘ambulatory and capable of self-care but unable to carry 
out any work activities; up and about for more than 50% of waking hours) 65,123. A PS 
of ECOG 2 is the minimum level of fitness required by a patient prior to being 
considered for treatment. Furthermore, patients with lung cancer are more likely to 
have a poor PS compared to those with other cancers131.  Indeed poor PS may also 
preclude patients from participating in clinical trials, thereby potentially excluding them 
from the opportunity to receive maximal treatment131.  
 
Although PS remains the gold standard prognostic marker and is used to guide 
treatment stratification, limitations such as its subjective nature have been the impetus 
for the development of objective measures of prognosis.   
 
There are numerous objective indices to stage and quantify the disease burden in a 
patient with cancer and many are themselves, predictive of survival. One clinical 
objective index which is measured routinely in oncology clinics including lung cancer 
clinics, is weight and the presence of weight loss. Weight loss is a very common 
symptom in lung cancer with 60% of patients having significant weight loss (10% loss 
of body weight) in the preceding six months132.  
 
Studies have linked weight loss in patients with lung cancer to reduced survival 
regardless of treatment received. In a study of patients receiving chemotherapy, those 
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with weight loss were less likely to complete their full cycle of chemotherapy treatment 
and more likely to experience toxicity from therapy, thereby reducing their opportunity 
to receive maximal anti-cancer treatment133. It is also recognised that patients with 
severe weight loss are often excluded from receiving concurrent chemo-radiotherapy, 
thereby precluding these patients from being administered possibly effective 
therapies134. Limitations of the treatments available and also the poor prognosis for all 
patients with lung cancer, will inevitably contribute to the increased psychological 
distress which patients with lung cancer are known to experience135. In lung cancer, 
patients with weight loss have greater levels of psychological distress, lower quality of 
life and increased levels of fatigue136.  Weight loss itself has been investigated and 
has been found to be an independent prognostic factor in patients with small cell lung 
cancer, non-small cell lung cancer and mesothelioma. Furthermore, stabilisation of 
weight during treatment for lung cancer can be associated with less disease 
progression in non-small cell lung cancer133, clearly demonstrating the importance of 
weight loss in this patient population. Therefore, in lung cancer weight loss has both 
symptomatic and prognostic relevance. 
 
Measures of the systemic inflammatory response have now been established as 
having independent prognostic value in cancer. Both CRP and albumin, two 
biomarkers of systemic inflammation, independently and combined as part of the GPS 
score, have been found to be of prognostic value in patients with advanced 
cancer116,137. The GPS has also been shown to be an independent predictor of survival 
in patients with inoperable lung cancer138. In addition, the GPS score has also been 
shown to correlate with weight loss in patients with advanced cancer137.  The mGPS 
score has also been shown to correlate with weight loss in patients with advanced 
cancer, and is associated with increased treatment toxicity, reduced treatment 
response and poor nutritional status139-141. The GPS must, however, be tested in a 
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Although weight loss, PS and the mGPS/GPS have each been shown to be of 
independent prognostic value in lung cancer, they have not been compared directly 
with each other.  
 
The primary aim of this study was to test and potentially validate these prognostic 
factors in patients with advanced lung cancer by analysing a biobank data set. A 
secondary aim was to assess if independent prognostic factors could be combined to 
improve survival prediction in patients with lung cancer. 
 
This study was of great importance to the thesis because methodologically it was a 
proof of concept study prior to the subsequent prospective study (Chapter 4). The data 
selection and analysis served as a platform on which to plan the subsequent 
prospective study.   
 
 
3.2 Materials and Methods 
 
The study was a retrospective analysis of a prospectively acquired biobank dataset 
which recruited consecutive patients from two University Hospitals in Greece: the first 
cohort was evaluated in the University Hospital of Herakleion between 6 February 
2006 and 12 October 2010 (with follow-up until 27 October 2011), and the second in 
University Hospital of Larissa between 30 March 2010 and 13 December 2013 (with 
follow-up until 1 June 2013). Whilst the data were collected by colleagues in Greece, 
data analysis was performed by the thesis author (CS). Ethical approval was granted 
for this study in Greece. 
 
Eligible patients were 18 years of age or older, had newly diagnosed advanced lung 
cancer (stage IV) and were due to start systemic anti-cancer therapy.   
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The following data were collected: sex, age, cancer type, body mass index (BMI), 
percentage weight loss in the preceding 3 months, PS, albumin, CRP, and survival 
status at follow-up.  
 
Age, percentage weight loss in the preceding 3 months, PS, CRP and albumin were 
categorized using standard thresholds to aid comparison and stratification of results.  
 
PS was measured according to the ECOG classification which ranges from grade 0 
(fully active) to grade 5 (dead).  ECOG grades 0 and 1 were grouped into one category 
owing to similar survival in these groups. Age was divided into patients under 65 years 
of age, between 65 and 74 years and greater than 74 years of age. Cachexia was 
defined as >5% weight loss, in line with the international consensus classification20.  
 
CRP and albumin values were used to calculate the mGPS score for each patient. The 
limit of detection for CRP was 5mg/L. The mGPS was calculated as follows: 
CRP≤10mg/L = 0, CRP > 10mg/L = 1, CRP > 10mg/L and albumin < 35g/L = 2.   
 
Statistical analysis was performed using SPSS version 19. All statistical testing was 
conducted at the 5% level, and 95% confidence intervals (CI) are reported throughout. 
Where n<10, these groups were not reported. 
 
Individuals’ demographic indices and categories were analysed and compared to their 
survival status.  Survival time was calculated in days and defined as the time from 
study entry until death, or censored if alive at follow-up date. Survival at 90 days was 
used as an outcome measure since clinical practice often uses an estimated survival 
of 90 days to decide between palliation and active treatment.. Survival curves were 
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plotted using Kaplan-Meier methods and the log-rank test was applied. Survival 
analysis was performed using Cox proportional hazards model and hazard ratios (HR) 
were calculated.  Multivariate survival analysis was conducted using a stepwise 
backward procedure to derive a final model of the variables that had a significant 
independent relationship with survival. Stratification by lung cancer histology was 
performed for the survival analysis.  Factors that were predictive of survival in the 
multivariate analyses were finally grouped together to assess whether they had better 
prognostic accuracy when grouped together. 
The study has been conducted and adheres to the Reporting Recommendations for 





There were 390 patients included and their demographics are detailed in Table 3-1. 
All patients had advanced lung cancer (all stage IV). The patients had non-small cell 
(n=288) (73.8%) or small cell lung cancer (n=102) (26.2%). The majority of patients 
were male (n=341, 87.4%) and the median age was 66 years (IQR 59-73). The median 
PS was 1 (IQR 1-2). Median survival was 7.8 months (IQR 3.5-13.6) reflecting the 
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Table 3-1 Patient Demographics (n= 390) 
Parameter n % Median (IQR) 
Sex (M/F) 341 / 49 87.4 / 12.6  
Primary Cancer Type 
Non-small cell lung 








Age (≤65/ 65-74/ ≥ 74years) 154 / 150 / 
86 





Survival (months)   7.8 (3.5-13.6) 
Weight loss in past 3 months 294 75.3 5.04 (0.8-10.2) 
Weight loss category in past 3 
months (%) 
Weight loss < 5.0% 











BMI (kg/m(2))   25.2 (22.5-
28.5) 
Performance Status (ECOG) (0-
1/2/3/4) 
  1 (1-2) 
(SD = standard deviation, IQR = interquartile range) (a defined as weight loss >5%) The table details 
patient demographics including sex Male (M) or female (F), cancer type including Non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC), number of patients in each age group, median 
survival, the presence of weight loss and degree of weight loss experienced, body mass index (BMI) 
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The minimum and median follow-up for survivors was 0.6 months and 12.8 months, 
respectively. At the time of cessation of data collection, 107 patients were alive and 
283 had died. The median weight loss in the previous three months was 5.0% (IQR 
0.8-10.2). The median BMI was 25.2 (IQR 22.5-28.5). The relationship between 
clinico-pathological factors and survival is illustrated in Table 3-2.  On univariate 
survival analysis, older age (p=0.004), male sex (p=0.009), histological subtype 
(p=0.007), weight loss (%) in the previous 3 months (p=0.001), PS (p<0.001) and 
mGPS (p<0.001) were significant predictors of survival. On multivariate analysis only 
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Table 3-2 The relationship between clinic-pathological factors and survival in patients with 
metastatic lung cancer (n=390) 









Sex (M/F) 341/ 49 87.4/12.6 0.60 (0.41-
0.88) 
0.009   
Age (≤65/ 65-74/ ≥ 
74years) 







(NSCLC vs SCLC) 
288/102 73.8/26.2 1.39 (1.10- 
1.77) 
0.007   
Weight loss (%) 
Category in past 3 
months (1/2)a 
195/195 50.0/50.0 1.49 (1.18- 
1.88) 
0.001   
Performance 
Status (ECOG)  
(0-1/2/3/4) 












(a Weight loss (%) category: 1 = weight loss <5%, 2= weight loss >5.1% (cancer cachexia)) The table 
details patient demographics including sex Male (M) or female (F), cancer type including Non-small cell 
lung cancer (NSCLC) and small cell lung cancer (SCLC), number of patients in each age group, median 
survival, the presence of weight loss and degree of weight loss experienced, body mass index (BMI), 
ECOG Performance Status summary(ECOG score of 0-4) and number of patients with mGPS scoring 
of 0-2. Hazard ratio (HR) and statistical significance for each variable detailed after testing on univariate 
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Figure 3-1, Figure 3-2 and Figure 3-3 show Kaplan Meier survival curves for weight 
loss, PS and mGPS respectively. Figure 3-1 shows that weight loss is associated with 
reduced survival (log rank p = 0.001). 
 
 
Figure 3-1 Kaplan Meier curve demonstrating the relationship between weight loss and 
survival. 
The graph details survival in months on x-axis and cumulative survival which is the probability of 
surviving on the y-axis. The blue line refers to the patients with a weight loss less than 5% in the 
preceding 3 months. The green line refers to the patients with a weight loss greater than 5% in the 
preceding 3 months. A weight loss greater than 5% in the preceding 3 months is associated with worse 
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Figure 3-2 shows that decreasing PS was associated with worse survival (log-rank p< 
0.001).  
 
Figure 3-2 Kaplan-Meier curve demonstrating the relationship between Performance Status 
and survival 
The graph details survival in months on x-axis and cumulative survival which is the probability of 
surviving on the y-axis. The blue line refers to the patients with an ECOG Performance Status of 0-1. 
The green line refers to patients with an ECOG Performance Status of 2. The grey line refers to patients 
with an ECOG Performance Status of 3. The purple line refers to patients with an ECOG Performance 
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Figure 3-3 shows that increasing mGPS was associated with poorer survival (log-rank 
p< 0.001). 
 
Figure 3-3 Kaplan-Meier curve demonstrating the relationship between mGPS and survival 
Figure 3-3 shows that increasing mGPS was associated with poorer survival (log-rank p< 0.001). The 
graph details survival in months on x-axis and cumulative survival which is the probability of surviving 
on the y-axis. The blue line refers to the patients with an mGPS score of 0. The green line refers to 
patients with an mGPS score of 1. The grey line refers to patients with an mGPS of 2. An mGPS score 
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Table 3-3 shows the relationship between survival at 90 days and mGPS and PS. 
Survival was compared across all categories for both mGPS and PS.  
 
Table 3-3 Relationship between mGPS, PS, and survival at 90 days 


























































The table details the relationship between worsening ECOG Performance Status and increasing 
mGPS score. The lowest row demonstrates the 90 day  survival relationship between any PS and 
worsening mGPS score. The end column demonstrates the 90 day survival relationship between any 
mGPS score and worsening ECOG Performance Status. Each percentage details the number of 
patients alive at 90 days. Where n<10, analysis was not performed.  
 
 
On multivariate analysis only PS (HR 1.74 CI 1.50-2.02) and mGPS (HR 1.67, CI 1.40-
2.00) predicted survival (p<0.001). For PS, survival at 90 days  ranged from 99% 
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(ECOG 0-1) to 74% (ECOG 2). For mGPS, survival at 90 days ranged from 99% 
(mGPS0) to 71% (mGPS2). When used in combination, survival at 90 days ranged 





The results of this study show that older age, male sex, weight loss, histological cancer 
type, poorer PS and markers of the systemic inflammatory response (mGPS), all have 
prognostic value in patients with advanced lung cancer. PS and the mGPS carry the 
greatest prognostic value, however it is of interest that the mGPS has strong 
prognostic accuracy and performs almost identically to PS. In addition, the 
combination of PS and mGPS points to a potential new approach to prognostication 
in advanced lung cancer.   
 
PS (measured either by Karnofsky or ECOG classification) still remains the gold 
standard prognostic measure and the results of the present study support this143,144.  
However, the key limitation of PS is that it is an entirely subjective assessment of a 
patient’s physical activity and functioning129,145,146.  It has been shown that marked 
discrepancies often exist between clinicians’ and patients’ assessments of PS147. 
Furthermore, clear inter-observer variability has been demonstrated148. Therefore it is 
important that the limitations of using a prognostic measure which is subjective and is 
variable, such PS, are considered. This aspect is of fundamental importance when the 
majority of treatment decisions in advanced lung cancer are deeply influenced by PS.    
 
These findings demonstrate that the mGPS has independent prognostic value in 
advanced lung cancer, however a potential advantage over PS is that it is objective 
and is not subject to inter-observer bias138.  It is simple to measure, inexpensive and 
is widely available. Used either in isolation or, perhaps in combination with PS, the 
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present findings demonstrate its relevance in increasing accuracy of survival 
prediction in metastatic lung cancer137. This has also been shown in other cancer 
types116.  
 
Weight loss has long been regarded a “poor” prognostic sign in lung cancer. This study 
specifically examined weight loss greater than 5%. Cancer cachexia is defined as 
weight loss greater than 5% and felt by many to be the most adverse weight-related 
prognostic factor in cancer. However the findings suggest that the use of weight loss 
as an early, prognostic factor in lung cancer is of considerably less value compared to 
both PS and mGPS and therefore it could be suggested that weight loss should not 
be assessed routinely in the clinic. For this to happen it would potentially mean a 
change to current practice, as weight loss is a source of concern for patients, families 
and clinicians. It is regularly recorded at clinic appointments and may be used as a 
trigger for additional investigations (suspected disease recurrence or progression) and 
dietetic referral, or as a starting point for end of life discussions. In addition, the 
confirmation of weight loss in cancer is often upsetting for patients and they should 
receive information regarding how to manage it.  
 
Although weight loss has traditionally been thought of as a prognostic factor, its role 
may be limited. The findings demonstrate that PS and mGPS perform better than 
weight loss and are both independent predictors of survival in lung cancer. This study 
does confirm that weight loss is an important patient factor in lung cancer and also 
showed that the majority of patients with lung cancer experience weight loss; however 
other patient parameters are more strongly linked to survival. There are other studies 
looking at many cancer types which have demonstrated weight loss to be adversely 
associated with prognosis149. Weight loss has been identified as an independent 
prognostic marker for survival in patients with pancreatic cancer in one study150 and 
high weight loss has been shown to correlate with poor prognosis in patients with 
gastrointestinal cancer151. Yet in other research, weight loss has not been shown to 
be an independent prognostic variable in pancreatic cancer152. There has also been 
conflicting evidence in hospice patients with advanced cancer stating that weight loss 
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is linked to survival and other research stating it was not shown to be a statistically 
significant predictor of prognosis153.  
 
Weight loss is clinically important in patients with cancer, however weight loss per se 
does not distinguish between a loss of lean mass (muscle) and loss of fat mass.  These 
aspects of weight loss are very important in patients with cancer and may explain why 
there is conflicting evidence on the impact of a patient’s overall weight and weight loss 
on prognosis in advanced cancer154. 
 
A patient with weight loss in combination with anorexia and systemic inflammation can 
be labelled as having cancer cachexia152. Cancer cachexia is a multifactorial clinical 
syndrome in which there is loss of skeletal muscle mass which may be accompanied 
by loss of fat mass. The diagnostic criteria for cachexia are weight loss greater than 
5% or weight loss greater than 2% in individuals already showing depletion according 
to bodyweight and height (Body Mass Index<20kg/m2) or skeletal muscle mass 
(sarcopenia)155. The relevance of this is that cachexia is associated with poor 
prognosis in patients with cancer151. Cachexia is also present in 50% of patients who 
have active cancer and 80% of patients at the time of death156.  
 
In this study, the majority of patients (75.3%) had experienced weight loss in the 
preceding 3 months with a mean weight loss of 6.89%, which meets the diagnostic 
weight loss criterion for cachexia. There was also a clear association between 
systemic inflammation measured using the mGPS, and survival in this group of 
patients. The findings also demonstrate that cachexia (as per current definition) 155 
and BMI did not offer additional prognostic value in the presence of PS and mGPS. 
However, if these factors have limited prognostic use, their relative value should be 
re-evaluated.  This emphasises and also adds to the argument that a large component 
of cancer cachexia, a syndrome of weight loss associated with anorexia and systemic 
inflammation, is driven by systemic inflammation. It is significant because it is already 
known that high levels of systemic inflammation are associated with poor prognosis in 
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patients with advanced cancer113. Anorexia, another component of cachexia, is 
independently associated with an adverse prognosis in patients with cancer, 
irrespective of its link to the anorexia-cachexia syndrome53. The contribution that each 
of the components of cachexia contributes to survival is not clear, however the study’s 
results clearly demonstrate that systemic inflammation, which is a component of 
cachexia, is strongly related to survival in patients with cancer. Attempts have been 
made to improve cachexia either through parenteral nutrition or a multimodal 
approach, and monitoring the effect of both on systemic inflammation and cachexia 
management, in the hope that there is improvement in the patient’s tolerance of cancer 
treatment and prognosis33,157.  
 
There are other markers of systemic inflammation but the mGPS has been 
consistently tested and proven to demonstrate a strong association with prognosis 
regardless of tumour type116. PS was also shown to be equally significant on 
multivariate analysis in predicting prognosis in patients with advanced cancer. The 
statistical handling of the data results in this study has resulted in rigorous testing of 
the effect of mGPS and PS in prognostication in advanced cancer. In patients with 
cancer cachexia, the mGPS can be used as a composite summary of systemic 
inflammation and therefore inform the clinician on the degree of active inflammation 
impacting upon their cancer cachexia and prognosis. This could help guide treatments 
for cancer cachexia, specifically guiding when to intervene and attempt to alter the 
progression of systemic inflammation, which in turn could aid and advise the 
opportunities and appropriateness for maximal therapeutic treatment, or optimal 
supportive care, when looking after patients with cancer.  Early recognition of cancer 
cachexia through monitoring systemic inflammation associated with cancer cachexia 
could permit the early intervention of nutritional support, physical activity and reduce 
the systemic inflammatory response, the multimodal interventional approach to 
cachexia. Identifying and targeting each component of cancer cachexia is thought to 
be crucial in altering prognostic outcomes in patients with advanced cancer.  
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Other studies have demonstrated the prognostic importance of weight loss in patients 
with lung cancer and other cancers, which is not seen in this study’s cohort of patients. 
This may be due in part to the small sample size which also focussed on lung cancer 
and did not include all tumour types. Other studies have included populations of 
patients with much greater percentages of weight loss.  Specifically, the current study 
did not include gynaecological cancers or breast cancer. Much of the research linking 
weight changes to prognosis has been performed in patients with endometrial, 
cervical, breast and ovarian cancers and therefore the tumour types studied limit how 
the results can be extrapolated to apply to patients with different cancer types.  
 
There is an urgency for improved survival prediction in metastatic lung cancer. Recent 
work has demonstrated that approximately 10% of metastatic lung cancer patients 
receive anti-cancer therapy in the last 30 days of life, and patients with the shortest 
survival time after diagnosis received more anti-cancer therapy near the end of life67. 
A key consideration in deciding appropriate treatment in an advanced lung cancer 
patient is prognosis. In these patients, the benefits of anti-cancer therapy must be 
weighed against potential disadvantages, such as multiple hospital visits, adverse side 
effects and potentially life-threatening toxicity. Accurate assessment of prognosis is 
needed to inform such complex decisions between patients and clinicians.  
 
The results of the present study show that the combination of mGPS and PS are more 
accurate in survival prediction than either in isolation. It has been shown in other 
cancer types and has now been demonstrated in advanced lung cancer116. Using the 
combination of mGPS and PS may have considerable application in considering 
treatment options in advanced lung cancer; for example when to use chemotherapy in 
patients near the end of life. This approach has been supported in recent work which 
has shown the value of using the mGPS as a stratification factor in very advanced 
disease to reduce chemotherapy use67. The present study takes this approach one 
step further by combining mGPS with PS, to increase prognostic accuracy. This novel 
approach could then be used to guide the choice of oncology treatment in advanced 
lung cancer patients. 
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The present study has several limitations. There was a high proportion of men and 
SCLC in the cohort studied in keeping with the epidemiology of lung cancer in Greece. 
Furthermore, not all previously studied prognostic factors in advanced NSCLC have 
been examined. However as PS remains the gold standard prognostic marker in use 
clinically, its inclusion here is important. Details on cancer treatment are not available 
which would be of interest to assess the effect of response of chemotherapy in patients 
in poor prognostic groups. Although weight loss was examined, loss of lean mass as 
a component of this, was out with the remit of this thesis. The prognostic value of lean 





To conclude, weight loss is obviously a key parameter of the cachexia syndrome, 
however it does not distinguish between loss of lean mass and fat mass. As such while 
it may have prognostic value, in the setting of lung cancer, it is less useful than other 
factors such as PS or the mGPS  which are superior prognostic factors in metastatic 
lung cancer and, in combination, increase survival prediction in advanced lung cancer.   
With regard to the mGPS, the ability to calculate and determine objectively the severity 
of systemic inflammation, a key component of cancer cachexia, serves as a far more 
useful parameter and prognosticating tool, throughout all stages of a patient’s illness 
with cancer. 
This study demonstrates that markers of systemic inflammation predict survival in 
advanced lung cancer. The next step is to compare directly the markers of systemic 
inflammation in cancer to other clinical and biomarkers of proven prognostic 
significance in all types of cancer. 
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Chapter 4 IPAC study: Inflammatory biomarkers in 




It is clear that prognostication in cancer is possible, however accuracy of survival 
prediction depends on the accuracy of the tools or individual prognostic indices. The 
evidence from the systematic review and retrospective biobank analysis has 
highlighted a wide variety of prognostic factors, as determined by univariate and 
multivariate survival analyses, which predict survival in advanced cancer. Many 
individual prognostic markers can be viewed as surrogate markers of inflammation. 
 
Some prognostic markers are of greater significance than others. This has been 
demonstrated by the biobank analysis where on univariate analysis weight loss 
demonstrated prognostic accuracy, however it was outperformed by the mGPS and 
PS. There are numerous prognostic markers identified thus far in this thesis. Which 
tool or marker is best is as yet undetermined and in spite of much research they have 
not yet been directly compared in a single study. In order to refine prediction of 
prognosis in patients with advanced incurable cancer, a multicentre prospective 
observational study was performed; Inflammatory biomarkers in Prognosis in 





The aim of the IPAC study was to examine fully all the prognostic clinical indices and 
biomarkers already established as having independent prognostic value in the 
systematic review and biobank analysis, and determine which are most predictive of 
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survival in patients with advanced cancer. The study would assess all the validated 
prognostic factors in a prospective observational study. Thereafter this study aimed to 
determine which prognostic marker is of greatest significance in estimating survival in 





4.3.1 Study Setting 
 
The study was designed as a national multicentre study conducted in 16 oncology and 
palliative care units throughout the UK (including Scotland, England and Wales), all of 
which were coordinated from a single centre (Edinburgh). The centres were specialist 
palliative care in-patient units, specialist palliative care outpatient clinics, oncology in-





Ethical approval was granted by the National Ethics Committee (UK – 12/SS/0181) 
and was conducted in accordance with the Declaration of Helsinki and ICH GCP. All 
patients provided written informed consent. Data were collected between January 
2013 and September 2016. Patients were followed up for a minimum of three months 
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4.3.3 Inclusion and Exclusion Criteria 
 
Inclusion criteria were:  
 Patients 18 years old or greater 
 Advanced incurable cancer. (Defined as having metastatic disease 
[histological, cytological or radiological evidence] or those receiving anti-cancer 
therapy with palliative intent.)  
 Able to provide written informed consent 
 Able to provide a blood sample  
 ECOG (Eastern Cooperative Oncology Group) Performance Status 1-465.  
 
Exclusion criteria were: 
 ECOG Performance Status 0 (since they would be expected to outlive the 
length of the study) 
 Breast or prostate carcinomas with only bone metastases (owing to potentially 
long survival times, often measured in years, patients would potentially be 
expected to survive beyond the duration of study follow up) This was due to the 
fact that in many patients with breast or prostate cancer, metastatic bone 
disease is a chronic condition with an increasing range of treatments available 
to slow the progression of the underlying disease. The survival from the time of 
diagnosis varies among different tumour types. The median survival time from 
diagnosis of bone metastases from prostate cancer or breast cancer is 
measurable in years. The median survival for these patients was expected to 
extend beyond the duration of the study.  
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 Lack of capacity to consent (including patient with confusion, patients being 
treated under the Adults with Incapacity (Scotland) Act 2000 or patients being 
treated under the Mental Capacity Act (England and Wales) 2005).This was 
due to approval not being granted for the inclusion of patients with delirium by 
the National Ethics Committee.   
 
The study was officially opened in January 2013 and was open to recruitment for 30 
months (2 years and 6 months) until June 2016. Patients recruited into the study at 
the end of the recruitment period in June 2016 were reviewed for three months and 




4.3.4 Study Assessments 
 
Evaluation of patients 
 
Eligible patients who consented to take part in the study were registered on a secure 
web-based portal specifically designed for the IPAC study by the University of 
Edinburgh’s Wellcome Trust Clinical Research Facility, and baseline information 
entered. Patients were assigned a patient identifier number for the study by the 
website. After registration and enrolment, an electronic Case Report Form (CRF) was 
generated for each patient detailing the assessments to be performed.  
 
At baseline the assessment included a complete history and examination, 
demographic patient data, disease details, KPS158, ECOG Performance Status65, a 
timed up and go test, Clinician predicted survival, the European Organisation for the 
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Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-
C30) for global health, cognitive impairment and anorexia, ESAS (the Edmonton 
Symptom Assessment System) for dysphagia and xerostomia159, physical 
examination of peripheral oedema and ascites, height, weight, weight loss in the 
previous three months and a venous serum blood sample were performed. The 
baseline blood analyses included CRP, Albumin, WCC (including neutrophil and 
lymphocyte counts) and LDH. Blood was also taken and stored for future genotyping, 
DNA and RNA extraction and genomic analysis.  
 
Demographic patient data and disease details 
 
Demographic details of the patient including age, sex, current place of care (e.g. home, 
hospice, hospital) and disease details were recorded. The primary site of the cancer, 
histological type, tumour stage and sites of metastases if known were collected. 
Previous treatments with number of cycles of chemotherapy and total radiation therapy 
dosage administered (measured in Gray) were listed. Drug history including any 




The work performed prior to the study opening informed which prognostic variables 
were most accurate and these variables formed the basis of the assessment. 
 
KPS was recorded. The KPS is a subjective assessment of a patient’s ability to 
perform activities of daily living. Objective assessments of PS were also performed. 
These included a timed ‘up and go’ test which measured the time taken for a patient 
to rise from a chair, walk 3 metres, turn around, walk 3 metres back to the chair and 
return to the original sitting position. A two minute walk test was undertaken and the 
distance walked measured. If patients were not able to complete or attempt these 
activity assessments, this was recorded.  
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Patients’ symptom severity scores were recorded for the symptoms of dysphagia and 
xerostomia. The severity of each was rated according to the Edmonton Symptom 
Assessment Scale which varies from 0 (none present) to 10 (worst possible severity 
present)159.  
Physical examination signs detected on clinical examination, namely the presence or 
absence of dependent pitting oedema (sacral or peripheral leg/ankle) and ascites, 
were recorded. Evidence of the presence or absence of ascites was also obtained 
from radiological CT reports, if available. Patients were asked about whether they had 
experienced any weight loss in the preceding three months and if so, then asked to 
quantify the amount lost.  Weight and height measurements were taken at the time of 
the baseline assessment.  
The quality of the patient’s life was formally assessed using the EORTC-QLQ-C30 
questionnaire160, which is specifically designed to assess the quality of life of cancer 
patients161. Formal permission was granted to use this questionnaire as part of the 
study assessment.  
 
Clinician predicted survival 
 
The treating clinician was asked to estimate survival by selecting a category. The 
categories were days (less than 2 weeks), weeks (2 to 8 weeks) and months (greater 
than 8 weeks).  The estimate was recorded along with the clinician’s sex, specialty, 
age, seniority, number of years of experience in palliative medicine or oncology, and 




Patients were given the option of giving a sample of venous blood for biomarker 
analysis. Biomarkers analysed included CRP, albumin, LDH and WCC including 
lymphocyte and neutrophil counts.  
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Follow up information 
 
Patients were followed up for the remainder of the study or for a minimum of 3 months. 
Survival status was recorded at the end of the follow up period and if the patient was 




Analysis modelling included Cox proportional hazard models and logistic regression 
models. Univariate log regression was used to examine individual clinical and 
biomarkers. Multivariate log regression was used to examine the significant variables 
on univariate analysis. Kaplan Meier plots and log rank statistics were used to examine 
survival times. Multivariate Cox proportional hazard models were used to examine 
variables when building a multivariate log regression model. 
 
A database was constructed based upon the information collected in the online case 
report form managed by the Edinburgh’s Wellcome Trust Clinical Research Facility. 
Data were checked for accuracy in the event of outlying values and also checked for 
any missing values by a statistician at the Edinburgh Clinical Research Facility. The 
database was only accessible by the statistician and queries were passed onto the 
study team for clarification. The primary objective was to compare the prognostic value 
of the aforementioned clinical and laboratory factors. The secondary objectives were 
to assess if such factors had independent prognostic value and could be combined to 
improve prediction of survival at 30 days and 3 months from study entry.  These time 
points were chosen as clinically relevant for the management of patients with 
advanced cancer.  
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The following were grouped according to specific thresholds.  The mGPS was grouped 
as: CRP <10 mg/L = 0, CRP >10 mg/L = 1, CRP >10 mg/L and albumin < 35 g/L = 2.  
Weight loss was grouped as follows: <2.5%, 2.5-5.9%, 6-10.9%, 11-14.9, >15% 
according to thresholds described by Martin et al162.  White cell count (WCC), 
Neutrophil count (NC) and Lymphocyte count (LC) were categorised as above or 
below/equal to normal limits.  LDH was classified as abnormal if >250 U/L. EORTC 
QLQ-C30 scores were calculated using scoring procedures as described by Aaronson 
et al161. EORTC QLQ-C30 scales were analysed as discrete categories representing 
underlying continuous constructs and Patient Reported Outcome Measures (PROMs) 
(symptoms and quality of life variables) were defined as being present if the score was 
greater than 50. CPS was categorised into days [<14days], weeks [15-56 days] or 
months [>57 days]). For categorical variables with >2 categories (e.g. mGPS, ECOG-
PS, weight loss, CPS) these were treated as continuous variables in terms of Hazard 
Ratios in line with their proven prognostic value. The survival time was defined as the 
number of months from study entry until death, or censored if patients were alive at 
follow-up date.  
 
Univariate logistic regression was used to examine whether the clinical and/or 
biomarkers were predictive of death at 30 days and three months post consent.  
Multivariate survival analysis was done using a stepwise forward conditional 
procedure to derive a final model of markers that had a significant independent 
relationship with survival at 30 days and 3 months. Only variables with a p<0.1 were 
included in the model. To examine how biomarkers were related to either mGPS or 
ECOG-PS, Chi-Square tests (and Chi-Square tests for trend when appropriate) or 
Analysis of Variance (ANOVA) were used. All statistical testing was done at the 5% 
significance level with 95% confidence intervals reported. Statistical significance was 
taken as p<0.05 and all analyses were performed using IBM SPSS Version 23.0 
(SPSS, Chicago, IL). Where appropriate mean and standard deviations (SD) or 
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4.3.5 Sample Size Calculation 
 
The study was designed with the intended sample size of 500 patients which was 
determined to provide adequate statistical power by a statistician (ST) based at the 
Edinburgh’s Wellcome Trust Clinical Research Facility. Binary logistic regression is 
one of the most frequently applied statistical approaches for developing clinical 
prediction models. It relies on an Events Per Variable criterion (EPV), notably EPV ≥ 
10 to determine the minimal sample size required and the maximum number of 
candidate predictors that can be examined. As with logistic regression, Cox regression 
is a large sample method and the sample size needs to be large enough for the 
analysis to be valid. Simulations have been performed which indicated that, for Cox 
regression as for logistic regression, the total number of events is the key factor rather 
than the total sample size. Hence the number of deaths or survivors, whichever is 
smaller, needs to be large enough. It has been recommended that a sample should 
contain at least 10 events per variable used in a Cox regression equation163.  In this 
study it was estimated that there will be 25 events per parameter to plan the intended 
sample size, when using logistic regression to predict survival beyond the median 
survival time, , which compares favourably with the conventional guideline that one 





Five hundred and thirty nine (539) patents were enrolled into the IPAC study between 
January 2013 and September 2014. Seven patients were missing assessment 
information and therefore were excluded from analysis. A total of 532 patients were 
analysed. Full data on ECOG-PS, mGPS and CPS were available on 478 patients.  
The clinicopathological characteristics of the patients with advanced cancer is shown 
in Table 4-1. The mean (SD) age was 67.04 (12.08) years and 256 (54%) patients 
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were female. The minimum and median (IQR) follow up for survivors was 0 days and 
198 (137-273) days respectively. When study data collection stopped 194 (41%) 
patients were alive.  The median (IQR) survival was 4.3 (1.86-7.03) months. The most 
common cancer type was lung, present in 163 (36%) patients, and metastases were 
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Table 4-1 Clinicopathological characteristics of patients with advanced cancer (n=478) 
Parameter n (%) 
 Age (<65, 65-74, >74) 191(40), 140(29), 147(31) 
 Female  256 (54) 
Place of care 
  Home 341(71) 
  Hospital 30 (6) 
  Specialist Palliative Care Unit 93 (19) 
  Other 14 (3) 
Primary Cancer 
  Neurological 9 (2) 
  Lung 163 (36) 
  Gastrointestinal 99 (21) 
  Urological 23 (5) 
  Gynaecological 23 (5) 
  Melanoma 28 (6) 
  Haematological 10 (3) 
  Breast 50 (11) 
  Unknown Primary 8 (3) 
  Other 18 (4) 
Clinician Predicted Survival* 
    Days   8/463 (2) 
    Weeks  87/463 (19) 
    Months  368/463 (79) 
Performance Status (ECOG) 
1, 2, 3, 4 189(39), 201(42), 72(15), 16(3) 
mGPS 
0, 1, 2 178 (37), 99(21), 201(42) 
Patient Reported Outcome Measures [EORTC score, median (IQR)] 
Dyspnoea present  139/461 (30); [33 (0-67)] 
Global Health impaired 217/459 (47); [83 (50-100)] 
Cognitive impairment  331/461 (72); [83 (50-100)] 
Anorexia  159/461 (34); [33 (0-67)] 
Distant Metastases present 377/446 (85) 
Weight loss last 3 months (%) 
<2.5, 2.5-5.9, 6-10.9,11-14.9, >15 272(57), 31(7), 60(13) ,42(9), 
57(12) 
Biomarkers [median (IQR)] 
Elevated LDH (>250 U/L) 335/446 (75%); [394 (251-557)] 
Elevated White Cell Count (>11 x109/L) 124/470 (26%); [7.7 (5.6-11.4)] 
Elevated Neutrophil Count >7.5 x 109/L 148/469 (32%); [5.2 (3.5-8.8)] 
Elevated Lymphocyte Count >3.0 x109/L 
 
20/469 (4%); [1.2 (0.8-1.70)] 
The table details patient demographics including age, sex, place of care, primary cancer site, Clinician 
Predicted Survival, ECOG Performance Status, mGPS scoring, Patient reported Outcome Measures 
obtained from the European Organisation for Research and Treatment of Cancer Quality of life 
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Questionnaire Core 30 score, the presence of metastases, the percentage of weight loss in the 




The relationship between clinicopathological factors and survival at 30 days and 3 
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Table 4-2 The relationship between clinicopathological factors and survival (30 day and 3 month) in patients with advanced cancer 
The table details patient demographics including age group, sex, clinician predicted survival, ECOG Performance Status, mGPS score, Patient Reported 
Outcome Measures, percentage weight loss in the preceding 3 months and biomarker results.  Hazard ratio (HR) and statistical significance for each variable 
detailed after testing on univariate analysis for both 30 day and 3 month survival. Table was composed jointly with BL. 
 
 Death at 30 days Death at 3 months 
  Univariate  Univariate 
 % HR (95% CI) P % HR (95% CI) P 
Age (<65/65-74/>74) 13/13/18 1.23 (0.92-1.63) 0.16 28/39/37 1.19 (1.00-1.43) 0.056 
Sex (male/ female) 16/13 0.78 (0.49-1.26) 0.31 39/31 0.76 (0.56-1.04) 0.084 
Clinician Predicted Survival*       
Days/Weeks/Months  100/37/8 0.15 (0.10-0.22) <0.001 100/72/25 0.20 (0.15-0.26) <0.001 
Performance Status (ECOG)       
1/2/3/4 2/13/38/75 3.71 (2.84 -4.85) <0.001 13/37/71/94 2.90 (2.42-3.47) <0.001 
mGPS       
0/1/2 2/14/26 3.15 (2.13-4.65) <0.001 9/38/55 2.57 (2.08-3.19) <0.001 
       
Patient Reported Outcome Measures       
Dyspnoea (N/Y) 10/22 2.32 (1.41-3.82)  0.001  26/49 2.26 (1.64-3.11) <0.001 
Global Health (N/Y) 19/8 0.40 (0.27-0.69)  0.001  43/24 0.46(0.33-0.64) <0.001 
Cognitive Impairment (N/Y) 21/10 0.45 (0.27-0.75)  0.002  42/29 0.61 (0.44-0.85) 0.003 
Anorexia (N/Y) 10/20 2.21 (1.34-3.63)  0.002 26/46 2.09 (1.52-2.88) <0.001 
Distant Metastases (N/Y) 10/15 1.57 (0.72-3.45)  0.56  33/36 1.14 (0.73-1.77) 0.56 
Weight loss last 3 months (%)       
<2.5/2.5-5.9/6-10.9/11-14.9/>15 13/3/10/7/32 1.21(1.04-1.41) 0.017 28/23/37/45/56 1.26 (1.14-1.39) <0.001 
Biomarkers       
LDH <=250/>250 U/L 5/18 3.50 (1.51-8.11) 0.003  15/40 3.09 (1.86-5.11) <0.001 
White Cell Count <=11/>11 x109/L 7/33 5.53 (3.24-8.76) <0.001  24/60 3.54 (2.59-4.84) <0.001 
Neutrophil Count <=7.5/ >7.5 x 109/L 7/29 5.23 (3.12-8.56) <0.001  23/57 3.45 (2.52-4.72) <0.001 
Lymphocyte Count <=3.0/>3.0 x109/L 14/10 0.71 (0.18-2.88) 0.63  35/15 0.39 (0.13-1.29) 0.11 
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On univariate analysis, the following factors predicted death at 30 days: CPS 
(p<0.001), ECOG-PS (p<0.001), mGPS (<0.001), dyspnoea (p=0.001), global health 
(p=0.001), cognitive impairment (p=0.002), anorexia (p=0.002), weight loss (p=0.017), 
LDH (p=0.003), WCC (p<0.001) and NC (p<0.001). The following factors predicted 
death at 3 months: CPS (p<0.001), ECOG-PS (p<0.001), mGPS (p<0.001), dyspnoea 
(p<0.001), global health (p<0.001), cognitive impairment (p=0.003), anorexia 
(p<0.001), weight loss (p<0.001), LDH (p<0.001), WCC (p<0.001) and NC (p<0.001) 
(Table 4-3). 
 
The multivariate analysis of survival at 30 days and 3 months is shown in Table 4-3. 
The following factors independently predicted death at 30 days: ECOG-PS (HR 2.15, 
95%CI 1.40-3.30, p<0.001), mGPS (HR 2.03, 95%CI 1.23-3.35, p=0.006), and NC 
(HR 3.18, 95%CI 1.67-6.01), p<0.001). The following factors independently predicted 
death at 3 months: ECOG-PS (HR 1.91, 95%CI 1.47-2.49, p<0.001), mGPS (HR 1.77, 
95%CI 1.36-2.31, p<0.001), weight loss (HR, 1.15, 95%CI 1.03-1.29, p=0.013), LDH 
(HR 2.00, 95%CI 1.15-3.47, p=0.013) and WCC (HR 2.50, 95%CI 1.71-3.66, p<0.001). 
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Table 4-3 The relationship between clinicopathological factors and survival (30 day and 3 month) in patients with advanced cancer: univariate and 
multivariate analysis 
The table details patient demographics including age group, sex, clinician predicted survival, ECOG Performance Status, mGPS score, Patient Reported 
Outcome Measures, percentage weight loss in the preceding 3 months and biomarker results.  Hazard ratio (HR) and statistical significance for each statistically 
significant variable after testing on univariate and multivariate analysis for both 30 day and 3 month survival. The table has removed the results for non-
statistically significant prognostic markers on multivariate analysis. Table was composed jointly with BL. 
 Death at 30 days Death at 3 months 
 Univariate Multivariate Univariate Multivariate 
 HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Age (<65/65-74/>74) 1.23 (0.92-1.63) 0.158   1.19 (1.00-1.43) 0.056   
Sex (male/ female) 0.78 (0.49-1.26) 0.309   0.76 (0.56-1.04) 0.084 0.59 (0.41-0.86) 0.006 
Clinician Predicted Survival         
Days/Weeks/Months  0.15 (0.10-0.22) <0.001    0.20 (0.15-0.26) <0.001 0.65 (0.42-0.99) 0.047 
Performance Status (ECOG)         
1/2/3/4 3.71 (2.84 -4.85) <0.001  2.15 (1.40-3.30)  <0.001 2.90 (2.42-3.47) <0.001 1.96 (1.50 -257) <0.001 
mGPS         
0/1/2 3.15 (2.13-4.65) <0.001 2.03 (1.23-3.35)  0.006 2.57 (2.08-3.19) <0.001 1.79 (1.37-2.33) <0.001 
Patient Reported Outcome Measures         
Dyspnoea (N/Y) 2.32 (1.41-3.82)  0.001   2.26 (1.64-3.11) <0.001   
Global Health (N/Y) 0.40 (0.27-0.69)  0.001   0.46(0.33-0.64) <0.001   
Cognitive Impairment (N/Y) 0.45 (0.27-0.75)  0.002   0.61 (0.44-0.85) 0.003   
Anorexia (N/Y) 2.21 (1.34-3.63)  0.002   2.09 (1.52-2.88) <0.001   
Distant Metastases (N/Y) 1.57 (0.72-3.45)  0.379 
2(0.72- 
  1.14 (0.73-1.77) 0.564   
Weight loss last 3 months (%)         
 <2.5/2.5-5.9/6-10.9/11-14.9/>15 1.21(1.04-1.41) 0.017    1.26 (1.14-1.39) <0.001 1.16 (1.03-1.30) 0.012 
Biomarkers         
LDH <=250/>250 U/L 3.50 (1.51-8.11) 0.003   3.09 (1.86-5.11) <0.001 2.30 (1.32-4.01) 0.003 
White Cell Count <=11/>11 x109/L 5.53 (3.24-8.76) <0.001   3.54 (2.59-4.84) <0.001   
Neutrophil Count <=7.5/ >7.5 x 109/L 5.23 (3.12-8.56) <0.001  3.18 (1.67-6.01)  <0.001 3.45 (2.52-4.72) <0.001 2.67 (1.83-3.93) <0.001 
Lymphocyte Count <=3.0/>3.0 x109/L 0.71 (0.18-2.88) 0.627   0.39 (0.13-1.29) 0.111   
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The relationship between ECOG-PS and mGPS and survival at 30 days and 3 months, 
is shown in Table 4-4. Survival at 30 days, according to ECOG-PS, varied from 98% 
(ECOG-PS 1) to 25% (ECOG-PS 4).  Survival at 30 days, according to the mGPS, 
varied from 98% (mGPS 0) to 74% (mGPS 2). When used in combination survival at 
30 days ranged from 100% (ECOG-PS1, mGPS 0) to 31% (ECOG-PS 4, mGPS 2).  
 
Survival at 3 months, according to ECOG-PS, varied from 87% (ECOG-PS 1) to 6% 
(ECOG-PS 4).  Survival at 3 months, according to the mGPS, varied from 91% (mGPS 
0) to 46% (mGPS 2). When used in combination survival at 3 months ranged from 
97% (ECOG-PS1) to 8% (ECOG-PS 4, mGPS 2). 
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Table 4-4 The relationship between Performance Status, mGPS and the survival rate (%) at 30 days and 3 months, in patients with advanced 
cancer (n=478) 
 



































































































Survival rate, not reported where n<10. 
The table details the relationship between worsening ECOG Performance Status and increasing mGPS score. The lowest row demonstrate the 30 days and 3 
month survival relationship between any Performance Status and worsening mGPS score. The end two columns demonstrate the 30 days and 3 month survival 
relationship between any mGPS score and worsening ECOG Performance Status. Each percentage details the number of patients alive at 30 days and 3 
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The relationship between circulating neutrophil counts (NC), ECOG-PS and mGPS in 
patients with advanced cancer in shown in Table 4-5. In those patients with ECOG-
PS 0-1, the absolute NC (p<0.001 ANOVA) and the proportion with elevated NC (χ2TREND 
p<0.001) was greater with higher mGPS.  In those patients with mGPS 0, the absolute 
NC (p=0.011) and the proportion with elevated NC (χ2TREND p=0.008) was greater with 
higher ECOG-PS.  
 
The relationship between ECOG-PS and NC and survival at 30 days and 3 months, is 
shown in Table 4-6. Survival at 30 days, according to ECOG-PS, varied from 98% 
(ECOG-PS 1) to 25% (ECOG-PS 4).  Survival at 30 days, according to the NC, varied 
from 94% (normal NC) to 70% (abnormal NC). When used in combination survival at 
30 days ranged from 99% (ECOG-PS1, normal NC) to 47% (ECOG-PS 3, abnormal 
NC).  Survival at 3 months, according to ECOG-PS, varied from 87% (ECOG-PS 1) to 
6% (ECOG-PS 4).  Survival at 3 months, according to the NC, varied from 93% (normal 
NC) to 70% (abnormal NC). When used in combination survival at 3 months ranged 
from 91% (ECOG-PS1, normal NC) to 22% (ECOG-PS 3, abnormal NC).  
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*Median (interquartile range) **patients (n) with NC  
The table details the relationship between worsening ECOG Performance Status, neutrophil count and increasing mGPS score. The lowest two rows 
demonstrate relationship between any Performance Status, neutrophil count and worsening mGPS score. Table was composed jointly with BL. 
ECOG-
PS 












3.7 (2.77-4.90)  5.35 (4.25-7.86) 5.69 (4.00-9.00) 4.60 (3.20-6.89) 
 Neutrophil count** 
(<7.5/ >7.5x109/L) 





4.30 (2.99-6.10) 6.20 (3.48 -9.18) 7.39 (5.13-11.46) 5.60 (3.60-9.09) 
 Neutrophil count** 
(<7.5/ >7.5x109/L) 





 5.56 (4.34-8.87) 7.20 (4.90-12.29) 7.10 (4.70-10.76) 
 Neutrophil count** 
(<7.5/ >7.5x109/L) 





  9.72-4.25-11.86) 9.66 (3.97-11.68) 
 Neutrophil count** 
(<7.5/ >7.5x109/L) 





3.82 (2.80-5.36) 5.60 (4.17-8.69) 7.13 (4.70 -10.81) 5.20 (3.51 -8.80) 
 Neutrophil count** 
(<7.5/ >7.5x109/L) 
149/ 28 67/ 32 105/ 88 321/ 148 
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Table 4-6 The relationship between the neutrophil count and Performance Status and the survival rate at 30 days and 3 months, in patients with 
advanced cancer (n=469) 
 Neutrophil count <=7.5 x 
109/L 
n=321 












































































Survival rate (SE), not reported where n<10. 
The table details the relationship between worsening ECOG Performance Status and an elevated or lowered neutrophil count. Each percentage details the 





Chapter 4 IPAC Study 
The relationship between circulating Lactate Dehydrogenase, ECOG-PS and mGPS 
in patients with advanced cancer in shown in Table 4-7.
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Table 4-7 The relationship between Lactate Dehydrogenase, ECOG-PS and mGPS in patients with advanced cancer (n=446). 
The table details the relationship between worsening ECOG Performance Status, lactate dehydrogenase level and increasing mGPS score. The lowest two 
rows demonstrate relationship between any Performance Status, lactate dehydrogenase level and worsening mGPS score. Table was composed jointly with 
BL. 










Lactate Dehydrogenase* 324.00 (214.50-468.00) 322.00 (231.00-542.00) 273.00 (203.00-513.00) 310.00 (213.500-
495.50) 
 Lactate Dehydrogenase 
** 
(< 250/>250 U/L) 
34/59 12/21 23/32 69/112 
2 
n=184 
Lactate Dehydrogenase* 398.00 (261.00-510.00) 482.00 (367.00-623.00) 395.00 (280.00-549.00) 416.00 (297.00-558.25) 
 Lactate Dehydrogenase 
** 
(< 250/>250 U/L) 
15/53 2/41 15/59 31/153 
3 
n=65 
Lactate Dehydrogenase*  572.00 (394.00-920.00) 512.00 (334.00-817.00) 572.00 (334.50-816.00) 
 Lactate Dehydrogenase 
** 
(< 250/>250 U/L) 
2/5 0/11 7/40 9/56 
4 
n=16 
Lactate Dehydrogenase*   537.00 (366.50-721.50) 504.50 (361.25-664.75) 
 Lactate Dehydrogenase 
** 
(< 250/>250 U/L) 
0/0 0/3 2/11 2/14 
1-4 
(n= 446) 
Lactate Dehydrogenase* 369.00 (234.00-495.00) 441.50 (311.00-602.75) 398.00 (251.00-626.00) 394.00 (250.75-557.25) 
 Lactate Dehydrogenase 
** 
(< 250/>250 U/L) 
50/117 14/76 47/142 111/335 
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In those patients with ECOG-PS 0-1, there was no relationship with higher mGPS for 
either LDH (p=0.914 ANOVA) or the proportion of patients with elevated LDH 
(χ2p=0.795). In those patients with mGPS=2, LDH (p=0.002 ANOVA) and the proportion 
with elevated LDH (χ2TREND p=0.002) was greater with higher ECOG-PS. The 




Figure 4-1 Bar chart demonstrating the relationship between clinician predicted survival and 
Performance Status 
The bar chart details ECOG Performance Status (1-4) on the x-axis and Clinician Predicted Survival on 
the y-axis. The Clinician Predicted Survival refers to months (blue bar), weeks (orange bar) and days 
(grey bar). With an ECOG Performance Status of 1, an increased percentage of patients surviving 
months are alive at 3 months, and correctly identified by clinicians. With an ECOG Performance Status 
of 4, an increased percentage of patients identified as surviving weeks are alive at 3 months. With an 
ECOG Performance Status of 4, 38% of patients who were estimated to survive days are alive at 3 
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4.5 Discussion 
 
The multicentre prospective observational study evaluated key biomarkers and clinical 
markers which were already established as having independent prognostic 
significance. The study identified CPS, mGPS, ECOG-PS, dyspnoea, Global Health, 
cognitive impairment, anorexia, weight loss, LDH, WCC and NC as having prognostic 
significance at 30 days on univariate analysis. The factors with prognostic significance 
at 3 months on univariate analysis were CPS, ECOG-PS, mGPS, dyspnoea, global 
health, cognitive impairment, anorexia, weight loss, LDH, WCC and NC. Multivariate 
analysis identified ECOG-PS, mGPS and neutrophil count as having prognostic 
significance at 30 days. ECOG-PS, mGPS, weight loss, LDH and WCC were identified 
as having prognostic significance at 3 months on multivariate analysis.  
The indices with greatest prognostic significance at predicting survival were mGPS, 
ECOG-PS, neutrophil count and LDH.  
 
As previously noted in the earlier chapters, mGPS, neutrophil count and LDH are 
objective markers of inflammation with no inter-observer bias. It should be noted that 
male sex and the presence of weight loss in the preceding 3 months were predictive 
of survival at 3 months on multivariate analysis, however these were less predictive 
compared to the aforementioned indices.  The study confirmed that male sex is a 
negative predictor of survival, as it is globally, with women’s life expectancy exceeding 
that of men’s worldwide, regardless of a diagnosis of cancer especially in industrialised 
countries165. The incidence of cancer in men is declining due to recent rapid declines 
in prostate cancer diagnoses. This current study excluded patients with prostate 
cancer and bone metastases only and overall this study had few patients with a 
prostate cancer diagnosis, thus making the prognostic significance at 3 months of 
male gender due to other confounding factors, or that the men had a crucial selective 
combination of other prognostic factors, which this study has not extrapolated further. 
By identifying male sex as a negative predictor of survival, this result is comparable 
with other research into survival which states that ‘women may be intrinsically more 
robust than men in coping with cancer’166.  
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Socioeconomic status and social support networks, including access to palliative care, 
are of great importance in survival. In this study, the majority of patients were residing 
at home and many were enrolled at clinic settings where patients were attending for 
routine review and follow up appointments. The majority of the study centres were 
within NHS centres where a multidisciplinary team approach, including access to 
palliative care, is used when looking after patients with cancer, which inevitably 
impacts upon patient wellbeing and thus survival. Whether male patients choose to 
partake in or opt out of full multidisciplinary care was not reviewed in this study.  
 
The combination of individualised ECOG-PS and mGPS scores was able to 
demonstrate survival at 30 days and 3 months with a range from 100% survival to 8% 
survival. A relationship was seen between circulating NCs, ECOG-PS and mGPS. 
Patients with a higher mGPS score, which reflects higher markers of systemic 
inflammation, had an elevated NC. Patients with an mGPS score of 0 however with a 
worse ECOG-PS, had elevated NCs. The combination of individualised ECOG-PS and 
NCs was able to demonstrate survival at 30 days and 3 months with a range from 99% 
survival to 22% survival. The total WCC was of prognostic significance at 3 months on 
multivariate analysis. This supports previous reviews and research which have 
identified WCC as an independent prognostic factor167-169.  The NC is an objective 
marker in prognosis, however this study demonstrates that the selective combination 
of mGPS and ECOG-PS is a better overall predictor of survival with a wider prediction 
of survival and the addition of NC does not improve accuracy of survival prediction in 
combination with ECOG-PS. It has already been shown that the selective combination 
of objective markers of systemic inflammation are of prognostic significance in the form 
of the mGPS. When it is combined with ECOG-PS, it has again been shown to be of 
heightened prognostic value and additive in its survival prediction.  
 
The relationship between LDH and its relationship to survival was of interest. LDH has 
been studied extensively in patients with cancer and its relationship to survival and 
outcome in patients undergoing either systemic chemotherapy or surgical treatment 
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for cancer. It should be noted that much of the research into LDH is looking at LDH on 
univariate analysis. It has been thought that it is a marker of inflammation and is often 
measured in oncology clinics as a surrogate marker of disease activity. This study did 
not demonstrate any direct relationship with elevated inflammation and mGPS score 
or poor ECOG-PS and LDH. This could be due to the fact that the patients enrolled 
into the study already had advanced incurable cancer, the majority of which had 
metastases to other main organs which is reflected in an elevated LDH level for nearly 
50% of the patients enrolled. What is of more interest is that approximately 50% of the 
patients had normal levels of LDH in spite of having advanced incurable cancer and 
the majority of patients whose survival was analysed at 3 months had a normal LDH 
level (p<0.001). The study demonstrates that LDH is one biomarker which is of less 
use in predicting survival when compared to other objective biomarkers. The study did 
demonstrate a relationship between CPS and ECOG-PS demonstrating that CPS was 
inaccurate in patients with a good ECOG-PS and improved survival prediction 
accuracy with poor ECOG-PS. The most accurate survival prediction was ‘months’, 
however the accuracy of this to patients compared to the selective combination of 
objective markers of survival prediction was less.  
 
Lastly, although LDH was consistently associated with survival at 30 days and 3 
months on univariate analysis it was only associated with survival at 3 months on 
multivariate analysis.  Moreover, the hazard ratio of LDH, compared with univariate 
analysis, was lower on multivariate analysis (HR 2.00 vs HR 3.09).  This may reflect 
the relationship between LDH and ECOG-PS where ECOG-PS was directly 
associated with elevated LDH activity. 
 
Weight loss was also shown to be of prognostic significance. Weight loss is a surrogate 
marker of cancer cachexia and therefore a marker of systemic inflammation. It follows 
that the more accurate and objective marker of systemic inflammation, namely the 
mGPS, is a more accurate index to use when ascertaining survival.  
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A number of limitations should be acknowledged. This study provided an extensive 
and rigorous investigation into the majority of the prognostic markers identified as 
being linked to survival in advanced incurable cancer. Not every marker was studied, 
but the main and most important prognostic indices were included. The markers 
selected were those identified on a rigorous systematic review and only those which 
were assessed in populations of greater than 100 and examined and validated in two 
or more independent datasets were included.  The clinical syndrome of “confusion” 
has been noted to be an independent prognostic marker in advanced incurable cancer 
and was included by way of the EORTC-QLQ-C30 questionnaire in the form of 
cognitive impairment. Confusion per se and hypercalcaemia which is often associated 
with confusion were not included in this study after discussions at the National Ethics 
Committee. The National Ethics Committee did not grant approval for the inclusion of 
patients with delirium and therefore the importance and prognostic significance of this 
clinical factor in advanced cancer cannot be further elucidated by this study. Weight 
loss was not subtyped as lean muscle mass loss or fat loss and therefore more 
detailed examination of weight loss could have taken place and been linked to survival 
using muscle mass analysis from CT scans. More socioeconomic status data, 
including patients’ access to multidisciplinary care and palliative care, could have been 
collected in light of the results linking poorer survival to male sex.  
 
Overall this study combined and then compared all the prognostic markers in 
advanced cancer. It adds to the research already conducted and confirms that the 
selective combination of objective biomarkers, combined with an assessment of the 
patient’s fitness (itself a marker of lean muscle mass and therefore usable as a marker 
of systemic inflammation), are the most accurate markers of survival and 30 day and 
3 month prognosis in patients with advanced incurable cancer.  
 
Through a process of thorough and rigorous statistical analysis with direct comparison 
of all the biomarkers, the most predictive markers of survival were identified and were 
mGPS, ECOG-PS, NC, weight loss, LDH and WCC. Weight loss, LDH and WCC had 
prognostic significance at 3 months; NC had prognostic significance at 30 days; only 
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mGPS and ECOG-PS both had prognostic significance and predicted survival at 30 
days and 3 months.
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Chapter 5 Discussion 
 
5.1 Background to the Thesis 
 
Cancer is one of the main causes of death in the UK. It is of great public interest to 
clinicians and to patients as individuals, both in terms of public health and health 
economics.  Most cancers are incurable and diagnosed at an advanced stage or 
progress rapidly to an advanced stage where the focus of treatment switches to good 
end of life care.  
 
The origins of cancer lie in inflammation. The local cancer microenvironment is one of 
inflammation and it also gives rise to systemic inflammation. Inflammation allows 
cancer to propagate and metastasise. The literature review outlined in this thesis 
suggests that there is a link between cancer inflammation and the sequelae of cancer. 
Cancer inflammation is directly linked to symptoms because they are caused by 
cancer inflammation and the inflammatory mediators released as a direct 
consequence of cancer or in response to the presence of cancer. This inflammatory 
cascade directly correlates with symptoms, disease burden and prognosis.  
 
Traditionally PS is used to estimate prognosis since PS worsens with an increase in 
cancer inflammation and progression. Specific symptoms and inflammatory markers 
in patients with advanced incurable cancer are linked to cancer inflammation and 
therefore prognosis. Prognostic factors, individually or in combination, have been 
examined in the medical literature and scientific fields. Specific clinical markers, either 
related to the patient or disease history, along with biomarkers, have been identified 
as being independently significant prognostic indicators. Identifying these prognostic 
markers and ascertaining prognosis is important to enable good end of life care in 
incurable cancer where the only good treatment is palliative care to prevent distress.  
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The aim of this thesis was to determine the strongest prognostic markers in advanced 
incurable cancer, and to determine which, if any, of these were related to systemic 
inflammation. In this thesis the numerous prognostic markers have been identified, 
tested, compared and validated. The aims of this thesis have been met. There has 
been a thorough examination of all the prognostic markers and the prognostic tools in 
advanced cancer to clarify which prognostic markers are most predictive of survival in 
advanced cancer, through performing a systematic review, an analysis of a biobank 
dataset and a prospective observational study. 
 
 
5.2 Main Findings 
 
The literature was reviewed in Chapter 1 and Chapter 2. By looking at all existing 
prognostic tools, all individual prognostic markers which have been previously 
validated in patients with advanced incurable cancer have been reviewed. The most 
extensively tested and validated prognostic markers are PS, clinician predicted 
survival, anorexia, dyspnoea, delirium, disease status, mGPS, the presence of 
oedema, global health, the presence of metastases, heart rate, dysphagia, weight 
loss, fatigue, WCC, lymphocyte count, CPS, albumin, and vitamin B12. When these 
markers have been combined in selective combinations in tools, their ability to 
accurately predict survival increases. Some markers were notable for having been 
robustly validated through extensive testing on univariate and multivariate analysis.  
 
As is evident, these prognostic markers are both clinical markers and biomarkers. A 
number of tools (combinations of markers) were identified. These included the PaP, 
PPI and GPS/mGPS and these were found to predict survival. All of these tools had 
links to systemic inflammation. Some of the tools are simpler to use than others and 
more objective, which is of greater potential clinical utility and relevance. These tools 
cover a variety of different populations and therefore direct comparison of studies is 
difficult, highlighting the fact that a larger study incorporating all the important 
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prognostic indices identified in the systemic review was needed to enable direct 
comparison.  
 
In line with the hypothesis that inflammation is related to cancer prognosis a common 
theme which became evident is that inflammatory biomarkers namely CRP, WCC, Alb 
are linked to prognosis. There is biological rationale that the clinical symptoms which 
are also related to prognosis, are also related to inflammation. This applies to weight 
loss and reduced mobility (a surrogate for PS). Weight loss has been identified as a 
prognostic marker. However, the definition of weight loss per se must be interrogated 
and clarified prior to linking weight to prognosis in cancer. Loss of lean mass, a key 
component of cachexia, has been demonstrated to be linked directly to systemic 
inflammation and therefore is an external surrogate markers of the internal 
inflammation ongoing in patients with cancer.  
 
Other symptoms such as dysphagia and xerostomia have been shown to be of 
prognostic significance. The action of oesophageal motility and therefore its 
impairment relies on muscle activity. Sarcopenia, which is loss of lean muscle mass, 
inevitably leads to reduced muscle activity and therefore dysphagia. 
 
It can follow that a reduction in PS is due to or a consequence of reduced lean muscle 
mass and therefore the prognostic symptom of dysphagia is a consequence of 
sarcopenia. Impairment of oesophageal motility, reduced swallowing and sarcopenic 
dysphagia are therefore due to reduced PS overall and result from underlying 
inflammation from cancer cachexia. Similarly, for the symptom of xerostomia it can be 
linked to either medications prescribed for advanced incurable cancer or to 
sarcopenia, cachexia and reduced PS. The bite force and jaw closing muscles are 
associated with good muscle tone which is lower in patients with cancer, sarcopenia 
and cachexia. The symptom of xerostomia arises when a patient has muscle atrophy 
and therefore forced bite closure is not performed 100% or to the maximal effect, due 
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to overall weakness of muscles. Other symptoms identified as being related to 
systemic inflammation are anorexia, oedema, ascites and fatigue.  
 
In the next step of this thesis, a retrospective biobank analysis of an existing 
prospectively collected dataset was performed. In addition to mGPS (incorporating 
CRP and albumin) and PS, the parameters of weight loss and BMI were specifically 
examined, given the literature review suggested that these parameters are also linked 
to systemic inflammation. It was important to compare these parameters to PS, 
because this is the method used in current clinic practice, to assess prognosis and 
cancer progression.  This study clarified that although weight loss is important, CRP 
and albumin (combined in mGPS) performed better than weight loss and BMI, and 
equally as well as PS in the prediction of prognosis and cancer progression.  An 
important finding was that inclusion of the objectively measured mGPS tool was 
required in the next prospective study, outlined in Chapter 4.  
 
The ultimate aim of the thesis was to compare all the prognostic markers to identify 
those of greatest prognostic significance and survival accuracy. Objective markers 
appear to be more useful in clinical practice, but have not been directly tested against 
the subjective prognostic markers. Chapter 4 detailed a multi-centre prospective 
observational cohort study into the prognostication of advanced cancer, IPAC. This 
study was designed on the background of work performed and conclusion reached 
earlier in this thesis. The study was designed and performed to incorporate all the 
clinical markers of prognosis and biomarkers of prognosis and compare them all 
against each other, not just in one cancer population but in numerous cancer types.  
The study population was large and by performing the study in a number of centres 
throughout the UK, it is directly relevant to current clinical practice in the UK, as distinct 
from other previous studies which have been performed in the non-UK population. The 
inclusion criteria were deliberately broad to minimise bias.  
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An important finding from the preliminary studies, and supported by the findings in 
Chapter 4 is that the main clinical prognostic factor was PS and therefore symptoms 
related to a reduction in PS can therefore be expected to be of prognostic significance. 
When all the prognostic markers were compared in the IPAC study, certain prognostic 
themes recur after univariate and multivariate testing. These are listed below: 
 
 The statistically significant prognostic markers for 30 day survival on univariate 
analysis were CPS, mGPS, ECOG-PS, dyspnoea, Global health, cognitive 
impairment, anorexia, weight loss, LDH, WCC and NC. 
 
 The statistically significant prognostic markers for three month survival on 
univariate analysis were CPS, ECOG-PS, mGPS, dyspnoea, global health, 
cognitive impairment, anorexia, weight loss, LDH, WCC and NC.  
 
 The statistically significant prognostic markers for 30 day survival on 
multivariate analysis were ECOG-PS, mGPS and NC.  
 
 The statistically significant prognostic markers for three month survival on 
multivariate analysis were ECOG-PS, mGPS, weight loss, LDH and WCC.  
 
 The indices with greatest prognostic significance were ECOG-PS, mGPS, LDH 
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5.3 Potential Implications of Thesis Findings 
 
It has been demonstrated that PS, the gold standard in terms of prognostication is very 
accurate when used to predict survival. It is a subjective clinical parameter.  
 
This thesis has shown that mGPS, WCC and LDH are equally as accurate in predicting 
prognosis in patients with advanced cancer. The thesis has compared all the many 
validated prognostic indices, clinical and biomarkers in a robust prospective study and 
these four parameters have the greatest prognostic significance. These parameters 
are directly linked to systemic inflammation, the inflammatory burden of cancer, and 
therefore cancer inflammation. To the author’s knowledge, it is the first time that all the 
validated prognostic markers have been compared in a prospective study. It is also 
the first time that all the prognostic markers have been examined in advanced cancer, 
and not just one specific cancer type. The prognostic parameters detailed above can 
be interpreted by clinicians across a variety of cancer specialities and used by them 
to estimate prognosis. These parameters are tested regularly in clinical practice and 
are not obscure. These parameters are readily available in all clinical settings in the 
UK. The prognostic indices were also examined for the first time in determining 
survival at three months and 30 days. Up until this work, most studies have focussed 
on examining prognostic markers in relation to three month survival.  Determining 30 
day survival is of greater benefit to patients being looked after in oncology and 
palliative medicine, both to guide treatment decisions and develop tailored 
management plans for patients.   
 
A further important conclusion from this thesis is that prognosis in advanced cancer is 
directly related to the degree of inflammation. Each of the prognostic markers identified 
can be attributed to systemic inflammation, the cornerstone of cancer progression. 
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5.4 Future directions 
 
The main foundation work for prognostication in advanced cancer has been 
established here through comparing all the validated prognostic markers in a 
prospective study. This thesis paves the way for future research now to focus on those 
prognostic markers which have been found to be of prognostic significance. The thesis 
has examined all the validated markers. Re-studying prognostic markers which are 
not of prognostic significance is of no benefit to advancing knowledge in 
prognostication in advanced cancer. The future should focus on creating a new 
prognostic tool to aid clinical decision making and benefit patient care.  
 
A desirable tool is one which is likely to be used in clinical practice. At present only 
single parameters such as PS, are used to ascertain prognosis in clinical practice. A 
new tool must therefore be a combination of the indices with greatest prognostic 
significance and be kept to the minimum number of indices to aid better uptake and 
use in clinical practice.  
 
A new prognostic tool incorporating the markers found to be of greatest prognostic 
significance namely ECOG-PS, mGPS, LDH, WCC, weight loss and NC could be 
created, tested and then validated for use in patients with advanced cancer. 
Alternatively tools could be created for estimating 30 day and three month survival. A 
prognostic tool for 30 day mortality using ECOG-PS, mGPS and NC and a prognostic 
tool for three month mortality using ECOG-PS, mGPS, weight loss, LDH and WCC 
could be created, tested and validated for patients with advanced cancer. Once 
validated these tools could be used to estimate a minimum of 30 day prognosis which 
could be of immense clinical use in guiding patient treatment and referrals to palliative 
care. Tools incorporating these prognostic markers would be objective, easy to use, 
and using parameters which are readily available in clinical practice. Prior to 
introducing such a tool into the clinical environment, the tool would have to be 
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evaluated in a testing population, then validated in a training population in a cohort of 
patients with all types of cancer and prognostic accuracy assessed.  
 
The IPAC study tested ECOG in combination with albumin and CRP, the clinical 
markers of greatest prognostic significance, and accuracy of survival prediction was 
confirmed. The advantage of such a tool combining only ECOG-PS and mGPS is that 
it relies on a subjective clinical parameter already used extensively in clinical practice 
and one which clinicians are comfortable using, with the addition of objective markers 
using clinical markers tested routinely. It would, therefore, not incur additional cost in 
the UK. It is not burdensome, in that the parameters are easy to recall, easy to locate 
in a patient’s notes, easy to test if not already performed, and cost is minimal. 
  
The main advantage of such a tool would be the benefit to the patients in that survival 
accuracy in the IPAC study was proven and this would enable advance care planning 
and better care for patients with cancer. This type of tool, with indices which are 
markers of inflammation, is the natural choice in the oncology world where 
inflammation is the treatment target.  The inflammation burden due to cancer is linked 




5.5 Strengths and Limitations 
 
The IPAC study contained within the thesis and the thesis itself has not included 
haematological malignancies and patients with breast or prostate cancers with bone 
metastasis only. Haematological malignancies were not examined formally because 
they directly affect the full blood count parameters due to direct disease effect and 
therefore determination of the effect of inflammation due to cancer and the effect of 
direct disease activity would have been difficult and would have skewed the results. 
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The patients with breast or prostate cancer with bone metastases only were not 
included due to their being expected to outlive the study given survival is estimated to 
be several years. Cognitive impairment was included as part of the global health 
questionnaire, however delirium per se was not permitted by the Ethics committee as 
a parameter to investigate.  The cohort did not include equal numbers of all different 
cancer types, however the results did not demonstrate any prognostic significance to 
patients having a diagnosis of a specific cancer, so this limitation is less clinically 
important. The cancer populations were those being cared for in the specific oncology 
or hospice centres and are subject to local variation in terms of disease incidence and 
prevalence.  
 
This thesis has performed a thorough review of all the prognostic tools in advanced 
cancer, focussed on the inflammatory markers linked to cancer survival and performed 
a national multicentre study in centres across Scotland, England and Wales. It took 
place in oncology, hospice and palliative care centres in both inpatient and outpatient 
settings, enabling more patients to have access to the study.   It did not interfere with 
any treatment patients received. The minimum follow up was for three months, which 
was the maximal survival time period being studied.  
 
One limitation was that patients could only take part on one clinical study and a 
simultaneous study which, as a clinical CTIMP, took priority, prevented recruitment of 
patients to this study. Patients with cancer are frequently used in clinical trials for new 
medications and it was this conflict with other trials which often prevented recruitment. 
In some circumstances, the conflicting trial would grant permission for their patients to 
be recruited into the IPAC study. 
  
In the IPAC study, the follow up times varied. Patients recruited at the start of the IPAC 
study were followed up for longer ,compared to those recruited at the end of the study 
who were only followed up for the minimum three months. Ideally the follow up time 
for all studies looking at prognosis would be until every patient in the study dies, 
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however this is not practical when results are awaited to improve and change current 
clinical practice and ideally benefit patients now, in addition to future patients.   
 
The topic of patients dying and estimating survival is an emotionally charged one., 
However clinicians need to be targeted to utilise the results of this study to prevent 
patients receiving unnecessary treatment in the last three months of life, which may 
cause increased symptoms and distress with no survival benefit, compared to fast-
tracking these patients to the palliative care teams where symptoms can be controlled. 
One concern is that these data could be used against patients and be used to ration 
treatments which are of benefit, including access to palliative care, if the patient’s 
survival is estimated to be more than 30 days.  
 
 
5.6 Final Words 
 
This thesis has undertaken a comprehensive review and investigation into the 
background of systemic inflammation and its significance to prognostication. The 
findings of the original researchers namely Hippocrates, Galenus and Celsus have 
been investigated and confirmed by researchers such as Virchow, Karin and 
Manotovani. Their work into the importance of the systemic inflammatory response 
has provided the foundation on which all work on prognosis is based. This current 
work has demonstrated the valid importance of systemic inflammation in the tumour 
microenvironment, in the biomarkers used to guide clinical management and in the 
aetiology of clinical symptoms and signs when estimating prognosis in advanced 
cancer.  A new prognostic tool for use in patients with advanced cancer has been 
proposed, namely a combination of prognostic markers, all strongly associated with 
systemic inflammation and, therefore, giving prognostic accuracy from a clinical, 
scientific and biochemical perspective.  
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Hippocrates was correct when he said one of the main tasks in medicine was to 
‘declare the past, diagnose the present and foretell the future’. What is clear is that the 
origins of inflammation and its links to disease and prognosis, identified by physicians 
even pre-dating the original researchers, such as Hippocrates, still holds true. The 
basic themes and tools in medicine are unchanged. What we have gained in this thesis 
is greater accuracy, certainty and validity in their use and application.  
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Appendix I: Systematic review search  
 
 
Database: Ovid MEDLINE(R) 1946 to Present with Daily Update, Embase Classic+Embase <1947 to 2015 Week 14> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     neoplasm.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1024167) 
2     cancer.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3421033) 
3     malignancy.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (251965) 
4     tumo?r$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3908264) 
5     carcinoma.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1530087) 
6     1 or 2 or 3 or 4 or 5 (6273610) 
7     model.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3945411) 
8     tool.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (657880) 
9     7 or 8 (4498731) 
10     prognosis.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1151044) 
11     prediction.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (498913) 
12     progno$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1332771) 
13     10 or 11 or 12 (1765582) 
14     terminal care.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (48093) 
15     palliat$.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (173421) 
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16     hospice.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (26506) 
17     14 or 15 or 16 (217896) 
18     6 and 9 and 13 and 17 (1735) 
19     limit 18 to "all adult (19 plus years)" [Limit not valid in Embase; records were retained] (1626) 
20     limit 19 to english language (1499) 
21     limit 20 to humans (1370) 
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Systematic Review
Claribel P.L. Simmons, MBChB, MRCP, Donald C. McMillan, PhD, Kerry McWilliams, MBChB, MRCP,
Tonje A. Sande, MD, PhD, Kenneth C. Fearon, MDy, Sharon Tuck, BSc, Marie T. Fallon, MD, and Barry J. Laird, MD
University of Edinburgh (C.P.L.S., K.M., T.A.S., K.C.F., S.T, M.T.F, B.J.L.), Edinburgh; Department of Surgical Sciences (D.C.M.),
University of Glasgow, Glasgow, UK; and European Palliative Care Research Centre (B.J.L.), Norwegian University of Science and
Technology, Trondheim, NorwayAbstract
Purpose. In 2005, the European Association for Palliative Care made recommendations for prognostic markers in
advanced cancer. Since then, prognostic tools have been developed, evolved, and validated. The aim of this systematic review
was to examine the progress in the development and validation of prognostic tools.
Methods. Medline, Embase Classic and Embase were searched. Eligible studies met the following criteria: patients with
incurable cancer, >18 years, original studies, population n $100, and published after 2003. Descriptive and quantitative
statistical analyses were performed.
Results. Forty-nine studies were eligible, assessing seven prognostic tools across different care settings, primary cancer
types, and statistically assessed survival prediction. The Palliative Performance Scale was the most studied (n ¼ 21,082),
comprising six parameters (six subjective), was externally validated, and predicted survival. The Palliative Prognostic Score
composed of six parameters (four subjective and two objective), the Palliative Prognostic Index composed of nine parameters
(nine subjective), and the Glasgow Prognostic Score composed of two parameters (two objective) and were all externally
validated in more than 2000 patients with advanced cancer and predicted survival.
Conclusion. Various prognostic tools have been validated but vary in their complexity, subjectivity, and therefore clinical
utility. The Glasgow Prognostic Score would seem the most favorable as it uses only two parameters (both objective) and has
prognostic value complementary to the gold standard measure, which is performance status. Further studies comparing all
proved prognostic markers in a single cohort of patients with advanced cancer are needed to determine the optimal
prognostic tool. J Pain SymptomManage 2017;53:962e970. 2016 American Academy of Hospice and Palliative Medicine. Published
by Elsevier Inc. All rights reserved.
Key Words
Prognostic tools, cancer, reviewIntroduction
Estimating prognosis is a fundamental component
in the management of patients with advanced cancer
for several reasons. First, accurate estimation of prog-
nosis can help inform whether anticancer treatment is
likely to be beneficial.1,2 Second, it may relieve patient
and carer anxiety associated with prognosticDrs. Simmons and McMillan are joint first authors and Drs.
Fallon and Laird are joint senior authors.
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Published by Elsevier Inc. All rights reserved.uncertainty.3 Third, it can help with end-of-life care
planning, including place of care.
However, in patients with advanced cancer, the ceil-
ing limit of the TNM classification system is often
reached (i.e., M1) and as such is of limited value. As
such, in the clinic, prognosis is based on various fac-
tors including stage of disease, performance status,Address correspondence to: Barry J. Laird, MD, Edinburgh Can-
cer Centre, Western General Hospital, Crewe Road, Edin-
burgh, UK. E-mail: barry.laird@ed.ac.uk
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trajectories. However, the subjective nature of these
may result in estimates of prognosis that are inaccu-
rate, potentially misleading, and may result in anti-
cancer therapies being given inappropriately.2,4e6
In an attempt to improve prognostic accuracy, in
2005, the European Association of Palliative Care
(EAPC) published recommendations on the use of
prognostic markers in patients with advanced cancer.7
These recommendations were informed by eight
studies examining different prognostic tools, which
had been published in the preceding decade
(1993e2003), and recommended a number of prog-
nostic tools and their utilization. These tools were
the Terminal Cancer Prognostic Score, the Palliative
Performance Scale, the Palliative Prognostic Index,
and the Palliative Prognostic Score.
Because these recommendations were made, a
plethora of prognostic tools devised for use in patients
with advanced cancer have been developed; however,
to date they have not been presented together and
comparison made. To this end, the aim of this system-
atic review was to examine and compare prognostic
tools in patients with advanced cancer and make rec-
ommendations for their use.Methods
The following databases were searched: Medline
(2003e2015) and Embase Classic and Embase
(2003e2015). The search focused on studies of prog-
nostic tools in patients with advanced cancer regard-
less of the original primary tumor. The search terms
are listed in Appendix I. A hand search of key journals
and relevant citations was carried out. The date of the
last literature search was April 30, 2015.
Eligibility Criteria
Eligible studies met the following inclusion criteria:
population with advanced cancer (defined as an incur-
able cancer), original studies, study population n $100
and age $18 years, quantitative clinical and/or bio-
markers were examined, a multivariate statistical model
was described, the tool had been examined and validated
in two or more independent data sets, published in En-
glish, publishedafter 2003 (enddateoforiginal literature
search), and full article was available.7 The primary
outcomemeasurement examinedwas survival prediction
(likelihood of death) based on the use of the prognostic
tool in the specific patient population. Studies were
excluded if a univariate survival analysis was described
only, the tool was designed for use in one specific popula-
tion with one specific cancer type (e.g., only patients with
specific stage of lung cancer), or qualitative indices were
used exclusively to predict survival.Data Extraction and Analysis
The initial database search was undertaken and du-
plicates removed. Two authors (C. S. and K. M.) inde-
pendently screened each study for eligibility based on
the abstract and finally each full text article. From this,
the necessary data for descriptive and quantitative an-
alyses were extracted by C. S. and T. S., independently.
These included the descriptors of the patient popula-
tion, length of survival, and information regarding sur-
vival predictions. The analysis of each study was
performed using standard quality assessment criteria
which were then summarized for statistical analysis
and comparison where possible.8 Studies are pre-
sented according to the prognostic tool described.
Where studies examined both populations with cancer
and noncancer, only those populations with cancer
were included in the analysis.Results
The literature search process is shown in Figure 1.
After abstract review, 179 articles were reviewed in
full and this resulted in 49 studies fulfilling the eligi-
bility criteria.
From the 49 eligible studies, seven different prog-
nostic tools were identified. A summary of these is
detailed in Table 1. The tools identified were the Palli-
ative Prognostic Score (PaP, eight studies), Delirium-
PaP (D-PaP, two studies), B12/C-Reactive Protein In-
dex (BCI, one study), Prognosis in Palliative Care
Study (PiPS, one study), Palliative Prognostic Index
(PPI, eight studies), Palliative Performance Scale
(PPS, 18 studies), and the Glasgow Prognostic Score
(GPS, 10 studies).
A detailed description of these seven prognostic
tools is given in Appendices II and III. These tools
used a combination of clinical and/or biomarker pa-
rameters. The most common clinical parameters
used were performance status, anorexia, and dyspnea.
The most common biomarkers were C-reactive pro-
tein, white cell count, lymphocyte count, and albumin.
The number of parameters used ranged from two
(GPS, BCI) to 17 (PiPS B), and the mean number
was seven. The largest single population studied for
each of the prognostic tools is summarized in
Table 2. Details of all studies included in this review
are summarized in Supplementary Table 1.
To date, there have been eight studies (combined
total n ¼ 2694) examining the PaP in patients with
advanced cancer. Patient cohorts were unselected
but included patients with a variety of cancer diagno-
ses including cancer of the head and neck, lung,
skin, breast, gastrointestinal tract, genitourinary tract,
prostate, gynecologic, neuroendocrine, and hemato-
logic tissue. The studies were from groups in Australia
Fig. 1. Flow chart of the review process.
964 Vol. 53 No. 5 May 2017Simmons et al.(one study), Italy (two studies), Brazil (one study),
Japan (one study), Canada (two studies), and the
U.S. (one study), thereby providing external valida-
tion of the tool. Two studies (n ¼ 910) examined
the D-Pap in patients with advanced cancer.10,16 This
included patients with cancers of the head and neck,
lung, breast, gastrointestinal tract, and genitourinary
tract. Both the PaP and D-PaP predict survival in pa-
tients with advanced cancer. The D-PaP tool has not
been as extensively validated compared with the PaP;
however, both perform similarly compared with each
other.10
To date, one study comprising 329 patients exam-
ined the BCI in patients with advanced cancer.11 The
patient population included those with a diagnosis
of cancer of the head and neck, lung, breast, gastroin-
testinal tract, genitourinary tract, prostate, gyneco-
logic, neuroendocrine, and hematologic tissue. This
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PaP ¼ Palliative Prognostic Score; D-PaP ¼ Delirium-PaP; BCI ¼ B12/C-Reactive P
nostic Index; PPS ¼ Palliative Performance Scale; GPS ¼ Glasgow Prognostic Sco
aClinical refers to signs or symptoms which are of prognostic significance.
bBiomarkers refers to serum biomarkers of prognostic significance.
cStudies eligible for inclusion.One study (n ¼ 1018) has examined the PiPS.12 The
patients included those with diagnoses of gastrointes-
tinal, lung, unknown primary, breast, urologic, gyne-
cologic, central nervous system, hematologic, and
head and neck cancers. This study reported that the
area under the curve varied between 0.79 (PiPS A)
and 0.86 (PiPS B) and suggested that PiPS is at least
equal to and may be better than the clinician’s pre-
dicted survival.
Eight studies (n ¼ 5929) have examined the prog-
nostic value of the PPI.10,17e24 The patients included
those with cancer of the head and neck, lung, breast,
gastrointestinal tract, genitourinary tract, prostate, gy-
necologic, and hematologic tissue. The studies were
based in Japan (three studies), Italy (one study),
Taiwan (two studies), U.S. (one study), and Canada
(one study). Recently, studies have examined a change
in PPI scores, and this approach to researching the
PPI appears more consistent, accurate, and clinically
useful.1
gnostic Tools
Cancer Types (Mixed/Single) Number of Studiesc






Mixed and single 10
rotein Index; PiPS ¼ Prognosis in Palliative Care Study; PPI ¼ Palliative Prog-
re.
Table 2
Summary of Prognostic ToolsdLargest Population Studied Per Tool
Tool Authors Cancer N Survival Outcome Survivala HRa Summary P valuea
PaP Tarumi et al.9 Various 777 Continuous 35 Days d Multivariate Cox regression model
on overall survival:
<0.001
Including age, gender, diagnosis,
initial PPS, initial PaP, MMSE
score, and presence/absence of
delirium on initial consultation.
Log-rank test: PaP Group A vs.
Group B vs. Group C
D-PaP Maltoni et al.10 Various 549 Categorical (21 and 30 days) 22 Days d AUC 0.73 (95% CI 0.71e0.74) <0.0001
BCI Kelly et al.11 Various 329 Categorical (90 days) 42 Days d Log-rank test: <0.001 (Group 1 vs.
Group 2 P ¼ 0.091)BCI Group 1 vs. Group 2 vs. Group
3
PiPS Gwilliam et al.12 Various 1018 Continuous <1e14 Weeks d AUC ¼ 0.79e0.86 d
PPI Kao et al.13 Various 2392 Continuous 5 Weeks 0.63 Multivariate Cox Regression: <0.001
Adjusting for age, gender, primary
cancer origin, referring medical
department, and the interval
between the hospital admission
and referral dates
PPS Casarett et al.14 Various 7391 Categorical
(7 days)
d d Multiple logistic regression: <0.001
Probability of dying between PPS
groups.
GPS Laird et al.15 Various 2456 Categorical
(3 months)
3.2 Months 1.51e2.27 Multivariate Cox proportional






Including age, cognitive function,
dyspnea, appetite loss, quality of
life, physical function, role
function, fatigue, BMI,
performance status, and mGPS.
HR 1.62e2.05
Validation sample:
Including quality of life, physical
function, emotional function,




Comparing levels of mGPS
PaP ¼ Palliative Prognostic Score; D-PaP ¼ Delirium-PaP; BCI ¼ B12/C-Reactive Protein Index; PiPS ¼ Prognosis in Palliative Care Study; PPI ¼ Palliative Prognostic Index; PPS ¼ Palliative Performance Scale; GPS ¼

































966 Vol. 53 No. 5 May 2017Simmons et al.Eighteen studies (n ¼ 21,082) have examined the
PPS. The patients included those with diagnoses of
cancer of the head and neck, lung, breast, gastrointes-
tinal tract, genitourinary tract, prostate, gynecologic,
neuroendocrine, and hematologic tissue. The studies
were based in the U.S. (six studies), Spain (one study),
Canada (eight studies), Italy (one study), Singapore
(one study), and South Korea (one study), thereby
providing external validation of the tool. Because of
the numerous subgroups within the tool, earlier re-
ports had stated it was not highly discriminating in
the intermediate scores.7 Studies taking place after
2005 tackled this issue and focused on the significance
of a 10% decrement in PPS score or poorer PPS
scores. A strong ordering effect across the different
PPS categories was demonstrated, with highly accurate
scores for a PPS of 40% or less. Patients with PPS cat-
egories greater than 50% had lower hazard ratios than
patients with lower PPS scores.
Ten studies (n ¼ 5163) have examined the GPS. The
patients included those with diagnoses of cancer of
the head and neck, lung, skin, breast, gastrointestinal
tract, genitourinary tract, prostate, gynecologic,
neuroendocrine, and hematologic tissue. EightTable
Clinical and Biomarkers
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PaP ¼ Palliative Prognostic Score; D-PaP ¼ Delirium-PaP; BCI ¼ B12/C-Reactive P
nostic Index; PPS ¼ Palliative Performance Scale; GPS ¼ Glasgow Prognostic Scostudies were from groups based in the U.K., one study
was from Japan, and one study examined data from an
international biobank of patients, providing external
validation of this tool.
A descriptive comparison of the individual clinical
and biomarkers parameters included in the each of
the prognostic tools is listed in Table 3. The number
of markers ranges from two (GPS) to 17 (PiPS B).
The PPS is composed of six parameters (six subjec-
tive), the PaP composed of six parameters (four sub-
jective, two objective), the PPI composed of nine
parameters (nine subjective), and the GPS composed
of two parameters (two objective).
To date, there have been limited studies on the
direct comparison of the prognostic value of the
above tools. One study compared the performance
of the PaP to the D-PaP, PPS, and PPI and concluded
that the PaP showed superior accuracy and repro-
ducibility.10 The PaP was also directly compared
with the PPS and PPI tools in separate studies.9,24
Tarumi et al.9 concluded that the PPS and the PaP
performed similarly in survival prediction, whereas
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rotein Index; PiPS ¼ Prognosis in Palliative Care Study; PPI ¼ Palliative Prog-
re; PS ¼ performance status; CPS ¼ clinician-predicted survival.
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tween the GPS and Eastern Cooperative Oncology
Group (ECOG) performance status15 and between
the GPS and the PPI25 and reported that the GPS
had prognostic value independent of ECOG-PS15
and PPI.15,25Discussion
Since the European Association for Palliative Care
recommendations for prognostic tools were published
in 2005, there have been a number of prognostic tools
developed, evolved, and validated.7 The PPS has been
studied in the greatest number of patients, externally
validated, and consistently predicts survival in patients
with advanced cancer. Other prognostic tools of note
that have been validated and consistently predict sur-
vival are the PaP, the PPI, and the GPS. In addition,
the latter (based on the combination of C-reactive pro-
tein and albumin) has been extensively validated since
the original review.
Most of the prognostic tools (PPS, PaP, and the PPI)
depend largely on the assessment of functional status
as a core component. Therefore, their use in routine
practice has been sparse compared with Karnofsky
Performance Score or the simplified Eastern Cooper-
ative Oncology Group Performance Score.26,27 In
addition, the relatively complex scoring systems of
these prognostic tools may have prejudiced their
routine use, whereas the similarities but clear differ-
ences in these are confusing and make comparison
challenging. Therefore, it would be important to ratio-
nalize these subjective assessments into a simpler
scheme with as advocated by Harding et al.28
From the present review, it is also clear that many of
the tools, such as PaP, PPI, PPS, and even performance
status, are predominantly subjective and it could be
argued that where possible, these should be made
more objective. For example, one such way would be
to examine if skeletal muscle mass is related to func-
tional status and whether it can be a surrogate marker
of physical function. This would seem plausible as skel-
etal muscle indices are increasingly recognized to have
prognostic value.29
Although various prognostic tools have been vali-
dated, they vary in their complexity, subjectivity, and
therefore their clinical utility. The GPS would seem
the most favorable as it uses only two parameters
(both objective) and has prognostic value comple-
mentary to ECOG performance status, most
commonly used assessment of patient physical func-
tion, in the oncology of advanced disease. Further
studies, comparing all externally validated prognostic
tools in a single cohort of patients with advanced can-
cer, are needed to determine the optimal prognostic
tools.The search strategy in the present review was
comprehensive and included the main medical data-
bases and a detailed search strategy (Appendix I).
However, there were three notable studies not
included in the review. Feliu et al.30 reported the
development and validation of a prognostic nomo-
gram for terminally ill patients with cancer in almost
900 patients. However, it is of interest that the nomo-
gram included the components ECOG-ps, lactate de-
hydrogenase, lymphocyte count, and albumin
concentrations that have been used in other externally
validated prognostic scores, such as PaP, that have
been examined in the present review. The second
study by Kim et al.31 reported the external validation
of PiPS A and PiPS B in 202 terminally ill patients
with cancer. Finally, our search was limited to April
30, 2015. This excluded a large external validation
study (n ¼ 2426) of the modified PiPS A and PiPS B
prognostic tools reported by Baba et al.32 in May
2015. Nevertheless, the present review is therefore a
step toward the viewpoint of Harding et al. that ‘‘it
would be important to rationalize these subjective as-
sessments into a simpler scheme with judicious selec-
tion and refinement of existing tools’’ (The PRISMA
Symposium 1: outcome tool use. Disharmony in Euro-
pean outcomes research for palliative and advanced
disease care: too many tools in practice).28
Limitations
It is clear that with the exception of the GPS and
contrary to the Reporting Recommendations for Tu-
mor Marker Prognostic Studies (REMARK) guide-
lines, hazard ratio and 95% CI have been reported
inconsistently in the prognostic tools developed for
use in patients with advanced cancer. This precluded
meaningful meta-analysis in the present systematic re-
view. Therefore, future research should directly
compare these validated prognostic tools within all
advanced cancer types using similar statistical ap-
proaches, in keeping with the REMARK guidelines.33
The present systematic review updated a previous
review published a decade ago. The majority of the
prognostic tools examined had less than five indepen-
dent reports of their prognostic value, and therefore, a
meta-analysis of the validated prognostic tools was not
meaningful and a formal estimate of bias was not car-
ried out. However, the data from each article were pre-
sented in detail (Supplementary Table 1) enabling the
reader to draw conclusions as to their quality and the
likelihood of bias using standard criteria. As a result,
the present systematic review is largely descriptive giv-
ing an update in the progress of prognostic tools in
the field.
Several key aspects of prognostic tools remain
elusive, and the present article was unable to address
these due to paucity of primary data. To illustrate, it
968 Vol. 53 No. 5 May 2017Simmons et al.is not clear if certain tools have greater utility in spe-
cific tumor types and/or at certain points in the can-
cer journey. Furthermore, the potential role of these
clinical tools in clinical practice is unclear as their use-
fulness in treatment stratification or place of care
planning is unknown; both these are unlikely to be ad-
dressed unless such tools are incorporated into
routine clinical practice.
It is also clear that another challenge is to imple-
ment the right tool at the right point in the patient’s
cancer journey. This is important as this can affect
different aspects of care, for example, whether to treat
with anticancer therapy, preferred place of death, etc.
To date, the application of the right tool, at the right
time, remains elusive and is likely to require a combi-
nation of mixed methodologies to achieve this.Conclusion
Prognosis remains a central tenet of care in cancer
and validated tools applied correctly may serve to
improve patient care. Since the previous systematic re-
view and recommendations, many prognostic tools
that have been examined are not integrated into
routine clinical care. It could be argued that the multi-
tude of tools available may have actually confused cli-
nicians as to the optimal tool for use. Furthermore, as
performance status remains at the forefront of clinical
decision making regarding prognosis, tools which
build on this would seem preferable, for example,
the GPS and ECOG-PS. To provide some clarity as to
the optimal prognostic tool, studies are needed which
compare all independent prognostic markers, in a sin-
gle population. Such studies are eagerly awaited.Disclosures and Acknowledgments
This work was supported by Medical Research Scot-
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Supplementary Table 1
Prognostic Tools
Tool Authors Cancer N Survival Outcome Survivala Summary HRb P-valuea
PaP Glare et al.34 Various 100 Categorical
(4 w)
12 w Log rank (test for trend): d
Probability of surviving 1 month: Group
A vs. Group B vs. Group C
<0.0001
Tassinari et al.35 Various 173 Continuous 26 w Multivariate Cox regression model on
overall survival:
d
Including age, tumor type, number of
metastatic sites, performance status,
ESAS, PaP score.
0.022
Naylor et al.36 Various 250 Categorical
(30 d)
95 d Log-rank test: PaP Group A vs. Group B
vs. Group C
d <0.0001
Hyodo et al.37 Various 208 Continuous 27 d Cox proportional hazards:
PaP Group B vs. Group A 0.536 (0.36e0.779) 0.002
PaP Group B vs. Group C 3.72 (2.59e5.35) <0.001
Tarumi et al.9 Various 777 Continuous 35 d Multivariate Cox regression model on
overall survival:
d
Including age, gender, diagnosis, initial
PPS, initial PaP, MMSE score, and
presence/absence of delirium on
initial consultation.
Log-rank test: PaP Group A vs. Group B
vs. Group C
<0.001
Maltoni et al.10 Various 549 Categorical
(21 and 30 d)
22 d Log-rank test
PaP Group A vs. Group B vs. Group C
d <0.001
Kim et al.24 Various 415 Categorical
(4 w)
d A score of >10 was the optimal cutoff for
predicting survival at four weeks
d d
Hui et al.38 Various 222 Continuous 106 d Cox proportional hazards regression
analysis with backward selection:
Incorporating age, sex, PaP, PPI, serum
albumin, fat-free mass, unadjusted
phase angle, handgrip strength,
maximal inspiratory pressure, and
standardized phase angle.
1.07 (1.02e1.13) 0.008
Log-rank test: PPI Group A vs. Group B
vs. Group C
<0.001
D-PaP Maltoni et al.10 Various 549 Categorical
(21 and 30 d)
22 d D-PaP Group A vs. Group B vs. Group C d <0.001
Scarpi at al16 Various 361 Categorical
(30 d)
4 w ‘‘Validation by calibration’’ and K statistic 1.6 (1.22e1.99) <0.001
BCI Kelly et al.11 Various 329 Categorical
(90 d)
42 d Log-rank test:
BCI Group 1 vs. Group 2 vs. Group 3
d <0.001
PiPS Gwilliam et al.12 Various 1018 Continuous <1e14 w Logistic regression
AUC ¼ 0.79e0.86
d d
PPI Stone et al.19 Various 194 Continuous Group 1: 68 d
Group 2: 21 d
Group 3: 5 d
Cox proportional hazards:
The hazard ratio associated with a one-





































Tool Authors Cancer N Survival Outcome Survivala Summary HRb P-valuea
Survival of less than three weeks was
predicted with a PPV of 86% and
negative predictive value NPV of 76%.
Maltoni et al.10 Various 549 Categorical
(21 and 30 d)
22 d PPI Group A vs. Group B vs Group C d <0.001
Cheng et al.22 Various 623 Categorical
(21 d)
d Cox proportional hazards:
Group C vs. Group A: 0.19 (0.10e0.24) <0.001
Group C vs. Group B: 0.54 (0.43e0.69) <0.001
Kim et al.24 Various 415 Categorical
(4 w)
d Optimal scores for predicting
four-week survival over 4.5
d d
Arai et al.23 Various 374 Categorical
(3 w)
d Multivariate Cox proportional hazards
model on predicting death within
three weeks:
Including gender, age, BMI, BT, systolic
and diastolic blood pressures, PR,




Kao et al.13 Various 2392 Continuous 5 w Multivariate Cox regression:
Adjusting for age, gender, primary cancer
origin, referring medical department,
and the interval between the hospital
admission and referral dates
0.63 <0.001
Hui et al.38 Various 222 Continuous 15 w Log-rank test: PPI Group A vs. Group B
vs. Group C
Cox proportional hazards regression
analysis with backward selection:
Incorporating age, sex, PaP, PPI, serum
albumin, fat-free mass, unadjusted
phase angle, handgrip strength,






Miura et al.39 Various 1160 Categorical
(3 w, 6 w)
<8 w Cox regression analysis:








PPS Head et al.40 Various 261 Continuous 29 d Cox proportional hazards model on
overall survival:
Independent variables included PPS
score category, comorbidity status,





Harrold et al.41 Various 214 Categorical
(7 d, 30 d, 90 d,
180 d)
d Univariate Cox proportional hazards
modeling:
The area under the receiver operating
characteristic curve:
To measure predictive accuracy in cancer
patients and noncancer patients.
0.96 <0.001
Sanchez et al.42 Various 250 Continuous 32 d Cox regression analysis on overall
survival: PPS # 50
Adjusted for anorexia; compromised oral



























mental state; confused or in coma;
coherent language; orientation in




Lau et al.43 Various 647 Continuous 10 d Log-rank test on overall survival:
PPS groups
d <0.001
Olajide et al.44 Various 157 Continuous 9 d Proportional hazards regression model
on overall survival:
Including PPS, dyspnea, pain, fatigue,
and agitated delirium.
10% Decrease in PPS results in HR of
1.65
1.65 (1.42e1.92) <0.001
Lau et al.45 Various 126 Continuous Cox regression 0.29 to 0.93 <0.001
Lau et al.46 Various 347 Continuous 37 d Log-rank test on overall survival:
Initial PPS groups
Increasing HR with increasing PPS group
Multivariable Cox proportional hazards
model on overall survival:
Including gender, diagnosis, site, and
PPS. Increasing HR with increasing








Weng et al.47 Various 492 Continuous 18 d Log-rank test on overall survival
PPS Group A vs. Group B vs. Group C
Cox proportional hazards model on
overall survival:






Younis et al.48 Various 180 Continuous 35 d Multivariate analysis with Cox
proportional hazards model on overall
survival:
Including executed advanced directives,
Medicare/Medicaid insurance, PPS,
and gender.
1.73 (PPS <50) <0.05
Lau et al.49 Various 5097 Continuous 39 d Log-rank test on overall survival
PPS groups compared
Cox proportional hazards model on
survival:
Including age, gender, location,
diagnosis category, and initial PPS.
Increasing HR with PPS group (PPS 70








Selby et al.50 Various 1622 Continuous 26.5 d Multivariate logistic regression analysis
on overall survival:
Including gender and PPS.




Tarumi et al.9 Various 777 Continuous 43 d Cox proportional hazards model on
overall survival:
Including age, gender, diagnosis, initial
PPS, and survival curve time in days,









































Tool Authors Cancer N Survival Outcome Survivala Summary HRb P-valuea
presence/absence of delirium on
initial consultation (PPS 90% [0.21]
PPS 40% [0.45])
Casarett et al.14 Various 7391 Categorical
(7 d)
d Multiple logistic regression:
Probability of dying between PPS groups.
d <0.001
Maltoni et al.10 Various 549 Categorical
(21 and 30 d)
22 d Log-rank test:
PPS Group A vs. Group B vs. Group C
d <0.0001
Mei et al.51 Various 296 Categorical
(90 d)
d Multivariate Cox proportional hazards
model on overall survival:
Including albumin, gender, and baseline






Kim et al.24 Various 415 Categorical
(4 w)
d Optimal scores for predicting
survival #30
d d
Lee et al.52 Various 606 Continuous d Change in score >30% significantly
associated with survival
2.66 (2.19e3.22) d
Jang et al.53 Various 1655 Continuous 133 d Log-rank test for trend:
Median survival between groups.
d <0.001
GPS Sharma et al.54 Ovary 154 Continuous 39.9 m Multivariate Cox proportional hazard
model on cancer-specific survival:
Including GPS, histologic subtype,
ascites, performance status, ALP, CRP,
and primary debulking surgery.
1.68 (1.16e2.45) <0.001
Crumley et al.55 Gastro-
oesophageal
258 Continuous d Multivariate Cox regression model on
cancer-specific survival:
Including tumor site, stage, alkaline
phosphatase, the GPS, and treatment.
1.51 (1.22e1.86) <0.001
Glen et al.56 Pancreas 187 Categorical
(12 m)
4.6 m Multivariate Cox regression analysis on
overall survival:
Prognostic scores as covariates.
1.72 (1.40e2.11) <0.001
Ramsey et al.57 Renal 119 Continuous 8 m Multivariate Cox proportional hazards
model on cancer-specific survival:
Including lactate dehydrogenase,
hemoglobin, calcium, white cell count,
neutrophil count, albumin, and C-
reactive protein.
2.35 (1.51e3.67) <0.001










Partridge et al.59 Various 296 Categorical
(2 w, 4 w)
d Multivariable Cox regression model on
overall survival:
Including sex, primary cancer site, age,
hemoglobin, and white cell count

























Leung et al.60 Lung 261 Continuous 8 m Multivariate analysis on cancerespecific
survival:
1.67 (1.28e2.19) 0.0001
Pinato et al.61 Lung 171 Continuous 9.7 m Multivariate Cox proportional hazard
model on overall survival:
Including gender, histologic subtype, PS,
the European Organization for the
Research and Treatment of Cancer





Laird et al.15 Various 2456 Categorical
(3 m)
3.2 m Multivariate Cox proportional hazards











Including age, cognitive function,
dyspnea, appetite loss, quality of life,
physical function, role function,
fatigue, BMI, performance status, and
mGPS (mGPS 1 [HR 1.62] mGPS 2
[2.05])
Validation sample:
Including quality of life, physical
function, emotional function, pain,
BMI, performance status, and mGPS.
(mGPS 1 [1.58] mGPS [2.06])
Log-rank test:
Comparing levels of mGPS
Miura et al.39 Various 1160 Categorical
(3 w, 6 w)
d Multivariate Cox regression analysis on
overall survival:
Adjusted for primary cancer site, age, and
gender.
GPS ¼ 1 1.07 (0.78e1.49) 0.673
GPS ¼ 2 1.36 (1.01e1.87) 0.046
D-PaP ¼ Delirium-PaP; BCI ¼ B12/C-Reactive Protein Index; PiPS ¼ Prognosis in Palliative Care Study; PPI ¼ Palliative Prognostic Index; PPS ¼ Palliative Performance Scale; GPS ¼ Glasgow Prognostic Score; MMSE ¼
Mini-Mental State Examination; AUC ¼ area under the curve; PPV ¼ positive predictive value; NPV ¼ negative predictive value; BT ¼ body temperature; PR ¼ pulse rate; BMI ¼ body mass index; CRP ¼ C-reactive
protein; PS ¼ performance status; WBC ¼ white blood cell; d ¼ days, w ¼ weeks, m ¼ months.
Some studies compared several of these tools in one article which explains the disparity in the total number of studies versus papers.
aMedian.


































Database: Ovid MEDLINE(R) 1946 to Present With Daily Update, Embase ClassicþEmbase <1947 to 2015 Week 14>
Search Strategy
1 neoplasm.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1024167)
2 cancer.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3421033)
3 malignancy.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (251965)
4 tumo?r$.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3908264)
5 carcinoma.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1530087)
6 1 or 2 or 3 or 4 or 5 (6273610)
7 model.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (3945411)
8 tool.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (657880)
9 7 or 8 (4498731)
10 prognosis.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1151044)
11 prediction.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (498913)
12 progno$.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (1332771)
13 10 or 11 or 12 (1765582)
14 terminal care.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (48093)
15 palliat$.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (173421)
16 hospice.mp. [mp¼ti, ab, ot, nm, hw, kf, px, rx, ui, an, sh, tn, dm, mf, dv, kw] (26506)
17 14 or 15 or 16 (217896)
18 6 and 9 and 13 and 17 (1735)
19 limit 18 to ‘‘all adult (19 plus years)’’ [Limit not valid in Embase; records were retained] (1626)
20 limit 19 to english language (1499)
21 limit 20 to humans (1370)
22 remove duplicates from 21 (1088)
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The PaP
























Very low <12% 2.5








CPS ¼ clinician-predicted survival; WBC ¼ white blood cell.
Table A2
The D-PaP








































Total BCI Score ¼ Multiply Serum Vitamin B12 Level (pmol/L) by
Serum CRP Level (mg/L)




BCI ¼ B12/C-Reactive Protein Index; CRP ¼ C-reactive protein.
Table A4
The PiPS (A and B)
PiPS A PiPS B Score
Breast cancer Male genital organs The presence/absence





Male genital organs Distant metastases
Distant metastases Bone metastases
Liver metastases Mental test score
(0e10)























PiPS ¼ Prognosis in Palliative Care Study; ECOG ¼ Eastern Cooperative





















Risk Group PPI Score
Survival
A
Longer than six weeks #4
B
Shorter than six weeks >6
C
Shorter than three weeks >6
Table A6
The PPS
PPS Range Level of Function/Condition
100% / 0% Normal / death





CRP $ 10 mg/L Albumin $35 g/L 0
CRP > 10 mg/L Normal albumin 1
Normal CRP Albumin <35 g/L 1
CRP > 10 mg/L Albumin <35 g/L 2
mGPS
CRP # 10 mg/L albumin $35 g/L 0
CRP > 10 mg/L Normal albumin 1
CRP > 10 mg/L Albumin <35 g/L 2
GPS ¼ Glasgow Prognostic Score; CRP ¼ C-reactive protein.
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Palliative Prognostic Score and Delirium PaP
The PaP score was constructed by the Italian Multicentre and Study Group in Palliative Care and validated in
patients with advanced incurable cancer using 30 day survival probability. The D-PaP (Delirium-PaP) is a modi-
fied version of the PaP, incorporating a delirium assessment that slightly improved the predictive accuracy of the
PaP. The PaP and D-PaP are the only prognostic tools included in this review that use clinician-predicted survival
(CPS) as one of their indices. The PaP has six parameters: four subjective (clinical) and two objective (bio-
markers). The PaP and D-PaP both rely heavily on CPS, a subjective parameter that can add an extra 8.5 points
to the total score (PaP maximum 17.5; D-PaP maximum 19.5). The other parameters (biomarkers and symptoms)
contribute a maximum of 2.5 points making this tool heavily reliant on the clinician’s expertise in prognostica-
tion (Tables A1 and A2).
A key component of the PaP is clinician-predicted survival. It has been argued that CPS is dependent on phy-
sicians having sufficient knowledge and experience to make assess this adequately. From the eligible studies, it
was noted that oncologists’ (i.e., nonpalliative care specialists) CPS was shown to be well calibrated but individual
predictions imprecise. Using the CPS from nonspecialists still enabled, the PaP to predict the short-term survival
(30 days) of patients with advanced cancer ‘‘reasonably well.’’ The inclusion of CPS, therefore, does not detract
from the PaP score being a unique combination of physician’s judgment, corrected and integrated with a series
of other objective parameters, optimising the score. In spite of this, this tool is not used routinely. This may be
because of its heavy reliance on CPS, and therefore, clinicians do not need to use a tool that weights their existing
opinion heavily, and therefore, they could argue will not alter their survival estimate. The other components of
the tool have been individually validated for their accuracy in estimating prognosis; however, the individual
weighting of each parameter is not known because no study has compared every clinical and biomarker impor-
tant in prognosis in advanced cancer.
B12/CRP Index
The BCI was developed by a group at the University of London, U.K., following the EAPC’s recommendations
in 2005. It was initially validated in patients with advanced incurable cancer admitted to an elderly care facility. It
can estimate up to 90 day mortality. Of interest is that the BCI incorporates vitamin B12 levels as a marker of
prognosis; the rationale for this is that increased levels are present in myeloproliferative disorders, hepatocellular
carcinoma, and metastatic liver disease. It consists of two objective (biomarker) parameters, CRP and B12. How-
ever, vitamin B12 is not always analyzed routinely in patients and may explain the lack of further research into this
tool (Table A3).
Prognosis in Palliative Care Study
The PiPS was developed in a UK population with locally advanced or metastatic cancer. There are two versions
of the tool (PiPS A and PiPS B) and differ, in that PiPS B incorporates biomarkers when assessing survival. It pre-
dicts survival up to and greater than 55 days. The PiPS A has 13 subjective parameters, whereas the PiPS B has
nine subjective and eight objective (biomarker) parameters. The PiPS, similar to other tools, relies on subjective
parameters; however, in this case, they are orientated toward specific symptoms, signs, and disease burden, and
many are suggested by the EAPC as individual prognostic factors. The relative weighting of each of the prognostic
factors is not available in the public domain, instead the tool is accessed electronically and a score issued
(Table A4).
Palliative Prognostic Index
The PPI was developed in Japan in 1999, in patients with advanced incurable cancer. It divides survival into
three groups and estimates survival up to six weeks. Risk Group A (PPI score #4) has an estimated survival of
more than six weeks. Risk Group B (PPI score 5) has an estimated survival of less than six weeks but greater
than three weeks. Risk Group C (PPI score >6) has an estimated survival of less than three weeks. It consists
of nine subjective parameters (the PPS, oral intake, edema, dyspnea at rest and delirium) and reports the pres-
ence or absence of signs and symptoms with similar weighting given to the different parameters. One of the pa-
rameters used is the PPS that is a prognostic tool in its own right. By incorporating the PPS into the PPI, more
subjective parameters are incorporated, and while this may increase the prognostic accuracy, it may increases bias
and the complexity and reduce clinical utility (Table A5).
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The PPS was validated in a palliative care population in Canada. It provides a percentage score based on sub-
jective indices giving a survival estimate up to three months. Survival accuracy of intermediate scores has been
noted to be variable. It consists of six subjective parameters. Many of these parameters are focused on aspects
of performance status including ambulation, activity levels, and performance status itself. Performance status
is the gold standard in assessing a patient’s fitness; therefore, this tool is bias toward performance status in
that synonyms of performance status are included as parameters (e.g., levels of ambulation, activity, and self-
care). One of the other parameters is conscious level, which could have been objectified by incorporating the
Glasgow Coma Scale (Table A6).
In conclusion, the PPS has been extensively studied in a large patient population with advanced cancer,
including multiple cancer types. It has performed well in the majority of the studies looking at the tool individ-
ually, the only criticism being its better accuracy with lower PPS scores. It has also been compared several times
with other prognostic tools with varying results and again demonstrates comparable accuracy to other tools with
lower PPS scores. The components of this tool are heavily bias toward performance status and disease burden
emphasizing the importance of these clinical markers in prognosis.
The Glasgow Prognostic Score
The GPS was originally developed in patients with nonesmall cell lung cancer and subsequently refined to the
mGPS. The GPS combines CRP and albumin to give a score of 0, 1, or 2, with increasing score suggesting
decreased survival: CRP <10 ¼ 0; CRP $10 ¼ 1 (albumin $35); and CRP >10 þ albumin <35 ¼ 2. It has
been validated in individual cancer types in addition to large populations of patients with advanced incurable
cancer.25 The GPS is entirely objective as the information needed to calculate the score is based on biomarker
results. The GPS has been developed since the EAPC’s recommendations in 2005 and meets the requirements
set that any prognostic tool is quick and easy to use, and its scoring system is very simple. The GPS is also able
to predict survival accurately several months before death. It fulfills the EAPC’s recommendations of being quick
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a b s t r a c t
Objectives: In patients with advanced incurable lung cancer deciding as to the most appropriate treatment
(e.g. chemotherapy or supportive care only) is challenging. In such patients the TNM classification system
has reached its ceiling therefore other factors are used to assess prognosis and as such, guide treatment.
Performance status (PS), weight loss and inflammatory biomarkers (Glasgow Prognostic Score (mGPS))
predict survival in advanced lung cancer however these have not been compared. This study compares
key prognostic factors in advanced lung cancer.
Materials and methods: Patients with newly diagnosed advanced lung cancer were recruited and demo-
graphics, weight loss, other prognostic factors (mGPS, PS) were collected. Kaplan–Meier and Cox
regression methods were used to compare these prognostic factors.
Results: 390 patients with advanced incurable lung cancer were recruited; 341 were male, median age
was 66 years (IQR 59–73) and patients had stage IV non-small cell (n = 288) (73.8%) or extensive stage
small cell lung cancer (n = 102) (26.2%). The median survival was 7.8 months. On multivariate analysis
only performance status (HR 1.74 CI 1.50–2.02) and mGPS (HR 1.67, CI 1.40–2.00) predicted survival
(p < 0.001). Survival at 3 months ranged from 99% (ECOG 0–1) to 74% (ECOG 2) and using mGPS, from 99%
(mGPS0) to 71% (mGPS2). In combination, survival ranged from 99% (mGPS 0, ECOG 0–1) to 33% (mGPS2,
ECOG 3).
Conclusion: Performance status and the mGPS are superior prognostic factors in advanced lung cancer.
In combination, these improved survival prediction compared with either alone.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC. Introduction
In most patients that present with advanced lung cancer (stage
II–IV), there are the options of oncology treatment (including
hemotherapy, radiotherapy, targeted therapy) or best supportive
are (palliative care) alone [1]. The benefits of any treatment must
e balanced with the side-effects, which in cancer treatment often
re considerable.
∗ Corresponding author at: Edinburgh Cancer Centre, Western General Hospital,
rewe Road, Edinburgh, UK. Tel.: +44 7766503469; fax: +44 131 777 3564.
E-mail address: barry.laird@ed.ac.uk (B.J. Laird).
1 Joint senior authors.
ttp://dx.doi.org/10.1016/j.lungcan.2015.03.020
169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A fundamental factor influencing treatment decisions in
advanced lung cancer is the expected prognosis, however clini-
cians are often inaccurate in survival predictions, and can have a
tendency to overestimate the prognosis [2]. There are currently no
good predictors of the benefit of chemotherapy; however prognosis
is currently being used to select those who receive chemotherapy.
The most established factor for assessing prognosis is performance
status and this is advised in guidelines for lung cancer treatment
[3]. Furthermore, studies have shown that many patients receive
inappropriate anti-cancer treatment near the end of life [4]. Bet-
ter prognostic tools are needed to avoid unnecessary, potentially
harmful therapy during end of life.
In addition to performance status, various other factors have
been shown to independently predict survival in advanced lung
























































(p < 0.001) and mGPS (p < 0.001) were predictors of survival.
Figs. 1–3 show Kaplan–Meier survival curves for weight loss,
performance status and mGPS respectively.
Table 1
Patient demographics (n = 390).
Parameter n % Median (IQR)










154/150/86 39.5/38.5/22.1 66.0 (59.0–73.0)
Survival (months) 7.8 (3.5–13.6)
Weight loss in past 3
months
294 75.3 5.04 (0.8–10.2)
Weight loss category in
past 3 months (%)
Weight loss < 5.0%






BMI (kg/m2) 25.2 (22.5–28.5)C.P. Simmons et al. / Lun
ancer, such as weight loss and systemic inflammation. Weight
oss is common in patients presenting with lung cancer and typ-
cally worsens as disease progresses, with around 60% of patients
eporting significant weight loss in their last few months of life
5]. Studies have also linked weight loss in lung cancer to reduced
urvival, independent of treatment received. Furthermore, patients
ith weight loss are less likely to complete their intended course
f chemotherapy and are more likely to experience chemotoxic-
ty than patients without weight loss, independent of tumor status
5]. Weight loss in patients with lung cancer is therefore of symp-
omatic, predictive and prognostic relevance.
Measures of the systemic inflammatory response are of
ndependent prognostic value in cancer. A combination of the
nflammatory markers CRP (C-reactive protein) and albumin (Alb)
ermed the modified Glasgow Prognostic Score (mGPS), has been
he most extensively studied and validated prognostic scoring tool.
he mGPS score has also been shown to correlate with weight loss
n patients with advanced cancer, and is associated with increased
reatment toxicity, reduced treatment response and poor nutri-
ional status [6–8].
Although weight loss, performance status and the mGPS have
een shown to be of independent prognostic value in lung cancer,
hey have not been compared with each other. Therefore the pri-
ary aim of the present study was to compare these prognostic
actors in patients with advanced lung cancer, to assess which has
he greatest prognostic value in order to guide treatment. A sec-
ndary aim was to assess if independent prognostic factors could
e combined to improve survival prediction.
. Materials and methods
A prospective observational study was conducted. Consecutive
atients were recruited from two University Hospitals in Greece:
he first cohort was evaluated in the University Hospital of Her-
kleion between 6 February 2006 and 12 October 2010 (with
ollow-up until 27 October 2011) and the second in University Hos-
ital of Larissa between 30 March 2010 and 13 December 2013
with follow-up until 1 June 2013).
Eligible patients were 18 years of age or older, had advanced
ung cancer (stage IV NSCLC or extensive stage SCLC) and were due
o start systemic anti-cancer therapy.
The following data were collected: sex, age, cancer type, body
ass index (BMI), percentage weight loss in the preceding 3
onths, performance status, albumin, CRP, and survival status at
ollow-up.
Age, percentage weight loss in the preceding 3 months, perfor-
ance status, CRP and albumin were categorized using standard
hresholds to aid comparison and stratification of results.
Performance status was measured according to the Eastern
ooperative Oncology Group (ECOG) classification which ranges
rom grade 0 (fully active) to grade 5 (dead). ECOG grades 0 and 1
ere grouped into one category as this has been standard practice
n the majority of prospective phase III trials in lung cancer and sur-
ival changes dramatically in patients with PS2 versus PS0-1 [9,10].
ge was divided into patients less than 65 years of age, between
5 and 74 years and greater than 74 years of age. Cachexia was
efined as >5% weight loss, in line with the international consensus
lassification [11].
CRP and albumin values were used to calculate the mGPS score
or each patient. The limit of detection for CRP was 5 mg/L and all
amples were processed according to standardized laboratory pro-
edures. The mGPS was calculated as follows: CRP ≤ 10 mg/L = 0,
RP > 10 mg/L = 1, CRP > 10 mg/L and albumin < 35 g/L = 2.
Individuals’ demographic indices and categories were analyzed
nd compared to their survival status. Survival time was calculatedcer 88 (2017) 304–309 305
in months and defined as the time from study entry until death,
or censored if alive at follow-up date. Survival curves were plotted
using Kaplan–Meier methods and the log-rank test was applied.
Survival analysis was performed using Cox proportional hazards
model and hazard ratios (HRs) were calculated. Multivariate sur-
vival analysis was conducted using a stepwise backward procedure
to derive a final model of the variables that had a significant inde-
pendent relationship with survival. Stratification by primary cancer
site was performed for the survival analysis. Factors that were pre-
dictive of survival in the multivariate analyses were finally grouped
together to assess whether they had better prognostic accuracy
when grouped together.
Statistical analysis was performed using SPSS version 19. All sta-
tistical testing was conducted at the 5% level, and 95% confidence
intervals (CI) are reported throughout. Where n ≤ 10, these groups
were not reported.
The study has been conducted and adheres to the Reporting
Recommendations for Tumor Marker Prognostic Studies (REMARK)
guidelines [12].
3. Results
There were 390 patients included and their demographics are
detailed in Table 1. All patients had advanced incurable lung cancer
(stage IV NSCLC or extensive stage SCLC). The majority of patients
was male (n = 341, 87.4%) and the median age was 66 years (IQR
59–73). The median performance status was 1 (IQR 1–2). Median
survival was 7.8 months (IQR 3.5–13.6) reflecting the advanced dis-
ease staging of the population. The minimum and median follow-up
for survivors was 0.6 months and 12.8 months, respectively. At the
time of cessation of data collection, 107 patients were alive and 283
had died. Patients had either non-small cell lung cancer (n = 288)
(73.8%) or small cell lung cancer (n = 102) (26.2%).
The median weight loss in the previous three months was 5.0%
(IQR 0.8–10.2). The median BMI was 25.2 (IQR 22.5–28.5).
Clinico-pathological factors and survival were compared for this
cohort of patients and are detailed in Table 2. On univariate sur-
vival analysis, age (p = 0.004), sex (p = 0.009), tumor type (p = 0.007),
weight loss (%) in the previous 3 months (p = 0.001), performance
status (p < 0.001) and mGPS (p < 0.001) were significant predic-
tors of survival. On multivariate analysis only performance statusPerformance status
(ECOG) (0–1/2/3/4)
1 (1–2)
SD, standard deviation; IQR, interquartile range.
a Defined as weight loss >5%.
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Table 2
The relationship between clinic-pathological factors and survival in patients with metastatic lung cancer (n = 390).
Parameter n % Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Sex (M/F) 341/49 87.4/12.6 0.60 (0.41–0.88) 0.009
Age (≤65/65–74/≥74 years) 154/150/86 39.5/38.5/22.1 1.28 (1.08–1.50) 0.004
Tumor type (NSCLC versus
SCLC)
288/102 73.8/26.2 1.39 (1.10–1.77) 0.007
Weight loss (%) category in
past 3 months (1/2)a
195/195 50.0/50.0 1.49 (1.18–1.88) 0.001
Performance status (ECOG)
(0–1/2/3/4)
271/75/31/13 69.5/19.2/7.9/3.3 1.90 (1.65–2.18) <0.001 1.74 (1.50–2.02) <0.001
mGPS (0/1/2) 103/183/104 26.4/46.9/26.7 1.84 (1.54–2.19) <0.001 1.67 (1.40–2.00) <0.001









Fig. 1. Weight loss is associated with reduced survival (log rank p = 0.001). The
Table 3 shows the relationship between survival at 3 months and
GPS and performance status. Survival was compared across all
ategories for both mGPS and performance status. For performance
tatus, survival at 3 months ranged from 99% (ECOG 0–1) to 74%
able 3
he relationship between mGPS and performance status and the survival rate (%) at





































here n < 10, analysis not performed.nder the receiver operator curve (ROC) was 0.49 (95% CI = 0.43–0.55), p = 0.661.
(ECOG 2). For mGPS, survival at 3 months ranged from 99% (mGPS0)
to 71% (mGPS2). When used in combination, survival at 3 months
ranged from 99% (mGPS 0 and ECOG 0–1) to 33% (mGPS = 2 and
ECOG 3). Performance status does correlate with mGPS (Pearson
coefficient is 0.0206, p < 0.001) however this must be taken in the
context of the large sample size so limited inference can be drawn
from this.
4. Discussion
The results of this study show that age, sex, weight loss, tumor
type, performance status and markers of the systemic inflamma-
tory response (mGPS), all have prognostic value in patients with
advanced lung cancer. Performance status and the mGPS carry the
greatest prognostic value, however it is of interest that the mGPS
has strong prognostic accuracy and performs almost identically to
performance status. In addition, the combination of performance
status and mGPS points to a new method of prognosis in advanced
lung cancer.
Performance status (measured either by Karnofsky or ECOG
classification) still remains the gold standard prognostic measure
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Fig. 2. Decreasing performance status was associated with reduced survival (log-rank p < 0.001). The area under the ROC was 0.62 (95% CI = 0.56–0.68), p < 0.001.
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nd the results of the present study support this [13,14]. However,
he key limitation of performance status is that it is an entirely
ubjective assessment of a patient’s physical activity and function-
ng [15–17]. It has been shown that marked discrepancies often
xist between clinicians’ and patients’ assessments of performance
tatus [18]. Furthermore, clear inter-observer variability has been
emonstrated [19]. Therefore it is important that the limitations
f using a prognostic measure which is subjective and is variable,
uch as performance status, are considered. This aspect is of fun-
amental importance when the majority of treatment decisions
n advanced lung cancer are deeply influenced by performance
tatus.
In contrast, the mGPS has clear advantages. These findings sup-
ort that the mGPS has independent prognostic value in advanced
ung cancer, however a clear advantage over performance status
s that it is objective and has 100% inter-observer congruence. It
s simple to measure, inexpensive and is widely available. Used
ither in isolation or, perhaps even more, in combination with per-
ormance status, the present findings demonstrate its relevance in
ncreasing accuracy of survival prediction in metastatic lung cancer
20]. This has been shown in other cancer types [21].
The findings also suggest that the role of weight loss in advanced
ung cancer should be viewed with caution. Weight loss has long
een regarded a “poor” prognostic sign in lung cancer. This study
pecifically reviewed weight loss greater than 5%. Cancer cachexia
s defined as weight loss greater than 5% and felt by many to be
he most adverse weight related prognostic factor in cancer. How-
ver the findings suggest that the use of weight loss as an early,
rognostic factor in lung cancer is of considerably less value than
erformance status and mGPS and should not be assessed routinely
n the clinic. For this to happen it would mean a change of mind set,
s weight loss is a source of concern for patients, families and cli-
icians. It is regularly recorded at clinic appointments and may be
sed as a trigger for more investigations (suspected disease recur-
ence/progression) and dietetic referral or as a starting point for
nd of life discussions. In addition, the confirmation of weight loss
n cancer is often upsetting for patients/families and they need to
eceive information regarding how to manage this. The findings
lso demonstrate that cachexia (as per current definition) [11] and
MI did not offer additional prognostic value in the presence of per-
ormance status and mGPS. However, if these factors have limited
rognostic, their relative value should be re-evaluated.
There is an urgency for improved survival prediction in
etastatic lung cancer. Recent work has demonstrated that
pproximately 10% of metastatic lung cancer patients receive anti-
ancer therapy in the last 30 days of life [22], and patients with the
hortest survival time after diagnosis received more anti-cancer
herapy near the end of life. A key consideration in deciding appro-
riate treatment in an advanced lung cancer patient is prognosis.
n these patients, the benefits of anti-cancer therapy must be
eighed against potential disadvantages, such as multiple hospital
isits, side effects and potentially life-threatening toxicity. Accu-
ate assessment of prognosis is needed to inform such complex
ecisions between patients and clinicians.
The results of the present study show that the combination of
GPS and performance status are more accurate in survival predic-
ion than either in isolation. This has been shown in other cancer
ypes and has now been demonstrated in advanced lung cancer
21]. Using the combination of mGPS and performance status may
ave considerable application in considering treatment options in
dvanced lung cancer; for example when to use chemotherapy in
atients near the end of life. This approach has been supported in
ecent work which has shown the value of using the mGPS as a strat-
fication factor in very advanced disease to reduce chemotherapy
se [22]. The present study takes this approach one step further by
ombining mGPS with performance status, to increase prognostic
[
[
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accuracy. This novel approach could then be used to guide the
choice of oncology treatment in advanced lung cancer patients.
The present study has several limitations. There was a high
proportion of men and SCLC in the cohort studied in keeping
with the epidemiology of lung cancer in Greece. Furthermore not
all previously studied prognostic factors in advanced NSCLC have
been examined. However as performance status remains the gold
standard prognostic measure in use clinically, its inclusion here is
important. Details on cancer treatment, EGFR mutations and histo-
logical subtype (for NSCLC) are not available and this would be of
interest to assess the effect of response of chemotherapy in patients
in poor prognostic groups. All patients in the study were due to start
anti-cancer therapy and therefore the number of patients with PS
3 or 4 was small.
5. Conclusion
Performance status and mGPS are superior prognostic factors in
metastatic lung cancer and in combination increase survival pre-
diction in advanced lung cancer. In translating this to clinical care,
these factors should now be examined in the setting of treatment
stratification in the complex area of advanced lung cancer. Contin-
uing studies are eagerly awaited.
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What is the purpose of the study?  
We are approaching patients who have a diagnosis of cancer, in order to invite them to participate in 
a study in which we are analysing the relationship of certain symptoms, clinical markers and blood 
markers and their impact upon the length of survival for patients with cancer. This is to try and 
identify what factors help predict survival in cancer. This is with the aim of gaining information which 
may help clinicians predict the survival of patients with cancer in the future. This in turn should 
improve the care and management of future patients with cancer. 
 
Patients with cancer have many symptoms which can impact upon their overall wellbeing and quality 
of life. Significant levels of certain blood markers can also impact upon the wellbeing and quality of 
life of patients with cancer, thereby affecting their survival.  
 
We believe that the combination of certain clinical and blood markers can help predict survival in 
cancer. We believe that this may add extra information when assessing future patients with cancer 
and benefit their management.  
 
The study will be funded by Medical Research Scotland and sponsored by the University of 
Edinburgh and NHS Lothian.  
 
Why have I been invited?  
You are being invited to take part in this study because you have been identified by your doctor or 
nurse as someone who has cancer. 
 
Do I have to take part? 
No. Your participation in this study is entirely voluntary.  If you decide to take part, you will be given 
this information sheet to keep and you will be asked to sign a consent form.  You may choose not to 
take part or you may decide to stop taking part in the study at any time, without giving a reason.  This 
will not affect your current or future medical care.   
 
What happens if I decide to take part? 
If you are interested in taking part you will be contacted by the researcher to arrange a convenient 
time to meet. Before you take part in the study you will be asked to sign a consent form. 
 
How long will the study last?   
Invitation 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
 
• Part 1 tells you the purpose of this study and what will happen to you if you take part. 
   
• Part 2 gives you more detailed information about the conduct of the study.  
 
  Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part.  
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The study is open for 2 years during which time we may contact your doctor (hospital doctor or GP) 
to enquire on your progress.  
 
What will being in the study involve?   
If you take part in the study, the following will take place: 
• One interview which will focus on the completion of questionnaires regarding symptoms 
• Two brief walking tests assessing fitness and mobility (optional).  
o The first test involves timing how long it takes to stand from the sitting position in a 
chair, walk 3 meters and return to sitting in a chair.  
o The second test involves measuring the distance walked in 2 minutes. 
• The research team recording details about your cancer and medical problems from medical 
records 
• The research team following up on your progress at a minimum period of 3 months after entry 
into the study, by contacting your doctor or your GP. The study will be open for 2 years and 9 
months and follow up will cease at this point.  
 
It is part of a routine assessment by any clinical team to have a full physical examination and we will 
be collecting some data from recordings made at the time of this examination including height, weight 
and the presence of ankle or abdominal swelling. If the information is not available we would wish to 
perform a brief examination to examine for ankle or abdominal swelling and measure your height and 
weight.  
In addition to the above, the research team will record details about your cancer, including relevant 
medical history and results of relevant scans. Most of these details will be taken from your hospital 
case notes. Finally we will contact either your clinical team or your GP to see how you are getting on. 
 
Do I have to have any blood tests? 
You will be asked by the study doctor if you are willing to provide a blood sample (30mls). This is 
entirely optional and if you do not wish to give a blood sample you are still able to enter the study. 
This will not affect the care you receive in any way. 
 
It has been shown that significant levels of certain blood markers may aid in predicting survival in 
cancer. If you agree to give a blood sample, part of the sample will be analysed to measure 
these markers or the markers can be analysed from an existing blood sample taken on the 
day of consent.  
 
 It is anticipated that new blood markers will be discovered in the future to aid cancer management 
and help understand the course of cancer. These markers may have a genetic component to them.  
If you agree, the other part of the blood sample will be completely anonymised and analysed at a 
future date for specific genes (DNA and/or RNA) or markers, thought to be important in predicting 
survival in cancer. This sample and/or data collected from this may be analysed in another country. 
The blood sample will not be used for any other purpose. 
 
Will participating in the study affect my cancer treatment? 
No – you will still receive your planned cancer treatment. Participating in the study will not delay or 
affect your treatment in any way. 
 
Will I need to stay in hospital? 
No, you will not need to stay in hospital. You may be contacted via telephone by the study doctor or 
nurse.  
 
What do I have to do? 
  
   Page 3 of 6 IPAC PI/C Version 4 
 17/05/13 
You need to answer questions on your symptoms and have a blood sample taken if you consent to 
this.  
 
What are the possible disadvantages and risks of taking part? 
We do not expect any risk to be involved. One blood test is required, which we understand can be 
painful and cause some discomfort and damage to the skin. Either a doctor or a nurse who have 
experience and full competencies in this routine procedure will take the blood sample.  
 
What are the possible benefits of taking part? 
We may obtain more useful information about your symptoms from the interview which could help 
future patients with cancer. You will not directly benefit individually from the study, and the main 
benefit will be to provide information that may help with treatment of future patients with cancer.  
 
If you have any problems at any time you may wish to discuss these with your study doctor/nurse.  
Alternatively you can give them permission to contact your consultant, clinical nurse specialist or GP 
on your behalf. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in part 2. 
 
What information will be used for the study? 
We wish to record details of relevant medical conditions, information about the cancer itself, the 
symptoms you have as a result of cancer and your progress over your illness (minimum follow up 
period of 3 months) including survival. All results will be saved on computer files and transferred to 
the University of Edinburgh for analysis. Your personal details will be removed from results and 
replaced with a study number before copies are sent. The analysis will be done on NHS and 
University computers, and may be examined by experts from other parts of the UK or around the 
world. A list that links your details with the study number will be kept separate from all other 
information. Your involvement in the study will be recorded in your medical notes and your GP will be 
told that you are taking part in the study by letter. You will not be identified personally in any report 
arising from the study. Some of the information collected may help answer other questions about 
cancer management in the future. This might include sharing information with other researchers in 
other hospitals or countries. All information that is re-analysed or shared will be anonymous.  
 
Your medical records may be examined by relevant authorities (for example government bodies, 
NHS Research and Development staff) to ensure that the study has been conducted to proper 






If the information in Part 1 has interested you and you are considering participating, please 
read the additional information in Part 2 before making any decision. 
  




What if new information becomes available? 
Sometimes we get new information during the course of a study. If this happens your research doctor 
or nurse will tell you and discuss whether or not you should continue in the study. If you decide not to 
carry on, your research doctor or nurse will make arrangements for your care to continue. If you 
decide to continue you may have to sign an updated consent form. If the study is stopped for any 
other reason, we will tell you and arrange your continuing care. 
 
What will happen if I don’t want to carry on with the study? 
If you decide not to continue in the study, you are free to withdraw at any time and without having to 
give a reason.  A decision to withdraw at any time will not affect the standard of care you receive. If 
you withdraw from the study we will use the information collected up to your withdrawal.  
 
What if there is a problem?  
If you have a concern about any aspect of this study, you should speak to the researchers who will 
do their best to answer your questions – Insert contact details here. 
 
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital. 
 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this study, the normal 
NHS complaints mechanisms will be available to you.   
 
Will my taking part in this study be kept confidential? 
Yes, it is totally confidential. You will be allocated a study number to ensure you remain anonymous. 
Your date of birth, gender, the name of your condition and the information collected will be entered 
onto a secure database using NHS and University of Edinburgh computers.   
 
You can be assured that any data collected during the course of this study and any of the results 
published will not identify you personally.  Your medical records will only be available to the research 
doctors, your hospital consultant, responsible individuals from the Edinburgh Cancer Research UK 
Centre, trial sponsors and regulatory authority.  
 
With your permission, we would like to inform your general practitioner of your participation in this 
trial.  Your information will be stored securely and will be kept strictly confidential, with access 
provided only to authorised personnel. 
  
Your consent to take part in this study includes your consent to allow the use of the data in your 
medical/clinical records for the purposes of Cancer Research.  Your consent also includes allowing 
this data to be linked to data coming from other sources such as cancer registries and medical 
clinical records.  All data collected on your behalf will be treated in compliance with the European 
and UK applicable laws to ensure your confidentiality is maintained. 
 
Will my GP be informed? 
We will inform your GP by letter if you decide to take part. 
 
Will my oncologist (cancer doctor) be informed? 
We will inform your oncologist by letter if you decide to take part. 
 
What will happen to the results of the study? 
The results of this study may help with the treatment of future cancer patients. The results will help in 
the development of future studies in this area. These results will also be published in a scientific 
journal. 
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Who designed the study? 
A group of doctors from across the UK and Canada have designed this study. They are specialists in 
treating cancer symptoms and looking after patients with cancer.  
 
Who is organising and funding the study? 
It is being funded by Medical Research, Scotland and organised by the University of Edinburgh.    
 
Who has reviewed the study? 
This study has been reviewed and approved by the NHS Research Ethics Committee to confirm that 
this study considered the ‘rights and protection of patients’ health.  The study has also been reviewed 
by Medical Research Scotland, a local charity that funds research in Scotland, which is providing 
funding for the study.  
 
In addition, the study has been reviewed by the Research and Development Department of NHS 
GGC/Lothian and the Research and Development departments of all centres taking part. The study is 
sponsored by NHS Lothian/the University of Edinburgh. 
 
Can I get further information about the study? 
If you wish to discuss any other aspect of the study, you can do so with Dr. Barry Laird contactable 
on telephone number 0141 211 3418.  
 
Can I get independent advice about taking part in the study? 
Independent advice on taking part in medical research is available from ‘INVOLVE’, an NHS 
sponsored organisation (Website address:  http://www.invo.org.uk Email address: 
admin@invo.org.uk Telephone number: 02380 651 088)  
 
Contact for further information 
If you have further questions about your illness or clinical studies, please discuss them with your 
doctor. 
 
If you would like independent advice or further information you may also find it useful to contact 
Macmillan Cancer Support, an independent patient advisory group: Freephone 0808 808 00 00; 
website http://www.macmillan.org.uk, Head Office Address: Macmillan Cancer Support, 89 Albert 
Embankment, London, SE1 7UQ.   
 
Alternatively you can contact Cancer Research UK, Freephone 0808 800 4040, website 
http://www.cancerresearchuk.org, and address: Angel Building, 407 St John Street, London EC1V 
4AD 
 
If during the course of the study you have any questions regarding your participation or would like 
further study specific information before making your decision please contact: 
 
Doctor:  




Thank you for taking the time to read this information. 
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CONSENT FORM 
(Form to be on hospital headed paper) 
 
Name of Researcher (PI):  Dr Barry Laird 
Patient Identification Number for this trial:    
Title of Project:     IPAC Study 
  
Inflammatory biomarkers in Prognosis in Advanced Cancer: a multicentre prospective study  
 
      Please initial boxes 
 
1. I confirm I have read and understand the information sheet dated 17th May 
(Version 4) for the above study. I understand what is involved in taking part in 
this trial and I have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I agree that sections of any of my medical notes and data collected during the 
study may be looked at by local researchers, by responsible individuals from 
the Edinburgh Cancer Research UK Centre and the trial sponsors (NHS and 
the University of Edinburgh) where it is relevant to my taking part in research. I 
give permission for these individuals to have access to my records. 
 
4.  I understand that data from the study including my gender, date of birth, details 
of my condition and the results of blood tests will be entered onto a secure 
database using NHS and University of Edinburgh computers to be shared with 
the Palliative Medicine Research Group researchers (University of Edinburgh).  
I give permission for data to be used in this way. 
 
5. I give my permission for a letter and information regarding my participation in 
this study to be sent to my GP and oncologist/hospital doctor. 
 
6. I agree to the information detailed in this patient information sheet to be 
collected as part of this study 
  
7. I agree to analysis of clinical biomarkers from a blood sample taken on the day 
of consent.  
 
8. I agree to a blood sample being taken stored and analysed for future genetic 
analysis (DNA and/or RNA). 
 
9. I agree to take part in the above study. 
 
Please sign and date below: 
     
Name of Patient  Date  Signature 
     
Name of Person taking consent  Date  Signature 
When completed, 1 original for patient; 1 original for researcher; 1 copy to be kept with hospital notes 
 
 
 
 
 
 
 
 
 
